Liver cancer detection kit or device and detection method

Abstract

The present invention provides a kit or device for detecting liver cancer, as well as a method for detecting it. [Solution] A liver cancer screening test containing nucleic acids that can specifically bind to miRNA in the subject's sample. A kit or device for use, and a method for measuring the miRNA in vitro. Hmm, a method for detecting liver cancer.

Description

Technical Field

[0001] The present invention relates to a kit or device for detecting liver cancer, which contains a nucleic acid that can specifically bind to a specific miRNA and is used for detecting the presence or absence of liver cancer in a subject, and a method for detecting liver cancer, which includes measuring the expression level of the miRNA using the nucleic acid.

Background Art

[0002] The liver is the largest organ in the body located in the upper right of the abdomen, and its main roles are metabolism of nutrients and detoxification and excretion of harmful substances. According to the statistics of cancer by site in Japan in 2011 disclosed by the Cancer Countermeasure Information Center of the National Cancer Center, National Institute of Biomedical Innovation, Health and Nutrition, the number of patients with liver cancer was 4 7,271, that is, one in 35 Japanese people is affected by liver cancer, and the number of patients is the 6th cancer site. Also, men are nearly twice as likely to be affected as women. The number of deaths due to liver cancer is 30,690 for both men and women combined, and it is the cancer site with the 4th highest number of deaths. In the United States, the estimated number of patients with liver cancer in 2014 was also 33,190, and about 23,000 of them are said to die (Non-Patent Document 1).

[0003] Generally, primary liver cancer often refers to hepatocellular carcinoma, which accounts for about 80% of it, but in addition, there are also rarer cancer types such as intrahepatic cholangiocarcinoma and biliary cystadenocarcinoma, which account for 1 - 2% of all primary liver cancers.

[0004] The progression of liver cancer is defined separately for hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Non-Patent Document 2. Here, in particular, for hepatocellular carcinoma, the spread of the tumor (T0 - 4), lymph node metastasis (N0, N1 ​​), and depending on the degree of distant metastasis (M0, M1), Stage I (T1 / N0 / M0), Stage Stage II (T2 / N0 / M0), Stage IIIA (T3a / N0 / M0), Stage I Stage IIB (T3b / N0 / M0), Stage IIIC (T4 / N0 / M0), Stage IV It is classified as A(N1 / M0) or Stage IVB(M1).

[0005] The 5-year relative survival rate for liver cancer varies depending on the stage of progression. According to Non-Patent Literature 1, the cancer is limited to the liver. In localized cancers (stage 1, stage 2, and some stage 3), 28% were found in the liver. In cases where metastasis is found in adjacent areas (stage IIIC, stage IVA), the rate is 7%, and distant metastasis is... In cases where metastasis is observed (stage IVB), it is reported to occur in 2% of cases. Therefore, liver cancer is considered metastatic. If detected and treated at an early stage before migration is observed, it can significantly contribute to improving survival rates.

[0006] Treatment for liver cancer mainly involves surgical treatment such as resection or liver transplantation, as well as injection of drugs via puncture. The three main treatments are local therapies that destroy cancer cells by ablation, and hepatic artery embolization. These are often treated with drug therapy or radiation therapy. This is especially true for early-stage liver cancer where the cancer affects blood vessels and surrounding tissues. If this is not observed, the condition can often be cured by partial resection of the liver (Non-Patent Literature 1). Even if cancer is localized, there are reasons such as the tumor being large or being close to blood vessels. If surgical removal is not possible, a liver transplant is preferable, and if metastasis is found, systemic medication is used. Physical therapy and radiation therapy are performed (Non-patent document 1).

[0007] As described in Non-Patent Document 1, primary screening for liver cancer includes, in addition to visual inspection and palpation, There are imaging tests such as ultrasound, CT scans, MRI scans, and angiography. Also, the liver AFP (alpha-fetoprotein) and PIVKA are used as tumor markers for detection. Pivca-II (Pivca II) is one well-known example and is often performed in conjunction with ultrasound. If these primary examinations reveal findings suggestive of liver cancer, a secondary examination will be performed by inserting a needle into the lesion. A pathological examination is performed by puncturing the skin to collect cells or tissue and examining them under a microscope.

[0008] On the other hand, the most important primary cause of liver cancer is long-term infection with hepatitis B and C viruses. Since this is known, if liver cancer is suspected, in addition to the above primary tests, hepatitis virus will be tested. It may also be performed in conjunction with a smear test.

[0009] Although still in the research stage, as shown in Patent Documents 1-5, blood and liver tissue, among others, Liver cancer can be detected using the expression level of microRNAs (miRNAs) in biological samples. Methods for doing so have been reported.

[0010] Patent Document 1 describes the miRNAs in tissues, hsa-miR-92a-3p and hsa-m iR-92b-3p, hsa-miR-92a-2-5p and hsa-miR-92b- A method for detecting leukemia, breast cancer, and liver cancer using 5p as a marker has been described. .

[0011] Patent Document 2 describes hsa-miR-23a-3p, h contained in vesicles circulating in body fluids sa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-557, hsa-miR-564, hsa-miR-614, hsa-miR-150-3p, h Various cancers are diagnosed using miRNAs such as sa-miR-486-3p as markers. Methods have been reported.

[0012] Patent Document 3 discloses a method for detecting various diseases including liver cancer by using miRNAs such as hsa-miR-23b-3p, hsa-miR-30 c-1-3p, hsa-miR-125a-3p, hsa-miR-486-3p, etc. in tissues and body fluids as markers. There is.

[0013] Patent Document 4 discloses a method for detecting various pathological conditions including liver cancer by using miRNAs such as hsa-miR-16-5p, hs a-miR-92a-3p, hsa-miR-663a, hsa-miR-1913, h sa-miR-625-3p and proteins in vesicles circulating in body fluids as markers. There is.

[0014] Patent Document 5 shows that hsa-miR-187-5p, hsa-miR-92a-3 p, hsa-miR-16-5p, hsa-miR-30c-1-3p in plasma are markers for colorectal cancer, liver cancer, and lung cancer.

Prior Art Documents

Patent Documents

[0015]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Patent Document 5

Non-Patent Documents

[0016] ​ [Non-Patent Document 1] American Cancer Society “Liver Cancer”, 2013, p.5~8, 14~15, 17~23, 27~41 [Non-Patent Document 2] Sobin, L. et al., “TNM Classification of Malignant Tumors 7th Edition” 2010, p.104-107 [Non-Patent Document 3] HCCN Guidelines "Hepatobiliary Cancer, 2nd Edition", 2014, MS-4 [Non-Patent Document 4] Zhang, B. and Yang, B., 1999, Journal of Medical Screening, Vol. 6(2), pp. 108-110. [Non-Patent Document 5] Takahashi, A. et al., 2008, World Journal of Gastroenterology, Vol. 14(1), pp. 129-131. [Overview of the Initiative] [Problems that the invention aims to solve]

[0017] The object of this invention is to discover a novel liver cancer tumor marker and to specifically bind to that marker. The objective is to provide a method for effectively detecting liver cancer using available nucleic acids.

[0018] Liver cancer is difficult to detect early because it progresses without any noticeable symptoms. It is cancer. Furthermore, because most of the liver is housed within the right rib cage, detection by palpation is difficult. Yes. Currently, for the general public who do not have hepatitis virus infection or liver cancer risk factors such as cirrhosis, There is no established effective screening method for liver cancer (Non-Patent Document 1). Ultrasound examination This is a widely used liver cancer screening method because it is less burdensome for patients and is simple to use. However, detection can be difficult depending on the location of the cancer, and the test results depend on the skill of the medical technologist. Because it is highly dependent on the dose, it is considered desirable to use it in combination with tumor markers (non Patent Document 3). AFP is known as a tumor marker for detecting liver cancer, but AFP If an increase in this level is observed, it indicates that the liver cancer has already progressed, is inoperable, or has metastasized outside the liver. In many cases, this has already happened (Non-Patent Literature 1). Also, some liver cancers produce AFP. While it has been reported that this is not the case, AFP has shown that it is not present in cancers other than liver cancer, such as testicular cancer and ovarian cancer. The levels also rise, and even in non-cancerous liver diseases, such as persistent hepatitis virus infections. Because it is known to do so, it is considered a marker with low specificity (Non-Patent Literature 1). Example For example, if another cancer is misdiagnosed as liver cancer, the opportunity for appropriate treatment may be missed. Applying the wrong medical treatment can impose unnecessary financial and physical burdens on patients. Furthermore, a large-scale screening study targeting individuals infected with hepatitis B and patients with persistent hepatitis. According to the results (Non-Patent Document 4), the detection sensitivity of liver cancer by AFP testing is only 69%. Furthermore, its diagnostic performance is insufficient for use as a screening test for liver cancer. Although the examination and MRI scans are high-performance and capable of detecting liver cancer, they require specialized equipment. Because it requires specific procedures and the testing costs are high, it is unsuitable for widespread use as a primary test. .

[0019] Furthermore, although still in the research stage, microRNAs (miR) in biological samples, including blood, are being investigated. There are reports, as described below, that use the expression level of NA to identify liver cancer, but none of them It has not yet been put into practical use.

[0020] Patent Document 1 describes hsa-miR-92a-3p, a miRNA found in blood cells and tissues. hsa-miR-92b-3p, hsa-miR-92a-2-5p and hsa-miR A method for detecting leukemia, breast cancer, and liver cancer using -92b-5p as a marker is presented. However, this detection method requires surgical tissue removal to obtain a sample. This procedure is necessary, and because it places a heavy physical burden on the patient, it is not a desirable examination method. Furthermore, Patent Document 1 describes the specific accuracy and sensitivity for distinguishing liver cancer in relation to this detection method. Furthermore, there is no description of detection performance such as specificity, making it impractical for industrial use.

[0021] Patent Document 2 describes hsa-miR-23a-3p, h contained in vesicles circulating in body fluids sa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-557, hsa-miR-564, hsa-miR-614, hsa-miR-150-3p, h Various cancers are diagnosed using miRNAs such as sa-miR-486-3p as markers. A method has been reported. However, Patent Document 2 describes a specific method using this detection method. There is no description of the diagnostic methods for liver cancer, nor is there any mention of the accuracy, sensitivity, and specificity of the methods for identifying liver cancer. Since there is no description of detection performance such as the degree, its industrial practicality is limited.

[0022] Patent Document 3 describes hsa-miR-23b-3p and hsa-miR-30 in tissues and bodily fluids. c-1-3p, hsa-miR-125a-3p, hsa-miR-486-3p, etc. A method for detecting various diseases, including liver cancer, using miRNA as a marker has been demonstrated. However, this detection method is based on experimental results from a mouse model and may not be applicable to humans. The detection of liver cancer is unclear. Furthermore, Patent Document 3 describes the accuracy of distinguishing liver cancer. Furthermore, since there is no description of detection performance such as sensitivity and specificity, it has little industrial practical use.

[0023] Patent Document 4 describes hsa-miR-16-5p and hs contained in vesicles circulating in body fluids. a-miR-92a-3p, hsa-miR-663a, hsa-miR-1913, h Using miRNAs such as sa-miR-625-3p and proteins as markers, the liver Methods for detecting various pathological conditions, including cancer, are described. However, Patent Document 4 describes this There is no description of a specific method for diagnosing liver cancer using the detection method, and the above miR NA markers are unreliable because they have not been validated in independent sample groups.

[0024] Patent Document 5 describes hsa-miR-187-5p and hsa-miR-92a-3 in plasma. p, hsa-miR-16-5p, hsa-miR-30c-1-3p are associated with colorectal cancer and liver cancer. It has been shown to be a marker for organ cancer and lung cancer. However, these markers This is a marker used to distinguish colorectal cancer from a group consisting of liver cancer, lung cancer, and healthy individuals. It is not a marker for detecting liver cancer.

[0025] Thus, in detecting liver cancer, existing tumor markers have low performance, or Since the performance and detection methods of markers in the research stage have not been specifically described, these Using this method could lead to unnecessary additional tests due to the misidentification of healthy individuals as liver cancer patients. Furthermore, there is a possibility of missing treatment opportunities due to overlooking liver cancer patients. Measuring miRNAs, which consist of tens to hundreds of molecules, increases the cost of testing, therefore, health checkups It is difficult to use for large-scale screenings such as diagnosis. Also, when measuring tumor markers... Since taking liver tissue for this purpose is highly invasive and undesirable for the patient, a minimally invasive method is used. Detection is possible from blood samples, and liver cancer patients are identified as liver cancer patients, while healthy individuals are identified as healthy individuals. There is a need for highly accurate liver cancer markers that can clearly distinguish between different types of liver cancer. In particular, liver cancer is a disease that can be detected early. By treating the condition, the survival rate can be improved, and complete cure is possible with partial liver resection. Because this is often the case, it is a highly sensitive liver cancer marker that can detect even early-stage liver cancer. It is desperately desired. [Means for solving the problem]

[0026] In order to solve the above problems, the inventors have diligently studied and have found a way to extract liver from blood, which can be collected in a minimally invasive manner. We identified several genes that can be used as cancer detection markers, and nucleic acids that can specifically bind to them. We found that liver cancer can be significantly detected by using this method, and thus completed the present invention. I reached it.

[0027] <Summary of the Invention> In other words, the present invention has the following features.

[0028] (1) Liver cancer markers, miR-1343-3p, miR-6726-5p, m iR-6515-3p, miR-4651, miR-4257, miR-3188, mi R-6131, miR-6766-3p, miR-7641, miR-1249, miR -3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977 , miR-7110-5p, miR-6717-5p, miR-6870-5p, miR -663b, miR-6875-5p, miR-8072, miR-6816-5p, m iR-4281, miR-6729-5p, miR-8069, miR-4706, mi R-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6 857-5p, miR-1227-5p, miR-6741-5p, miR-451a miR-8063, miR-3622a-5p, miR-615-5p, miR-128 -1-5p、miR-6825-5p、miR-1260b、miR-4433-3p、 miR-4665-5p, miR-7845-5p, miR-1908-5p, miR- 6840-3p, miR-6765-5p, miR-296-5p, miR-3675- 3p, miR-6781-5p, miR-423-5p, miR-3663-3p, mi R-6784-5p, miR-6749-5p, miR-1231, miR-4746- 3p、miR-6780b-5p、miR-4758-5p、miR-3679-5p、 miR-3184-5p, miR-6125, miR-6721-5p, miR-679 1-5p, miR-3185, miR-1260a, miR-3197, miR-684 5-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p miR-4497 miR-1229-5p miR-6820-5p miR-67 77-5p, miR-3917, miR-5787, miR-4286, miR-687 7-5p, miR-1225-3p, miR-6088, miR-6800-5p, mi R-1246, miR-4467, miR-4419b, miR-1914-3p, mi R-4632-5p, miR-1915-5p, miR-3940-5p, miR-11 85-2-3p, miR-6746-5p, miR-5001-5p, miR-1228 -5p, miR-5572, miR-4327, miR-4638-5p, miR-67 99-5p, miR-6861-5p, miR-6727-5p, miR-4513, m iR-6805-3p, miR-6808-5p, miR-4449, miR-1199 -5p、miR-1275、miR-4792、miR-4443、miR-6891- 5p, miR-6826-5p, miR-6807-5p, miR-7150, miR- 4534, miR-4476, miR-4649-5p, miR-4525, miR-1 915-3p, miR-4516, miR-4417, miR-642b-3p, miR -3141, miR-5100, miR-6848-5p, miR-4739, miR- 4459、miR-1237-5p、miR-296-3p、miR-4665-3p、 miR-6786-5p, miR-4258, miR-6510-5p, miR-134 3-5p, miR-1247-3p, miR-6805-5p, miR-4492, mi R-1469, miR-1268b, miR-6858-5p, miR-3937, mi R-939-5p, miR-3656, miR-744-5p, miR-4687-3p miR-4763-3p miR-3620-5p miR-3195 miR-68 42-5p, miR-4707-5p, miR-642a-3p, miR-7113-3 p、miR-4728-5p、miR-5195-3p、miR-1185-1-3p、 miR-6774-5p, miR-8059, miR-3131, miR-7847-3 p, miR-4463, miR-128-2-5p, miR-4508, miR-680 6-5p, miR-7111-5p, miR-6782-5p, miR-4734, mi R-3162-5p, miR-887-3p, miR-6752-5p, miR-672 4-5p, miR-6757-5p, miR-4448, miR-671-5p, miR -3178, miR-4725-3p, miR-940, miR-6789-5p, mi R-4484, miR-4634, miR-4745-5p, miR-4730, miR -6803-5p, miR-6798-5p, miR-3648, miR-4783-3 At least one polynucleus selected from the group consisting of p and miR-6836-3p A liver cancer detection kit containing nucleic acids that can specifically bind to rheotides.

[0029] (2) miR-1343-3p is hsa-miR-1343-3p, and miR-67 26-5p is hsa-miR-6726-5p, and miR-6515-3p is hsa -miR-6515-3p, and miR-4651 is hsa-miR-4651. miR-4257 is hsa-miR-4257, and miR-3188 is hsa-m iR-3188, miR-6131 is hsa-miR-6131, miR- 6766-3p is hsa-miR-6766-3p, and miR-7641 is hsa- miR-7641 is hsa-miR-1249, and miR -3679-3p is hsa-miR-3679-3p, and miR-6787-5p is hsa-miR-6787-5p, and miR-4454 is hsa-miR-4454 Therefore, miR-3135b is hsa-miR-3135b, and miR-6765- 3p is hsa-miR-6765-3p, and miR-7975 is hsa-miR-7 975, and miR-204-3p is hsa-miR-204-3p, and miR- 7977 is hsa-miR-7977, and miR-7110-5p is hsa-miR -7110-5p, and miR-6717-5p is hsa-miR-6717-5p Yes, miR-6870-5p is hsa-miR-6870-5p, and miR-66 3b is hsa-miR-663b, and miR-6875-5p is hsa-miR-6 875-5p, miR-8072 is hsa-miR-8072, miR-6 816-5p is hsa-miR-6816-5p, and miR-4281 is hsa-m iR-4281 and miR-6729-5p are hsa-miR-6729-5p Therefore, miR-8069 is hsa-miR-8069, and miR-4706 is hsa- It is miR-4706, and miR-7108-5p is hsa-miR-7108-5p Yes, miR-4433b-3p is hsa-miR-4433b-3p, and miR- 6893-5p is hsa-miR-6893-5p, and miR-6857-5p is h sa-miR-6857-5p is hsa-miR-12 27-5p is, and miR-6741-5p is hsa-miR-6741-5p, miR-451a is hsa-miR-451a, and miR-8063 is hsa-mi It is R-8063, and miR-3622a-5p is hsa-miR-3622a-5p Yes, miR-615-5p is hsa-miR-615-5p, and miR-128- 1-5p is hsa-miR-128-1-5p, and miR-6825-5p is hsa -miR-6825-5p, and miR-1260b is hsa-miR-1260b Yes, miR-4433-3p is hsa-miR-4433-3p, and miR-46 65-5p is hsa-miR-4665-5p, and miR-7845-5p is hsa -miR-7845-5p, and miR-1908-5p is hsa-miR-1908 -5p, and miR-6840-3p is hsa-miR-6840-3p, mi R-6765-5p is hsa-miR-6765-5p, and miR-296-5p is hsa-miR-296-5p is hsa-miR-3675-3p is hsa-miR-36 75-3p, and miR-6781-5p is hsa-miR-6781-5p, miR-423-5p is hsa-miR-423-5p, and miR-3663-3p hsa-miR-3663-3p and miR-6784-5p is hsa-miR- 6784-5p, and miR-6749-5p is hsa-miR-6749-5p. Therefore, miR-1231 is hsa-miR-1231, and miR-4746-3p is h sa-miR-4746-3p and miR-6780b-5p is hsa-miR-6 It is 780b-5p, and miR-4758-5p is hsa-miR-4758-5p. Therefore, miR-3679-5p is hsa-miR-3679-5p, and miR-318 4-5p is hsa-miR-3184-5p, and miR-6125 is hsa-miR It is -6125, and miR-6721-5p is hsa-miR-6721-5p, miR-6791-5p is hsa-miR-6791-5p, and miR-3185 is It is hsa-miR-3185, and miR-1260a is hsa-miR-1260a. Yes, miR-3197 is hsa-miR-3197, and miR-6845-5p is hsa-miR-6845-5p is hsa-miR-6887-5p is hsa-miR-6 887-5p, and miR-6738-5p is hsa-miR-6738-5p. miR-6872-3p is hsa-miR-6872-3p, and miR-4497 hsa-miR-4497 and miR-1229-5p is hsa-miR-122 9-5p, and miR-6820-5p is hsa-miR-6820-5p, m iR-6777-5p is hsa-miR-6777-5p, and miR-3917 is h sa-miR-3917 is hsa-miR-5787, miR-4286 is hsa-miR-4286, and miR-6877-5p is hsa -miR-6877-5p, and miR-1225-3p is hsa-miR-1225 -3p, miR-6088 is hsa-miR-6088, miR-6800 -5p is hsa-miR-6800-5p, and miR-1246 is hsa-miR- 1246, miR-4467 is hsa-miR-4467, and miR-441 9b is hsa-miR-4419b, and miR-1914-3p is hsa-miR- 1914-3p, and miR-4632-5p is hsa-miR-4632-5p. Therefore, miR-1915-5p is hsa-miR-1915-5p, and miR-394 0-5p are hsa-miR-3940-5p, and miR-1185-2-3p are hs a-miR-1185-2-3p and miR-6746-5p is hsa-miR-6 746-5p, and miR-5001-5p is hsa-miR-5001-5p. miR-1228-5p is hsa-miR-1228-5p, and miR-5572 This is hsa-miR-5572, and miR-4327 is hsa-miR-4327. Therefore, miR-4638-5p is hsa-miR-4638-5p, and miR-679 9-5p is hsa-miR-6799-5p, and miR-6861-5p is hsa- miR-6861-5p and miR-6727-5p is hsa-miR-6727- 5p, miR-4513 is hsa-miR-4513, miR-6805- 3p is hsa-miR-6805-3p, and miR-6808-5p is hsa-mi It is R-6808-5p, and miR-4449 is hsa-miR-4449, mi R-1199-5p is hsa-miR-1199-5p, and miR-1275 is hs a-miR-1275, miR-4792 is hsa-miR-4792, m iR-4443 is hsa-miR-4443, and miR-6891-5p is hsa- miR-6891-5p is miR-6826-5p is hsa-miR-6826- It is 5p, and miR-6807-5p is hsa-miR-6807-5p, and miR -7150 is hsa-miR-7150, and miR-4534 is hsa-miR-4 534, miR-4476 is hsa-miR-4476, and miR-4649 -5p is hsa-miR-4649-5p, and miR-4525 is hsa-miR- 4525, and miR-1915-3p is hsa-miR-1915-3p, m iR-4516 is hsa-miR-4516, and miR-4417 is hsa-miR It is -4417, and miR-642b-3p is hsa-miR-642b-3p, miR-3141 is hsa-miR-3141, and miR-5100 is hsa-mi It is R-5100, and miR-6848-5p is hsa-miR-6848-5p. miR-4739 is hsa-miR-4739, and miR-4459 is hsa-m iR-4459 and miR-1237-5p is hsa-miR-1237-5p Therefore, miR-296-3p is hsa-miR-296-3p, and miR-4665- 3p is hsa-miR-4665-3p, and miR-6786-5p is hsa-mi It is R-6786-5p, and miR-4258 is hsa-miR-4258, mi R-6510-5p is hsa-miR-6510-5p, and miR-1343-5p hsa-miR-1343-5p and miR-1247-3p is hsa-miR- 1247-3p, and miR-6805-5p is hsa-miR-6805-5p. Therefore, miR-4492 is hsa-miR-4492, and miR-1469 is hsa- miR-1469 is hsa-miR-1268b, and m iR-6858-5p is hsa-miR-6858-5p, and miR-3937 is h sa-miR-3937 and miR-939-5p is hsa-miR-939-5p Therefore, miR-3656 is hsa-miR-3656, and miR-744-5p is hsa-miR-744-5p and miR-4687-3p is hsa-miR-46 87-3p, and miR-4763-3p is hsa-miR-4763-3p, miR-3620-5p is hsa-miR-3620-5p, and miR-3195 is hsa-miR-3195 is hsa-miR-6842-5p is hsa-miR-6842 -5p, and miR-4707-5p is hsa-miR-4707-5p, mi R-642a-3p is hsa-miR-642a-3p, and miR-7113-3p hsa-miR-7113-3p and miR-4728-5p is hsa-miR- 4728-5p, and miR-5195-3p is hsa-miR-5195-3p. Therefore, miR-1185-1-3p is hsa-miR-1185-1-3p, and miR -6774-5p is hsa-miR-6774-5p, and miR-8059 is hsa -miR-8059, and miR-3131 is hsa-miR-3131, mi R-7847-3p is hsa-miR-7847-3p, and miR-4463 is hs a-miR-4463 is and miR-128-2-5p is hsa-miR-128-2 -5p, miR-4508 is hsa-miR-4508, and miR-6806 -5p is hsa-miR-6806-5p, and miR-7111-5p is hsa-m iR-7111-5p and miR-6782-5p are hsa-miR-6782-5 p is, miR-4734 is hsa-miR-4734, and miR-3162-5 p is hsa-miR-3162-5p, and miR-887-3p is hsa-miR- 887-3p, and miR-6752-5p is hsa-miR-6752-5p. miR-6724-5p is hsa-miR-6724-5p, and miR-6757 -5p is hsa-miR-6757-5p, and miR-4448 is hsa-miR- 4448, and miR-671-5p is hsa-miR-671-5p, miR -3178 is hsa-miR-3178, and miR-4725-3p is hsa-mi It is R-4725-3p, and miR-940 is hsa-miR-940, and miR- 6789-5p is hsa-miR-6789-5p, and miR-4484 is hsa- miR-4484 is hsa-miR-4634, and miR -4745-5p is hsa-miR-4745-5p, and miR-4730 is hsa -miR-4730, and miR-6803-5p is hsa-miR-6803-5p Therefore, miR-6798-5p is hsa-miR-6798-5p, and miR-3 648 is hsa-miR-3648, and miR-4783-3p is hsa-miR- 4783-3p, and miR-6836-3p is hsa-miR-6836-3 The kit described in (1), which is p.

[0030] (3) The nucleic acid is a polynucleotide as shown in (a) to (e) below: (a) A base sequence represented by any of SEQ ID NOs. 1-167 and 714-729 or A polynucleotide consisting of a base sequence in which u is t, a variant thereof, Derivatives, or fragments thereof containing 15 or more consecutive bases, (b) Poly nucleotide, (c) A base sequence represented by any of SEQ ID NOs. 1-167 and 714-729 or A polynucleotide consisting of a base sequence complementary to the base sequence in which u is t. , its variants, its derivatives, or its fragments containing 15 or more consecutive bases, (d) A base sequence represented by any of SEQ ID NOs. 1-167 and 714-729 or A polynucleotide containing a nucleotide sequence complementary to the nucleotide sequence in which u is t, and (e) With any of the polynucleotides from (a) to (d) above under stringent conditions A hybridized polynucleotide, The kit according to (1) or (2), which is a polynucleotide selected from the group consisting of the following.

[0031] (4) The kit contains other liver cancer markers, miR-23b-3p, miR-2 3a-3p, miR-625-3p, miR-1228-3p, miR-614, miR -1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3 From the group consisting of p, miR-92b-5p, miR-92a-3p, and miR-663a Further comprising at least one selected polynucleotide and nucleic acids that can specifically bind to it. Hmm, a kit as described in any of (1) to (3).

[0032] (5) miR-23b-3p is hsa-miR-23b-3p, and miR-23a- 3p is hsa-miR-23a-3p, and miR-625-3p is hsa-miR- 625-3p, and miR-1228-3p is hsa-miR-1228-3p. miR-614 is hsa-miR-614, and miR-1913 is hsa-miR -1913, and miR-92a-2-5p is hsa-miR-92a-2-5p Therefore, miR-187-5p is hsa-miR-187-5p, and miR-16-5p hsa-miR-16-5p and miR-92b-3p are hsa-miR-92b -3p, and miR-150-3p is hsa-miR-150-3p, and miR- 564 is hsa-miR-564, and miR-125a-3p is hsa-miR-1 25a-3p, and miR-92b-5p is hsa-miR-92b-5p, m iR-92a-3p is hsa-miR-92a-3p, and miR-663a is The kit described in (4) is hsa-miR-663a.

[0033] (6) The nucleic acid is a polynucleotide as shown in (f) to (j) below: (f) A base sequence represented by any of sequence numbers 168 to 183 or the said base sequence A polynucleotide consisting of a base sequence in which u is t, its variants, its derivatives, or 1 The fragment containing 5 or more consecutive bases, (g) Polynucleotides containing a base sequence represented by any of sequence numbers 168-183, (h) A base sequence represented by any of sequence numbers 168-183 or the said base sequence A polynucleotide consisting of a base sequence complementary to the base sequence where u is t, and its variants. Its derivative, or a fragment thereof containing 15 or more consecutive bases, (i) A base sequence represented by any of sequence numbers 168 to 183 or the said base sequence A polynucleotide containing a base sequence complementary to the base sequence in which u is t, and (j) With any of the polynucleotides in (f) to (i) above under stringent conditions A hybridized polynucleotide, The kit according to (4) or (5), which is a polynucleotide selected from the group consisting of the following.

[0034] (7) The kit contains other liver cancer markers, miR-4688, miR-464 8, miR-6085, miR-6126, miR-6880-5p, miR-328- 5p, miR-6768-5p, miR-3180, miR-6087, miR-127 3g-3p, miR-1225-5p, miR-3196, miR-4695-5p, m iR-6732-5p, miR-638, miR-6813-5p, miR-665, m iR-486-3p, miR-4466, miR-30c-1-3p, miR-3621 , miR-6743-5p, miR-4298, miR-4741, miR-3619- 3p, miR-6824-5p, miR-5698, miR-371a-5p, miR- 4488, miR-1233-5p, miR-4723-5p, miR-24-3p, m iR-1238-5p, miR-4442, miR-3928-3p, miR-6716 -5p, miR-6089, miR-6124, miR-6778-5p, miR-55 At least one polynucleotide selected from the group consisting of 7 and miR-6090 A kit according to any one of (1) to (6), further comprising nucleic acids that can specifically bind to the drug.

[0035] (8) miR-4688 is hsa-miR-4688, and miR-4648 is hsa -miR-4648, and miR-6085 is hsa-miR-6085, mi R-6126 is hsa-miR-6126, and miR-6880-5p is hsa-m iR-6880-5p and miR-328-5p are hsa-miR-328-5p Yes, miR-6768-5p is hsa-miR-6768-5p, and miR-31 80 is hsa-miR-3180, and miR-6087 is hsa-miR-6087 Therefore, miR-1273g-3p is hsa-miR-1273g-3p, and miR -1225-5p is hsa-miR-1225-5p, and miR-3196 is hsa -miR-3196, and miR-4695-5p is hsa-miR-4695-5p Therefore, miR-6732-5p is hsa-miR-6732-5p, and miR-6 38 is hsa-miR-638, and miR-6813-5p is hsa-miR-68 13-5p, miR-665 is hsa-miR-665, and miR-486- 3p is hsa-miR-486-3p, and miR-4466 is hsa-miR-44 66, and miR-30c-1-3p is hsa-miR-30c-1-3p, m iR-3621 is hsa-miR-3621, and miR-6743-5p is hsa- It is miR-6743-5p, and miR-4298 is hsa-miR-4298, miR-4741 is hsa-miR-4741, and miR-3619-3p is hsa -miR-3619-3p and miR-6824-5p is hsa-miR-6824 -5p, miR-5698 is hsa-miR-5698, and miR-371a -5p is hsa-miR-371a-5p, and miR-4488 is hsa-miR- 4488, and miR-1233-5p is hsa-miR-1233-5p, m iR-4723-5p is hsa-miR-4723-5p, and miR-24-3p is hsa-miR-24-3p and miR-1238-5p is hsa-miR-123 8-5p, miR-4442 is hsa-miR-4442, miR-392 8-3p is hsa-miR-3928-3p, and miR-6716-5p is hsa- miR-6716-5p, and miR-6089 is hsa-miR-6089. miR-6124 is hsa-miR-6124, and miR-6778-5p is hsa -miR-6778-5p, and miR-557 is hsa-miR-557, and The kit described in (7) is the same as the hsa-miR-6090.

[0036] (9) The nucleic acid is a polynucleotide as shown in (k) to (o) below: (k) A base sequence represented by any of sequence numbers 184-224 or the said base sequence A polynucleotide consisting of a base sequence in which u is t, its variants, its derivatives, or 1 The fragment containing 5 or more consecutive bases, (l) Polynucleotides containing a base sequence represented by any of sequence numbers 184-224, (m) A base sequence represented by any of sequence numbers 184-224 or the said base sequence A polynucleotide consisting of a base sequence complementary to the base sequence where u is t, and its variants. Its derivative, or a fragment thereof containing 15 or more consecutive bases, (n) A base sequence represented by any of sequence numbers 184 to 224 or the said base sequence A polynucleotide containing a base sequence complementary to the base sequence in which u is t, and (o) With any of the polynucleotides (k) to (n) above under stringent conditions A hybridized polynucleotide, The kit according to (7) or (8), which is a polynucleotide selected from the group consisting of the following.

[0037] (10) The kit is selected from all liver cancer markers described in (1) or (2) At least two polynucleotides that can specifically bind to each of them A kit containing two or more nucleic acids, as described in any of (1) to (9).

[0038] (11) Liver cancer markers, miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, m iR-6131, miR-6766-3p, miR-7641, miR-1249, mi R-3679-3p, miR-6787-5p, miR-4454, miR-3135b , miR-6765-3p, miR-7975, miR-204-3p, miR-797 7, miR-7110-5p, miR-6717-5p, miR-6870-5p, mi R-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, m iR-7108-5p, miR-4433b-3p, miR-6893-5p, miR- 6857-5p, miR-1227-5p, miR-6741-5p, miR-451a , miR-8063, miR-3622a-5p, miR-615-5p, miR-12 8-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p , miR-4665-5p, miR-7845-5p, miR-1908-5p, miR -6840-3p, miR-6765-5p, miR-296-5p, miR-3675 -3p, miR-6781-5p, miR-423-5p, miR-3663-3p, m iR-6784-5p, miR-6749-5p, miR-1231, miR-4746 -3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p miR-3184-5p miR-6125 miR-6721-5p miR-67 91-5p, miR-3185, miR-1260a, miR-3197, miR-68 45-5p, miR-6887-5p, miR-6738-5p, miR-6872-3 p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6 777-5p, miR-3917, miR-5787, miR-4286, miR-68 77-5p, miR-1225-3p, miR-6088, miR-6800-5p, m iR-1246, miR-4467, miR-4419b, miR-1914-3p, m iR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1 185-2-3p, miR-6746-5p, miR-5001-5p, miR-122 8-5p, miR-5572, miR-4327, miR-4638-5p, miR-6 799-5p, miR-6861-5p, miR-6727-5p, miR-4513 miR-6805-3p, miR-6808-5p, miR-4449, miR-119 9-5p, miR-1275, miR-4792, miR-4443, miR-6891 -5p, miR-6826-5p, miR-6807-5p, miR-7150, miR -4534、miR-4476、miR-4649-5p、miR-4525、miR- 1915-3p, miR-4516, miR-4417, miR-642b-3p, mi R-3141, miR-5100, miR-6848-5p, miR-4739, miR -4459, miR-1237-5p, miR-296-3p, miR-4665-3p , miR-6786-5p, miR-4258, miR-6510-5p, miR-13 43-5p, miR-1247-3p, miR-6805-5p, miR-4492, m iR-1469, miR-1268b, miR-6858-5p, miR-3937, m iR-939-5p, miR-3656, miR-744-5p, miR-4687-3 p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6 842-5p, miR-4707-5p, miR-642a-3p, miR-7113- 3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p , miR-6774-5p, miR-8059, miR-3131, miR-7847- 3p, miR-4463, miR-128-2-5p, miR-4508, miR-68 06-5p, miR-7111-5p, miR-6782-5p, miR-4734, m iR-3162-5p, miR-887-3p, miR-6752-5p, miR-67 24-5p, miR-6757-5p, miR-4448, miR-671-5p, mi R-3178, miR-4725-3p, miR-940, miR-6789-5p, m iR-4484, miR-4634, miR-4745-5p, miR-4730, mi R-6803-5p, miR-6798-5p, miR-3648, miR-4783- At least one polynucleus selected from the group consisting of 3p and miR-6836-3p A device for detecting liver cancer, containing nucleic acids that can specifically bind to creotides.

[0039] (12) miR-1343-3p is hsa-miR-1343-3p, and miR-6 726-5p is hsa-miR-6726-5p, and miR-6515-3p is hs a-miR-6515-3p and miR-4651 is hsa-miR-4651. Therefore, miR-4257 is hsa-miR-4257, and miR-3188 is hsa- miR-3188 is hsa-miR-6131, and miR -6766-3p is hsa-miR-6766-3p, and miR-7641 is hsa -miR-7641, and miR-1249 is hsa-miR-1249, mi R-3679-3p is hsa-miR-3679-3p, and miR-6787-5p hsa-miR-6787-5p and miR-4454 is hsa-miR-445 4, and miR-3135b is hsa-miR-3135b, and miR-6765 -3p is hsa-miR-6765-3p, and miR-7975 is hsa-miR- 7975, and miR-204-3p is hsa-miR-204-3p, and miR -7977 is hsa-miR-7977, and miR-7110-5p is hsa-mi R-7110-5p is the same as miR-6717-5p, and hsa-miR-6717-5p is the same as miR-6717-5p. Therefore, miR-6870-5p is hsa-miR-6870-5p, and miR-6 63b is hsa-miR-663b, and miR-6875-5p is hsa-miR- 6875-5p, miR-8072 is hsa-miR-8072, miR- 6816-5p is hsa-miR-6816-5p, and miR-4281 is hsa- miR-4281 and miR-6729-5p are hsa-miR-6729-5p Yes, miR-8069 is hsa-miR-8069, and miR-4706 is hsa -miR-4706, and miR-7108-5p is hsa-miR-7108-5p Therefore, miR-4433b-3p is hsa-miR-4433b-3p, and miR -6893-5p is hsa-miR-6893-5p, and miR-6857-5p is hsa-miR-6857-5p is hsa-miR-1 227-5p, and miR-6741-5p is hsa-miR-6741-5p. miR-451a is hsa-miR-451a, and miR-8063 is hsa-m iR-8063 is the same as miR-3622a-5p, which is hsa-miR-3622a-5p Therefore, miR-615-5p is hsa-miR-615-5p, and miR-128 -1-5p is hsa-miR-128-1-5p, and miR-6825-5p is hs a-miR-6825-5p and miR-1260b are hsa-miR-1260b Therefore, miR-4433-3p is hsa-miR-4433-3p, and miR-4 665-5p is hsa-miR-4665-5p, and miR-7845-5p is hs a-miR-7845-5p and miR-1908-5p is hsa-miR-190 8-5p, and miR-6840-3p is hsa-miR-6840-3p, m iR-6765-5p is hsa-miR-6765-5p, and miR-296-5p hsa-miR-296-5p and miR-3675-3p are hsa-miR-3 675-3p, and miR-6781-5p is hsa-miR-6781-5p. miR-423-5p is hsa-miR-423-5p, and miR-3663-3 p is hsa-miR-3663-3p, and miR-6784-5p is hsa-miR -6784-5p, and miR-6749-5p is hsa-miR-6749-5p Yes, miR-1231 is hsa-miR-1231, and miR-4746-3p is hsa-miR-4746-3p and miR-6780b-5p is hsa-miR- It is 6780b-5p, and miR-4758-5p is hsa-miR-4758-5p. Yes, miR-3679-5p is hsa-miR-3679-5p, and miR-31 84-5p is hsa-miR-3184-5p, and miR-6125 is hsa-mi It is R-6125, and miR-6721-5p is hsa-miR-6721-5p. miR-6791-5p is hsa-miR-6791-5p, and miR-3185 HSA-MIR-3185 is HSA-MIR-3185, and MIR-1260A is HSA-MIR-1260A. Therefore, miR-3197 is hsa-miR-3197, and miR-6845-5p hsa-miR-6845-5p and miR-6887-5p is hsa-miR- 6887-5p, and miR-6738-5p is hsa-miR-6738-5p. Therefore, miR-6872-3p is hsa-miR-6872-3p, and miR-449 7 is hsa-miR-4497, and miR-1229-5p is hsa-miR-12 29-5p is, and miR-6820-5p is hsa-miR-6820-5p, miR-6777-5p is hsa-miR-6777-5p, and miR-3917 is hsa-miR-3917 and miR-5787 is hsa-miR-5787. miR-4286 is hsa-miR-4286, and miR-6877-5p is hs a-miR-6877-5p and miR-1225-3p is hsa-miR-122 5-3p, miR-6088 is hsa-miR-6088, miR-680 0-5p is hsa-miR-6800-5p, and miR-1246 is hsa-miR -1246, miR-4467 is hsa-miR-4467, miR-44 19b is hsa-miR-4419b, and miR-1914-3p is hsa-miR -1914-3p, and miR-4632-5p is hsa-miR-4632-5p Yes, miR-1915-5p is hsa-miR-1915-5p, and miR-39 40-5p is hsa-miR-3940-5p, and miR-1185-2-3p is h sa-miR-1185-2-3p and miR-6746-5p is hsa-miR- 6746-5p, and miR-5001-5p is hsa-miR-5001-5p. Therefore, miR-1228-5p is hsa-miR-1228-5p, and miR-557 2 is hsa-miR-5572, and miR-4327 is hsa-miR-4327. Yes, miR-4638-5p is hsa-miR-4638-5p, and miR-67 99-5p is hsa-miR-6799-5p, and miR-6861-5p is hsa -miR-6861-5p, and miR-6727-5p is hsa-miR-6727 -5p, miR-4513 is hsa-miR-4513, miR-6805 -3p is hsa-miR-6805-3p, and miR-6808-5p is hsa-m iR-6808-5p, miR-4449 is hsa-miR-4449, m iR-1199-5p is hsa-miR-1199-5p, and miR-1275 is h sa-miR-1275 and miR-4792 is hsa-miR-4792, miR-4443 is hsa-miR-4443, and miR-6891-5p is hsa -miR-6891-5p, and miR-6826-5p is hsa-miR-6826 -5p, and miR-6807-5p is hsa-miR-6807-5p, mi R-7150 is hsa-miR-7150, and miR-4534 is hsa-miR- 4534, miR-4476 is hsa-miR-4476, and miR-464 9-5p is hsa-miR-4649-5p, and miR-4525 is hsa-miR It is -4525, and miR-1915-3p is hsa-miR-1915-3p, miR-4516 is hsa-miR-4516, and miR-4417 is hsa-mi It is R-4417, and miR-642b-3p is hsa-miR-642b-3p. miR-3141 is hsa-miR-3141, and miR-5100 is hsa-m iR-5100 and miR-6848-5p are hsa-miR-6848-5p Therefore, miR-4739 is hsa-miR-4739, and miR-4459 is hsa- It is miR-4459, and miR-1237-5p is hsa-miR-1237-5p Yes, miR-296-3p is hsa-miR-296-3p, and miR-4665 -3p is hsa-miR-4665-3p, and miR-6786-5p is hsa-m iR-6786-5p, miR-4258 is hsa-miR-4258, m iR-6510-5p is hsa-miR-6510-5p, and miR-1343-5 p is hsa-miR-1343-5p and miR-1247-3p is hsa-miR -1247-3p, and miR-6805-5p is hsa-miR-6805-5p Yes, miR-4492 is hsa-miR-4492, and miR-1469 is hsa -miR-1469 is hsa-miR-1268b, miR-6858-5p is hsa-miR-6858-5p, and miR-3937 is hsa-miR-3937 and miR-939-5p is hsa-miR-939-5 p, miR-3656 is hsa-miR-3656, and miR-744-5p hsa-miR-744-5p and miR-4687-3p are hsa-miR-4 687-3p, and miR-4763-3p is hsa-miR-4763-3p. miR-3620-5p is hsa-miR-3620-5p, and miR-3195 This is hsa-miR-3195, and miR-6842-5p is hsa-miR-684 2-5p, and miR-4707-5p is hsa-miR-4707-5p, m iR-642a-3p is hsa-miR-642a-3p, and miR-7113-3 p is hsa-miR-7113-3p, and miR-4728-5p is hsa-miR -4728-5p, and miR-5195-3p is hsa-miR-5195-3p Yes, miR-1185-1-3p is hsa-miR-1185-1-3p, and mi R-6774-5p is hsa-miR-6774-5p, and miR-8059 is hs a-miR-8059, miR-3131 is hsa-miR-3131, m iR-7847-3p is hsa-miR-7847-3p, and miR-4463 is h sa-miR-4463, and miR-128-2-5p is hsa-miR-128- 2-5p, miR-4508 is hsa-miR-4508, miR-680 6-5p is hsa-miR-6806-5p, and miR-7111-5p is hsa- miR-7111-5p and miR-6782-5p are hsa-miR-6782- 5p, miR-4734 is hsa-miR-4734, miR-3162- 5p is hsa-miR-3162-5p, and miR-887-3p is hsa-miR -887-3p, and miR-6752-5p is hsa-miR-6752-5p Therefore, miR-6724-5p is hsa-miR-6724-5p, and miR-675 7-5p is hsa-miR-6757-5p, and miR-4448 is hsa-miR -4448, and miR-671-5p is hsa-miR-671-5p, mi R-3178 is hsa-miR-3178, and miR-4725-3p is hsa-m iR-4725-3p, miR-940 is hsa-miR-940, miR -6789-5p is hsa-miR-6789-5p, and miR-4484 is hsa -miR-4484, and miR-4634 is hsa-miR-4634, mi R-4745-5p is hsa-miR-4745-5p, and miR-4730 is hs a-miR-4730 and miR-6803-5p is hsa-miR-6803-5 p is, miR-6798-5p is hsa-miR-6798-5p, and miR- 3648 is hsa-miR-3648, and miR-4783-3p is hsa-miR -4783-3p, and miR-6836-3p is hsa-miR-6836- The device described in (11), which is 3p.

[0040] (13) The nucleic acid is a polynucleotide as shown in (a) to (e) below: (a) A base sequence represented by any of SEQ ID NOs. 1-167 and 714-729 or A polynucleotide consisting of a base sequence in which u is t, a variant thereof, Derivatives, or fragments thereof containing 15 or more consecutive bases, (b) Poly nucleotide, (c) A base sequence represented by any of SEQ ID NOs. 1-167 and 714-729 or A polynucleotide consisting of a base sequence complementary to the base sequence in which u is t. , its variants, its derivatives, or its fragments containing 15 or more consecutive bases, (d) A base sequence represented by any of SEQ ID NOs. 1-167 and 714-729 or A polynucleotide containing a nucleotide sequence complementary to the nucleotide sequence in which u is t, and (e) With any of the polynucleotides from (a) to (d) above under stringent conditions A hybridized polynucleotide, A polynucleotide selected from the group consisting of (11) or (12), the deba A chair.

[0041] (14) The device is a different liver cancer marker, miR-23b-3p, miR -23a-3p, miR-625-3p, miR-1228-3p, miR-614, m iR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5 p, miR-92b-3p, miR-150-3p, miR-564, miR-125a A group consisting of -3p, miR-92b-5p, miR-92a-3p, and miR-663a. Nucleic acids that can specifically bind to at least one polynucleotide selected from the above A device included in any of (11) to (13).

[0042] (15) miR-23b-3p is hsa-miR-23b-3p, and miR-23a -3p is hsa-miR-23a-3p, and miR-625-3p is hsa-miR -625-3p, and miR-1228-3p is hsa-miR-1228-3p Therefore, miR-614 is hsa-miR-614, and miR-1913 is hsa-mi It is R-1913, and miR-92a-2-5p is hsa-miR-92a-2-5p Yes, miR-187-5p is hsa-miR-187-5p, and miR-16-5 p is hsa-miR-16-5p, and miR-92b-3p is hsa-miR-92 b-3p, miR-150-3p is hsa-miR-150-3p, miR -564 is hsa-miR-564, and miR-125a-3p is hsa-miR- 125a-3p, and miR-92b-5p is hsa-miR-92b-5p, miR-92a-3p is hsa-miR-92a-3p, and miR-663a The device described in (14) is hsa-miR-663a.

[0043] (16) The nucleic acid is a polynucleotide as shown in (f) to (j) below: (f) A base sequence represented by any of sequence numbers 168 to 183 or the said base sequence A polynucleotide consisting of a base sequence in which u is t, its variants, its derivatives, or 1 The fragment containing 5 or more consecutive bases, (g) Polynucleotides containing a base sequence represented by any of sequence numbers 168-183, (h) A base sequence represented by any of sequence numbers 168-183 or the said base sequence A polynucleotide consisting of a base sequence complementary to the base sequence where u is t, and its variants. Its derivative, or a fragment thereof containing 15 or more consecutive bases, (i) A base sequence represented by any of sequence numbers 168 to 183 or the said base sequence A polynucleotide containing a base sequence complementary to the base sequence in which u is t, and (j) With any of the polynucleotides in (f) to (i) above under stringent conditions A hybridized polynucleotide, A polynucleotide selected from the group consisting of (14) or (15), the deba A chair.

[0044] (17) The device is a different liver cancer marker, miR-4688, miR-4 648, miR-6085, miR-6126, miR-6880-5p, miR-32 8-5p, miR-6768-5p, miR-3180, miR-6087, miR-1 273g-3p, miR-1225-5p, miR-3196, miR-4695-5p , miR-6732-5p, miR-638, miR-6813-5p, miR-665 , miR-486-3p, miR-4466, miR-30c-1-3p, miR-36 21, miR-6743-5p, miR-4298, miR-4741, miR-361 9-3p, miR-6824-5p, miR-5698, miR-371a-5p, mi R-4488, miR-1233-5p, miR-4723-5p, miR-24-3p , miR-1238-5p, miR-4442, miR-3928-3p, miR-67 16-5p, miR-6089, miR-6124, miR-6778-5p, miR- At least one polynucleate selected from the group consisting of 557 and miR-6090 The claims of any one of (11) to (16), further comprising nucleic acids that can specifically bind to ochide. device.

[0045] (18) miR-4688 is hsa-miR-4688, and miR-4648 is hs a-miR-4648, miR-6085 is hsa-miR-6085, m iR-6126 is hsa-miR-6126, and miR-6880-5p is hsa- miR-6880-5p is the same as miR-328-5p, and hsa-miR-328-5p is the same as miR-6880-5p. Therefore, miR-6768-5p is hsa-miR-6768-5p, and miR-3 180 is hsa-miR-3180, and miR-6087 is hsa-miR-608 7, and miR-1273g-3p is hsa-miR-1273g-3p, mi R-1225-5p is hsa-miR-1225-5p, and miR-3196 is hs a-miR-3196 and miR-4695-5p is hsa-miR-4695-5 p is, miR-6732-5p is hsa-miR-6732-5p, and miR- 638 is hsa-miR-638, and miR-6813-5p is hsa-miR-6 813-5p, miR-665 is hsa-miR-665, and miR-486 -3p is hsa-miR-486-3p, and miR-4466 is hsa-miR-4 It is 466, and miR-30c-1-3p is hsa-miR-30c-1-3p, miR-3621 is hsa-miR-3621, and miR-6743-5p is hsa -miR-6743-5p, and miR-4298 is hsa-miR-4298. miR-4741 is hsa-miR-4741, and miR-3619-3p is hs a-miR-3619-3p and miR-6824-5p is hsa-miR-682 4-5p, miR-5698 is hsa-miR-5698, miR-371 a-5p is hsa-miR-371a-5p, and miR-4488 is hsa-miR It is -4488, and miR-1233-5p is hsa-miR-1233-5p, miR-4723-5p is hsa-miR-4723-5p, and miR-24-3p hsa-miR-24-3p and miR-1238-5p is hsa-miR-12 38-5p, miR-4442 is hsa-miR-4442, miR-39 28-3p is hsa-miR-3928-3p, and miR-6716-5p is hsa -miR-6716-5p, and miR-6089 is hsa-miR-6089. miR-6124 is hsa-miR-6124, and miR-6778-5p is hs a-miR-6778-5p, and miR-557 is hsa-miR-557. And, the device described in (17) where miR-6090 is hsa-miR-6090. .

[0046] (19) The nucleic acid is a polynucleotide as shown in (k) to (o) below: (k) A base sequence represented by any of sequence numbers 184-224 or the said base sequence A polynucleotide consisting of a base sequence in which u is t, its variants, its derivatives, or 1 The fragment containing 5 or more consecutive bases, (l) Polynucleotides containing a base sequence represented by any of sequence numbers 184-224, (m) A base sequence represented by any of sequence numbers 184-224 or the said base sequence A polynucleotide consisting of a base sequence complementary to the base sequence where u is t, and its variants. Its derivative, or a fragment thereof containing 15 or more consecutive bases, (n) A base sequence represented by any of sequence numbers 184 to 224 or the said base sequence A polynucleotide containing a base sequence complementary to the base sequence in which u is t, and (o) With any of the polynucleotides (k) to (n) above under stringent conditions A hybridized polynucleotide, A polynucleotide selected from the group consisting of (17) or (18), the deba A chair.

[0047] (20) The device is a device for measurement by hybridization technology. A device as described in any of (11) to (19).

[0048] (21) The hybridization technology is nucleic acid array technology as described in (20) device.

[0049] (22) The device is selected from all liver cancer markers described in (11) or (12) A small number of polynucleotides that can specifically bind to each of at least two selected polynucleotides. A device according to any one of (11) to (21), comprising at least two nucleic acids.

[0050] (23)A kit as described in any of (1) to (10) or any of (11) to (22) Using the device described above, the expression level of the target nucleic acid in the subject's sample is measured, and the measured Using the measured expression levels and the control expression levels of healthy individuals, the study investigated the effects of liver cancer in subjects. To evaluate in vitro whether or not a patient has the disease, or whether or not they have liver cancer. A method for detecting liver cancer, including [details omitted].

[0051] (24) The method according to (23), wherein the subject is a human. (25) The method according to (23) or (24), wherein the specimen is blood, serum, or plasma.

[0052] <Definition of Terms> The terms used herein have the following definitions: Abbreviations such as nucleotide, polynucleotide, DNA, and RNA are used to represent "base pairings." Guidelines for the Preparation of Specifications Including Columns or Amino Acid Sequences (edited by the Japan Patent Office) and The practice shall follow the conventions of the relevant technical field.

[0053] In this specification, "polynucleotide" means RNA, DNA, and RNA / DNA ( It is used for nucleic acids that include all of the following (chimeric): This includes both genomic DNA and synthetic DNA. Furthermore, the above RNA includes tota l RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA This includes both non-coding RNA and synthetic RNA. In this specification, "synthetic DNA" and "synthetic RNA" refer to a predetermined base sequence (natural type sequence). It may be either a natural or non-natural sequence. Based on this, for example, using an automated nucleic acid synthesizer, human artificially produced DNA and RNA are referred to. In this specification, "non-natural sequence" is intended to be used in a broad sense, and includes sequences different from natural sequences, such as sequences containing substitutions, deletions, insertions and / or additions of one or more nucleotides (i.e., mutant sequences), sequences containing one or more modified nucleotides (i.e., modified sequences), etc. Also, in this specification, polynucleotides are used interchangeably with nucleic acids.

[0054] In this specification, a "fragment" is a polynucleotide having the base sequence of a continuous portion of a polynucleotide, and desirably has a length of 15 bases or more, preferably 17 bases or more, more preferably 1 9 bases or more.

[0055] In this specification, "gene" is used to include not only RNA and double-stranded DNA, but also each single-stranded DNA such as the positive strand (or sense strand) or complementary strand (or antisense strand) constituting them. It is not particularly limited by its length. Therefore, in this specification, "gene" includes double-stranded DNA containing human genomic DNA, single-stranded DNA (positive strand), single-stranded DNA having a sequence complementary to the positive strand

[0056] (complementary strand. including cDNA), microRNA (miRNA), and fragments thereof, as well as any of their transcripts. Also, the "gene" is not only the "gene" represented by a specific base sequence (or SEQ ID NO), but also RNA having the same biological function as the RNA encoded by these, such as homologs (i.e., homologs or orthologs), gene families and so on. are included. Also, the "gene" is not only the "gene" represented by a specific base sequence (or SEQ ID NO), but also RNA having the same biological function as the RNA encoded by these, such as homologs (i.e., homologs or orthologs), gene families This includes "nucleic acids" that encode variants and derivatives of such types. Specifically, the "nucleic acid" that codes for derivatives is the stringent described later. Under these conditions, a nucleotide sequence represented by any of sequence numbers 1 to 765, or a nucleotide sequence containing Nucleic acids are those that have a base sequence in which u is t, and a base sequence that hybridizes with the complementary sequence of u. One example is "...". Note that "gene" does not refer to a specific functional region, but rather, for example... This may include expression control regions, coding regions, exons, or introns. The "transmitter" may be contained within the cell, or it may be released outside the cell and exist independently. They may also be contained within vesicles called exosomes.

[0057] In this specification, "exosome" (also known as "exosome") refers to a substance secreted from a cell. Exosomes are vesicles enclosed in a lipid bilayer. Exosomes originate from multivesicular endosomes and are extracellular. When released into the environment, it contains internal biomolecules such as RNA, DNA, and proteins. It may be contained in. Exosomes are found in bodily fluids such as blood, serum, plasma, and lymph. It is known that...

[0058] In this specification, "transcript" refers to an RN synthesized using a gene's DNA sequence as a template. This refers to A. RNA polymerase is located in a region called the promoter, which is upstream of a gene. It binds to the DNA and attaches ribonucleotides to its 3' end so that it is complementary to the DNA base sequence. RNA is synthesized in this manner. This RNA contains not only the genes themselves, but also genes that regulate gene expression. From the transcription start site, including regions, coding regions, exons, or introns, the polyA sequence It includes the entire sequence, right down to the end.

[0059] Furthermore, in this specification, unless otherwise specified, "microRNA (miRNA)" means It is transcribed as a hairpin-like RNA precursor and possesses RNase III cleavage activity. It is cleaved by an sRNA-cleaving enzyme and incorporated into a protein complex called RISC, m It is intended to be used for non-coding RNAs of 15-25 nucleotides that are involved in the repression of RNA translation. Furthermore, the term "miRNA" as used herein is represented by a specific base sequence (or sequence number). Not only the "miRNA" itself, but also its precursor (pre-miRNA, p ri-miRNAs, and miRNAs with equivalent biological function, such as congeners. (i.e., homologs or orthologs), variants such as gene polymorphisms, and derivatives are also included. Includes. Such precursors, homologs, mutants, or derivatives include, specifically, miRBas e release 20 (http: / / www.mirbase.org / ) It can be identified, and under the stringent conditions described later, SEQ ID NOs 1-765 A base sequence that hybridizes with the complementary sequence of any of the specific base sequences represented by either of the following: The "miRNAs" that it possesses can be listed. Furthermore, the "miR" used in this specification "NA" may also be the gene product of the miR gene, and such a gene product is mature m iRNA (for example, 15-25 nucleotides involved in the translational repression of mRNA as described above, or 1 9-25 nucleotides non-coding RNA) or miRNA precursor (for example, as described above) This includes pre-miRNA or pri-miRNA.

[0060] In this specification, "probe" means RNA produced by gene expression or related thereto Polynucleotides used to specifically detect incoming polynucleotides and / or include polynucleotides complementary thereto.

[0061] As used herein, "primer" refers to a polynucleotide that specifically recognizes and amplifies RNA produced by gene expression or a polynucleotide derived therefrom and / or a polynucleotide complementary thereto. include polynucleotides complementary thereto.

[0062] Here, the complementary polynucleotide (complementary strand, reverse strand) refers to a polynucleotide having a base sequence defined by any of SEQ ID NOs: 1 to 765, or a base sequence in which u is t in the said base sequence, the full-length sequence of the polynucleotide consisting thereof, or a partial sequence thereof. (Here, for the sake of convenience, this is referred to as the sense strand). Based on the base pair relationship such as A:T(U), G:C with respect to the sense strand, it means a polynucleotide having a base complementary relationship. However, such a complementary strand is not limited to the case of forming a completely complementary sequence with the base sequence of the target sense strand, and may have a complementary relationship such that it can hybridize with the target sense strand under stringent conditions. Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. "

[0063] As used herein, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 10% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Here, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (for example, a measured value of the average of the background measurement value + 2 times the standard error of the background measurement value or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Specific examples of "stringent conditions" will be discussed later.

[0064] In this specification, "Tm value" refers to the state in which the double-stranded portion of a polynucleotide is denatured into a single-stranded portion. This refers to the temperature at which double-stranded and single-stranded fibers exist in a 1:1 ratio.

[0065] In this specification, "mutant" refers to a naturally occurring variant of nucleic acid resulting from polymorphism, mutation, etc. A variant of, or any of the base sequences of sequence numbers 1-765, or a sequence containing In a base sequence where u is t, or in a subsequence thereof, the deletion of one or more bases, Mutants including substitution, addition, or insertion, or each or a portion thereof of the said base sequence and about 90 Variants showing % identity of % or more, approximately 95% or more, approximately 97% or more, approximately 98% or more, approximately 99% or more A variant, or a polynucleotide or oligonucleotide containing the said base sequence or a partial sequence thereof. This refers to nucleic acids that hybridize with ocides under the stringent conditions defined above.

[0066] In this specification, “a number” means an integer of about 10, 9, 8, 7, 6, 5, 4, 3, or 2. It means...

[0067] In this specification, mutants are defined as mutants obtained using site-directed mutagenesis and PCR. It can be manufactured using well-known techniques such as the heterogeneous introduction method.

[0068] In this specification, "% identity" refers to the protein or Using a gene search system, with or without introducing gaps, It can be determined (Zheng Zhang et al., 2000, J.Comput.B) iol., Vol. 7, pp. 203-214; Altschul, SF et al., 1990, Jo Journal of Molecular Biology, Vol. 215, pp. 403-41 0; Pearson, WR et al., 1988, Proc. Natl. Acad. Sci (USA, Vol. 85, pp. 2444-2448).

[0069] In this specification, "derivative" means modified nucleic acids, and not limited to, for example, fluorophores. Bellated derivatives, modified nucleotides (e.g., halogens, alkyls such as methyl, methoxy) Reconstitution of nucleotides and bases containing alkoxy, thio, carboxymethyl, and other groups. nucleotides that have undergone processes such as double bond saturation, deamination, and substitution of oxygen molecules with sulfur molecules. Derivatives including (etc.), PNA (peptide adhesive acid; Niels en, PE et al., 1991, Science, Vol. 254, pp. 1497-500), L NA (locked nucleic acid; Obika, S. et al., 1998, This includes (Tetrahedron Lett., Vol. 39, pp. 5401-5404), etc. It means...

[0070] In this specification, a polynuclear selected from the group of miRNAs that are liver cancer markers described above. A "nucleic acid" that can specifically bind to a creotide is a synthesized or prepared nucleic acid, specifically This includes a "nucleic acid probe" or "primer" and detects the presence or absence of liver cancer in the subject. To do so, or to determine whether or not a person has liver cancer, the extent of the disease, and whether or not the liver cancer has improved or the degree of improvement. To diagnose the sensitivity to treatment for liver cancer, or for the prevention, improvement, or This is used directly or indirectly to screen for candidate substances useful for treatment. These are associated with the development of liver cancer and are present in the body, particularly in specimens of bodily fluids such as blood and urine. It specifically recognizes the transcript represented by one of the numbers 1 to 765 or its cDNA synthesis nucleic acid. Includes nucleotides, oligonucleotides, and polynucleotides that can bind together. These nucleotides, nucleotides, and polynucleotides possess the above properties. Based on this, a probe is used to detect the above-mentioned genes expressed in living organisms, tissues, or cells. Furthermore, it can be effectively used as a primer for amplifying the above-mentioned genes expressed in vivo. It is possible.

[0071] As used herein, the term "detection" refers to the use of the term to indicate an inspection, measurement, detection, or determination support. It can be replaced with other words. Also, in this specification, the term "evaluation" means inspection results or measurement results. It is used in a sense that includes supporting diagnosis or evaluation based on that.

[0072] As used herein, "subject" refers to humans, primates including chimpanzees, dogs, cats, etc. Any pet animal, livestock such as cows, horses, sheep, and goats, and rodents such as mice and rats It refers to mammals of this species. Furthermore, a "healthy body" is also a mammal of this type. This refers to animals that do not have the cancer being detected.

[0073] As used herein, "liver cancer" refers to "primary liver cancer," which originates in the liver. This means, for example, "hepatocellular carcinoma" in which liver cells become cancerous, and "mixed hepatocyte and cholangiocarcinoma" It shall include "ん".

[0074] As used herein, "P" or "P-value" refers to a statistical test under the null hypothesis. This indicates the probability of observing statistics that are more extreme than those actually calculated from the data. Therefore, the smaller the "P" or "P-value," the more significant the difference between the comparison groups can be considered.

[0075] In this specification, "sensitivity" is the value of (number of true positives) / (number of true positives + number of false negatives). This means that if the sensitivity is high, it will be possible to detect liver cancer at an early stage, and complete cancerous area This leads to a reduction in the rate of resection and recurrence.

[0076] In this specification, "specificity" means (number of true negatives) / (number of true negatives + number of false positives). It tastes good. If the specificity is high, it can lead to unnecessary additional tests due to misidentifying healthy individuals as liver cancer patients. This will prevent the implementation of certain practices, leading to reduced burdens on patients and lower medical costs.

[0077] In this specification, "accuracy" means the value of (number of true positives + number of true negatives) / (total number of cases). The accuracy indicates the percentage of all samples for which the classification result was correct, and the detection performance is evaluated. This will be the primary indicator.

[0078] In this specification, the term "specimen" that is subject to determination, detection, or diagnosis refers to the development of liver cancer, liver As organ cancer progresses and the therapeutic effect against liver cancer is exerted, the expression of the gene of the present invention changes. This refers to tissues and biomaterials that undergo transformation. Specifically, this includes liver tissue and its surrounding blood vessels, lymph nodes, and Organs, organs suspected of metastasis, skin, and bodily fluids such as blood, urine, saliva, sweat, and tissue exudate. This refers to serum, plasma, and other substances prepared from blood, such as feces and hair. Furthermore, extracts from these are also available. This refers to biological samples, specifically genes such as RNA and miRNA.

[0079] The term "hsa-miR-1343-3p gene" or "hsa-mi" used in this specification refers to the "hsa-mi" gene. The term "R-1343-3p" is used in the sequence number 1 of hsa-miR-1343-3. p gene (miRBase Accession No. MIMAT0019776) and This includes homologs or orthologs of other biological species. hsa-miR-1343- The 3p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71, p It can be obtained by the method described in 78-86. Also, "hsa-miR-13 "43-3p" has a hairpin-like structure as its precursor, "hsa-mir-1343". (miRBase Accession No. MI0017320, Sequence ID 225) It is known that...

[0080] The term "hsa-miR-6726-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6726-5p" is used in the sequence number 2 of hsa-miR-6726-5. p gene (miRBase Accession No. MIMAT0027353) and This includes homologs or orthologs of other biological species. hsa-miR-6726- The 5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22, p It can be obtained by the method described in 1634-1645. Also, "hsa-mi "R-6726-5p" has a hairpin-like structure as its precursor, "hsa-mir-6 726" (miRBase Accession No. MI0022571, Sequence ID) 226) is known.

[0081] The "hsa-miR-6515-3p gene" or "hsa-mi" used herein The term "R-6515-3p" is used in the sequence number 3 of hsa-miR-6515-3. p gene (miRBase Accession No. MIMAT0025487) and This includes homologs or orthologs of other biological species. hsa-miR-6515- The 3p gene was identified by Joyce CE et al., 2011, Hum Mol Genet, Vol. 20. It can be obtained by the method described on pages 4025-4040. Also, "hsa- "miR-6515-3p" has a hairpin-like structure as its precursor, "hsa-mir -6515 (miRBase Accession No.MI0022227, array) Number 227) is known.

[0082] The term "hsa-miR-4651 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4651 gene" used in this specification. The term "651" refers to the hsa-miR-4651 gene (miRB) described in Sequence ID No. 4. (Case Accession No. MIMAT0019715) and other biological species homologs It includes g or orthologs, etc. The hsa-miR-4651 gene is Perss Those described in on H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by law. Also, "hsa-miR-4651" is its precursor. The "hsa-mir-4651" (miRBase Access) has a hairpin-like structure. Ion No. MI0017279 (sequence number 228) is known.

[0083] The term "hsa-miR-4257 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4257 gene" used herein. The term "257" refers to the hsa-miR-4257 gene (miRB) described in Sequence ID No. 5. (Case Accession No. MIMAT0016878) and other biological species homologs It includes Goff or orthologs, etc. The hsa-miR-4257 gene is Goff The method described by LA et al., 2009, PLoS One, Vol. 4, e7192, is obtained It is possible. Also, "hsa-miR-4257" has a hairpin-like precursor. The structure is "hsa-mir-4257" (miRBase Accession No. .MI0015856 (sequence number 229) is known.

[0084] The term "hsa-miR-3188 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3188 gene" or "hsa-miR-3 The term "188" refers to the hsa-miR-3188 gene (miRB) described in Sequence ID No. 6. (Case Accession No. MIMAT0015070) and other biological species homologs It includes g or orthologs, etc. The hsa-miR-3188 gene is Stark By the method described in MS et al., 2010, PLoS One, Vol. 5, e9685 It can be obtained. Also, "hsa-miR-3188" is a hairpin as its precursor. "hsa-mir-3188" (miRBase Accession N) takes on a unique structure. o.MI0014232 (Sequence ID 230) is known.

[0085] The term "hsa-miR-6131 gene" or "hsa-miR-6" used in this specification refers to the "hsa-miR-6" gene. The term "131" refers to the hsa-miR-6131 gene (miRB) described in Sequence ID No. 7. (Case Accession No. MIMAT0024615) and other biological species homologs It includes g or orthologs, etc. The hsa-miR-6131 gene is Danne mann M et al., 2012, Genome Biol Evol, Vol. 4, pp. 552-555 It can be obtained by the method described in 64. Also, "hsa-miR-6131" Its precursor is "hsa-mir-6131" (miRBa Accession No. MI0021276, Sequence ID 231) is known. ru.

[0086] The "hsa-miR-6766-3p gene" or "hsa-mi" used in this specification The term "R-6766-3p" refers to hsa-miR-6766-3 as described in Sequence ID No. 8. p gene (miRBase Accession No. MIMAT0027433) and This includes homologs or orthologs of other biological species. hsa-miR-6766- The 3p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22, p It can be obtained by the method described in 1634-1645. Also, "hsa-mi "R-6766-3p" has a hairpin-like structure as its precursor, "hsa-mir-6 766" (miRBase Accession No. MI0022611, Sequence ID) 232) is known.

[0087] The term "hsa-miR-7641 gene" or "hsa-miR-7" as used herein refers to the "hsa-miR-7641 gene" used in this specification. The term "641" refers to the hsa-miR-7641 gene (miRB) described in Sequence ID No. 9. (Case Accession No. MIMAT0029782) and other species homologs It includes g or orthologs, etc. The hsa-miR-7641 gene is Yoo J K et al., 2013, Arch Pharm Res, Vol. 36, pp. 353-358. It can be obtained by the method described above. Also, "hsa-miR-7641" is its precursor. "hsa-mir-7641-1", "hsa-mir- 7641-2” (miRBase Accession No. MI0024975, M I0024976, SEQ ID NOs. 233 and 234 are known.

[0088] The term "hsa-miR-1249 gene" or "hsa-miR-1" as used herein refers to the "hsa-miR-1249 gene" used herein. The term "249" refers to the hsa-miR-1249 gene (miR) described in Sequence ID No. 10. Base Accession No. MIMAT0005901) and other species Homo morphology This includes log or orthologs. The hsa-miR-1249 gene is Mori n RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. It can be obtained by the following method. Furthermore, "hsa-miR-1249" is its precursor. "hsa-mir-1249" (miRBase Acce Scsion No. MI0006384 (Sequence No. 235) is known.

[0089] The "hsa-miR-3679-3p gene" or "hsa-mi" used in this specification The term "R-3679-3p" is used in the sequence number 11 of hsa-miR-3679- 3p gene (miRBase Accession No. MIMAT0018105) This includes homologs or orthologs of other biological species. hsa-miR-3679 -3p gene, Creighton CJ et al., 2010, PLoS One, Vol. 5, It can be obtained by the method described in e9637. Also, "hsa-miR-36 "79-3p" has a hairpin-like structure as its precursor, "hsa-mir-3679". (miRBase Accession No. MI0016080, Sequence ID 236) It is known that...

[0090] The term "hsa-miR-6787-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6787-5p" is used in the sequence number 12 of hsa-miR-6787- 5p gene (miRBase Accession No. MIMAT0027474) This includes homologs or orthologs of other biological species. hsa-miR-6787 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6787-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6787 (miRBase Accession No. MI0022632, Sequence Number) No. 237 is known.

[0091] The term "hsa-miR-4454 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "454" refers to the hsa-miR-4454 gene (miR) described in Sequence ID No. 13. Base Accession No. MIMAT0018976) and other species Homo morphology This includes log or orthologs. The hsa-miR-4454 gene is Jima The method described in DD et al., 2010, Blood, Vol. 116, e118-e127 Therefore, it can be obtained. Also, "hsa-miR-4454" is used as its precursor. "hsa-mir-4454" (miRBase Accessio) adopts an appin-like structure. The following is known: No.MI0016800 (Sequence ID 238).

[0092] The term "hsa-miR-3135b gene" or "hsa-miR-" used herein refers to the "hsa-miR-3135b gene" used herein. The term "3135b" refers to the hsa-miR-3135b gene described in Sequence ID No. 14. miRBase Accession No. MIMAT0018985) and other organisms This includes species homologs or orthologs. The hsa-miR-3135b gene is Jima DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by the following method. Also, "hsa-miR-3135b" is its precursor. The "hsa-mir-3135b" (miRBase Ac) has a hairpin-like structure as its body. Cession No. MI0016809 (Sequence No. 239) is known.

[0093] The "hsa-miR-6765-3p gene" or "hsa-mi" used in this specification The term "R-6765-3p" is used in the sequence number 15 of hsa-miR-6765- 3p gene (miRBase Accession No. MIMAT0027431) This includes homologs or orthologs of other biological species. hsa-miR-6765 -3p gene, Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m iR-6765-3p has a hairpin-like structure as its precursor, hsa-mir- 6765 (miRBase Accession No. MI0022610, Sequence Number) No. 240 is known.

[0094] The term "hsa-miR-7975 gene" or "hsa-miR-7" as used herein refers to the "hsa-miR-7975 gene" used herein. The term "975" refers to the hsa-miR-7975 gene (miR) described in Sequence ID No. 16. Base Accession No. MIMAT0031178) and other species Homo morphology This includes log or orthologs. The hsa-miR-7975 gene is Velt hut-Meikas A et al., 2013, Mol Endocrinol, online It can be obtained by the method described in the edition. Also, "hsa-miR-7975" Its precursor is "hsa-mir-7975" (miRBa Accession No. MI0025751, Sequence ID 241) is known. ru.

[0095] The term "hsa-miR-204-3p gene" or "hsa-miR" as used herein refers to the "hsa-miR" gene used in this specification. The term "-204-3p" refers to the hsa-miR-204-3p gene described in Sequence ID No. 17. The gene (miRBase Accession No.MIMAT0022693) and its This includes homologs or orthologs of other biological species. hsa-miR-204-3p The gene is described in Lim LP et al., 2003, Science, Vol. 299, p. 1540. It can be obtained by the method described. Also, "hsa-miR-204-3p" is "hsa-mir-204" (miRBase Ac), which takes on a hairpin-like structure as a precursor. Cession No. MI0000284 (Sequence No. 242) is known.

[0096] The term "hsa-miR-7977 gene" or "hsa-miR-7" as used herein refers to the "hsa-miR-7977 gene" used in this specification. The term "977" refers to the hsa-miR-7977 gene (miR) described in Sequence ID No. 18. Base Accession No. MIMAT0031180) and other species Homo morphology This includes log or orthologs. The hsa-miR-7977 gene is Velt hut-Meikas A et al., 2013, Mol Endocrinol, online It can be obtained by the method described in the edition. Also, "hsa-miR-7977" Its precursor is "hsa-mir-7977" (miRBa Accession No. MI0025753, Sequence ID 243) is known. ru.

[0097] The term "hsa-miR-7110-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-7110-5p" is used in the sequence number 19 of hsa-miR-7110- 5p gene (miRBase Accession No. MIMAT0028117) This includes homologs or orthologs of other biological species. hsa-miR-7110 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-7110-5p" has a hairpin-like structure as its precursor, "hsa-mir- 7110 (miRBase Accession No. MI0022961, Array No.) No. 244 is known.

[0098] The term "hsa-miR-6717-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-6717-5p" is used in the sequence number 20 of hsa-miR-6717- 5p gene (miRBase Accession No. MIMAT0025846) This includes homologs or orthologs of other biological species. hsa-miR-6717 The -5p gene is described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. It can be obtained by the method described. Also, "hsa-miR-6717-5p" is , and as its precursor, "hsa-mir-6717" (miRBas) takes on a hairpin-like structure. Accession No. MI0022551, Sequence ID 245 is known. .

[0099] The term "hsa-miR-6870-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6870-5p" is used in the description of hsa-miR-6870- in Sequence ID No. 21. 5p gene (miRBase Accession No. MIMAT0027640) This includes homologs or orthologs of other biological species. hsa-miR-6870 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m iR-6870-5p has a hairpin-like structure as its precursor, hsa-mir- 6870 (miRBase Accession No. MI0022717, Array No.) Number 246 is known.

[0100] The "hsa-miR-663b gene" or "hsa-miR-6" used in this specification The term "63b" refers to the hsa-miR-663b gene (miR) described in Sequence ID No. 22. Base Accession No. MIMAT0005867) and other species Homo morphology This includes log or orthologs. The hsa-miR-663b gene is Taka da S et al., 2008, Leukemia, Vol. 22, pp. 1274-1278. It can be obtained by the following method. Furthermore, "hsa-miR-663b" is its precursor. "hsa-mir-663b" (miRBase Acce Scsion No. MI0006336 (Sequence No. 247) is known.

[0101] The term "hsa-miR-6875-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6875-5p" is used in the description of hsa-miR-6875- in Sequence ID No. 23. 5p gene (miRBase Accession No. MIMAT0027650) This includes homologs or orthologs of other biological species. hsa-miR-6875 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6875-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6875 (miRBase Accession No. MI0022722, Array No.) Number 248 is known.

[0102] The terms "hsa-miR-8072 gene" or "hsa-miR-8" used herein refer to the "hsa-miR-8" gene used herein. The term "072" refers to the hsa-miR-8072 gene (miR) described in Sequence ID No. 24. Base Accession No. MIMAT0030999) and other species Homo morphology This includes log or orthologs. The hsa-miR-8072 gene is Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487, by the method described therein It can be obtained by [method]. In addition, "hsa-miR-8072" is a precursor of hair The "hsa-mir-8072" (miRBase Accession) has a n-like structure. No.MI0025908 (Sequence ID 249) is known.

[0103] The term "hsa-miR-6816-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6816-5p" is used in the sequence number 25 of hsa-miR-6816- 5p gene (miRBase Accession No. MIMAT0027532) This includes homologs or orthologs of other biological species. hsa-miR-6816 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6816-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6816 (miRBase Accession No. MI0022661, Sequence Number) No. 250 is known.

[0104] The terms "hsa-miR-4281 gene" or "hsa-miR-4" used herein refer to the "hsa-miR-4281 gene" used herein. The term "281" refers to the hsa-miR-4281 gene (miR) described in Sequence ID No. 26. Base Accession No. MIMAT0016907) and other species Homo morphology This includes log or orthologs. The hsa-miR-4281 gene is Goff By the method described in LA et al., 2009, PLoS One, Vol. 4, e7192 It can be obtained. Also, "hsa-miR-4281" is a hairpin as its precursor. The "hsa-mir-4281" (miRBase Accession N) has a unique structure. o.MI0015885 (Sequence ID 251) is known.

[0105] The term "hsa-miR-6729-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi The term "R-6729-5p" is used in the sequence number 27 of hsa-miR-6729- 5p gene (miRBase Accession No. MIMAT0027359) This includes homologs or orthologs of other biological species. hsa-miR-6729 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6729-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6729 (miRBase Accession No. MI0022574, Array No.) No. 252) is known.

[0106] The term "hsa-miR-8069 gene" or "hsa-miR-8" as used herein refers to the "hsa-miR-8" gene used in this specification. The term "069" refers to the hsa-miR-8069 gene (miR) described in Sequence ID No. 28. Base Accession No. MIMAT0030996) and other species Homo morphology This includes log or orthologs. The hsa-miR-8069 gene is Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487, by the method described therein It can be obtained by [method]. In addition, "hsa-miR-8069" is a precursor of hair "hsa-mir-8069" (miRBase Accession) takes on a n-like structure. No.MI0025905 (Sequence ID 253) is known.

[0107] The term "hsa-miR-4706 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "706" refers to the hsa-miR-4706 gene (miR) described in Sequence ID No. 29. Base Accession No. MIMAT0019806) and other species Homo morphology This includes log or orthologs. The hsa-miR-4706 gene is Pers Son H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the method. Also, "hsa-miR-4706" is its precursor and The "hsa-mir-4706" (miRBase Acces) adopts a hairpin-like structure. Sion No. MI0017339 (Sequence No. 254) is known.

[0108] The term "hsa-miR-7108-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-7108-5p" is used in the sequence number 30 of hsa-miR-7108- 5p gene (miRBase Accession No. MIMAT0028113) This includes homologs or orthologs of other biological species. hsa-miR-7108 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-7108-5p" has a hairpin-like structure as its precursor, "hsa-mir- 7108 (miRBase Accession No. MI0022959, Array No.) No. 255 is known.

[0109] The terms "hsa-miR-4433b-3p gene" or "hsa-m" used in this specification refer to the "hsa-miR-4433b-3p gene" or "hsa-m" gene. The term "iR-4433b-3p" is used in the HSA-MIR-4433 sequence number 31. 3b-3p gene (miRBase Accession No. MIMAT00304) 14) This includes homologs or orthologs of other biological species. hsa-miR-4 The 433b-3p gene was identified by Ple H et al., 2012, PLoS One, Vol. 7, e50. It can be obtained by the method described in 746. Also, "hsa-miR-4433 "b-3p" has a hairpin-like structure as its precursor, "hsa-mir-4433b". (miRBase Accession No. MI0025511, Sequence ID 256) It is known that...

[0110] The term "hsa-miR-6893-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6893-5p" is used in the sequence number 32 of hsa-miR-6893- 5p gene (miRBase Accession No. MIMAT0027686) This includes homologs or orthologs of other biological species. hsa-miR-6893 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6893-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6893 (miRBase Accession No. MI0022740, Array No.) No. 257 is known.

[0111] The term "hsa-miR-6857-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6857-5p" is used in the sequence number 33 of hsa-miR-6857- 5p gene (miRBase Accession No. MIMAT0027614) This includes homologs or orthologs of other biological species. hsa-miR-6857 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6857-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6857 (miRBase Accession No. MI0022703, Array No.) Number 258 is known.

[0112] The term "hsa-miR-1227-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-1227-5p" is used in the sequence number 34 of hsa-miR-1227- 5p gene (miRBase Accession No. MIMAT0022941) This includes homologs or orthologs of other biological species. hsa-miR-1227 -5p gene: Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-miR "-1227-5p" has a hairpin-like structure as its precursor, "hsa-mir-12 27" (miRBase Accession No. MI0006316, Sequence ID 2) 59) is known.

[0113] The term "hsa-miR-6741-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6741-5p" is used in the sequence number 35 of hsa-miR-6741- 5p gene (miRBase Accession No. MIMAT0027383) This includes homologs or orthologs of other biological species. hsa-miR-6741 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6741-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6741 (miRBase Accession No. MI0022586, Array No.) No. 260 is known.

[0114] The terms "hsa-miR-451a gene" or "hsa-miR-4" used herein refer to the "hsa-miR-4" gene used in this specification. The term "51a" refers to the hsa-miR-451a gene (miR) described in Sequence ID No. 36. Base Accession No. MIMAT0001631) and other species Homo morphology This includes log or orthologs. The hsa-miR-451a gene is Altu via Y et al., 2005, Nucleic Acids Res, Vol. 33, p. 2697. It can be obtained by the method described in -2706. Also, "hsa-miR-45 "1a" is a precursor that takes the hairpin-like structure of "hsa-mir-451a" (mi RBase Accession No. MI0001729 (Sequence ID 261) is known. It is being done.

[0115] The term "hsa-miR-8063 gene" or "hsa-miR-8" as used herein refers to the "hsa-miR-8" gene used in this specification. The term "063" refers to the hsa-miR-8063 gene (miR) described in Sequence ID No. 37. Base Accession No. MIMAT0030990) and other species Homo morphology This includes log or orthologs. The hsa-miR-8063 gene is Wang HJ et al., 2013, Shock, Vol. 39, pp. 480-487, by the method described therein It can be obtained by [method]. In addition, "hsa-miR-8063" is a precursor of hair The "hsa-mir-8063" (miRBase Accession) has a n-like structure. No.MI0025899 (Sequence ID 262) is known.

[0116] The terms "hsa-miR-3622a-5p gene" or "hsa-m" used herein refer to the "hsa-miR-3622a-5p gene" used herein. The term "iR-3622a-5p" is used in the HSA-MIR-3622 sequence number 38. 2a-5p gene (miRBase Accession No. MIMAT00180) 03) and other species homologs or orthologs are included. hsa-miR-3 The 622a-5p gene was identified by Witten D et al., 2010, BMC Biol, Vol. 8. It can be obtained by the method described on page 58. Also, "hsa-miR-3622 "a-5p" has a hairpin-like structure as its precursor, "hsa-mir-3622a". (miRBase Accession No. MI0016013, Sequence ID 263) It is known that...

[0117] The term "hsa-miR-615-5p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-615-5p" refers to the hsa-miR-615-5p variant described in Sequence ID No. 39. The gene (miRBase Accession No. MIMAT0004804) and its This includes homologs or orthologs of other biological species. hsa-miR-615-5p The transmission was described by Cummins JM et al., 2006, Proc Natl Acad Sci. It can be obtained by the method described in USA, Vol. 103, pp. 3687-3692. It can. Also, "hsa-miR-615-5p" has a hairpin-like structure as its precursor. To get "hsa-mir-615" (miRBase Accession No.MI0 003628 (Sequence ID 264) is known.

[0118] The terms "hsa-miR-128-1-5p gene" or "hsa-m" used herein refer to the "hsa-miR-128-1-5p gene" used herein. The term "iR-128-1-5p" refers to hsa-miR-128 as described in Sequence ID No. 40. -1-5p gene (miRBase Accession No. MIMAT00264) 77) and other species homologs or orthologs are included. hsa-miR-1 The 28-1-5p gene was identified by Lagos-Quintana M et al. in 2002, Curr It can be obtained by the method described in Biol, Vol. 12, pp. 735-739. Furthermore, "hsa-miR-128-1-5p" takes on a hairpin-like structure as its precursor. "hsa-mir-128-1" (miRBase Accession No.MI0 (000447, Sequence ID 265) is known.

[0119] The term "hsa-miR-6825-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6825-5p" is used in the sequence number 41 of hsa-miR-6825- 5p gene (miRBase Accession No. MIMAT0027550) This includes homologs or orthologs of other biological species. hsa-miR-6825 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6825-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6825 (miRBase Accession No. MI0022670, Array No.) No. 266 is known.

[0120] The term "hsa-miR-1260b gene" or "hsa-miR-" used herein is incorrect. The term "1260b" refers to the hsa-miR-1260b gene described in Sequence ID No. 42. miRBase Accession No. MIMAT0015041) and other organisms This includes species homologs or orthologs. The hsa-miR-1260b gene is The person described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. It can be obtained by law. Also, "hsa-miR-1260b" is its precursor and The "hsa-mir-1260b" (miRBase Acce) adopts a hairpin-like structure. Scsion No. MI0014197 (Sequence No. 267) is known.

[0121] The term "hsa-miR-4433-3p gene" or "hsa-mi" used in this specification refers to the "hsa-mi" gene. The term "R-4433-3p" is used in the sequence number 43 of hsa-miR-4433- 3p gene (miRBase Accession No. MIMAT0018949) This includes homologs or orthologs of other biological species. hsa-miR-4433 -3p gene, Jima DD et al., 2010, Blood, Vol. 116, e118-e It can be obtained by the method described in 127. Also, "hsa-miR-4433 -3p is a precursor of "hsa-mir-4433" (m iRBase Accession No. MI0016773 (Sequence ID 268) is known It is being done.

[0122] The "hsa-miR-4665-5p gene" or "hsa-mi" used herein The term "R-4665-5p" is used in the sequence number 44 of hsa-miR-4665- 5p gene (miRBase Accession No. MIMAT0019739) This includes homologs or orthologs of other biological species. hsa-miR-4665 -5p gene, Persson H et al., 2011, Cancer Res, Vol. 71, It can be obtained by the method described on pages 78-86. Also, "hsa-miR-4 "665-5p" has a hairpin-like structure as its precursor, "hsa-mir-4665 (miRBase Accession No. MI0017295, Sequence ID 269) ) is known.

[0123] The term "hsa-miR-7845-5p gene" or "hsa-mi" as used herein refers to the same gene used in this specification. The term "R-7845-5p" is used in the sequence number 45 of hsa-miR-7845- 5p gene (miRBase Accession No. MIMAT0030420) This includes homologs or orthologs of other biological species. hsa-miR-7845 The -5p gene was identified by Ple H et al., 2012, PLoS One, Vol. 7, e50746. It can be obtained by the method described. Also, "hsa-miR-7845-5p" Its precursor is "hsa-mir-7845" (miRBa Accession No. MI0025515, Sequence ID 270) is known. ru.

[0124] The term "hsa-miR-1908-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-1908-5p" is used in the sequence number 46 of hsa-miR-1908- 5p gene (miRBase Accession No. MIMAT0007881) This includes homologs or orthologs of other biological species. hsa-miR-1908 -5p gene, Bar M et al., 2008, Stem Cells, Vol. 26, p. 249. It can be obtained by the method described in 6-2505. Also, "hsa-miR-1 "908-5p" has a hairpin-like structure as its precursor, "hsa-mir-1908" (miRBase Accession No. MI0008329, Sequence ID 271) ) is known.

[0125] The term "hsa-miR-6840-3p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6840-3p" is used in the sequence number 47 of hsa-miR-6840- 3p gene (miRBase Accession No. MIMAT0027583) This includes homologs or orthologs of other biological species. hsa-miR-6840 -3p gene, Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m iR-6840-3p has a hairpin-like structure as its precursor, hsa-mir- 6840 (miRBase Accession No. MI0022686, Array No.) No. 272) is known.

[0126] The "hsa-miR-6765-5p gene" or "hsa-mi" used herein The term "R-6765-5p" is used in the sequence number 48, hsa-miR-6765- 5p gene (miRBase Accession No. MIMAT0027430) This includes homologs or orthologs of other biological species. hsa-miR-6765 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6765-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6765 (miRBase Accession No. MI0022610, Sequence Number) No. 240 is known.

[0127] The term "hsa-miR-296-5p gene" or "hsa-miR" as used herein refers to the "hsa-miR" gene used in this specification. The term "-296-5p" refers to the hsa-miR-296-5p variant described in Sequence ID No. 49. The gene (miRBase Accession No.MIMAT0000690) and its This includes homologs or orthologs of other biological species. hsa-miR-296-5p The gene was found in Houbaviy HB et al., 2003, Dev Cell, Vol. 5, p. 351- It can be obtained by the method described in 358. Also, "hsa-miR-296- "5p" is a precursor to "hsa-mir-296" (miR), which has a hairpin-like structure. Base Accession No. MI0000747 (Sequence ID 273) is known. It is.

[0128] The "hsa-miR-3675-3p gene" or "hsa-mi" used in this specification The term "R-3675-3p" is used in the sequence number 50 of hsa-miR-3675- 3p gene (miRBase Accession No. MIMAT0018099) This includes homologs or orthologs of other biological species. hsa-miR-3675 -3p gene, Vaz C et al., 2010, BMC Genomics, Vol. 11, p2 It can be obtained by the method described in 88. Also, "hsa-miR-3675- "3p" is a precursor of "hsa-mir-3675" (mi), which has a hairpin-like structure. RBase Accession No. MI0016076 (Sequence ID 274) is known. It is being done.

[0129] The term "hsa-miR-6781-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6781-5p" is used in the sequence number 51 of hsa-miR-6781- 5p gene (miRBase Accession No. MIMAT0027462) This includes homologs or orthologs of other biological species. hsa-miR-6781 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6781-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6781 (miRBase Accession No. MI0022626, Array No.) No. 275 is known.

[0130] The term "hsa-miR-423-5p gene" or "hsa-miR" as used herein refers to the "hsa-miR" gene used in this specification. The term "-423-5p" refers to the hsa-miR-423-5p variant described in Sequence ID No. 52. The gene (miRBase Accession No. MIMAT0004748) and its This includes homologs or orthologs of other biological species. hsa-miR-423-5p The gene was identified by Kasashima K et al., 2004, Biochem Biophys R. It can be obtained by the method described in es Commun, Vol. 322, pp. 403-410. Yes, it is possible. Also, "hsa-miR-423-5p" has a hairpin-like structure as its precursor. Take "hsa-mir-423" (miRBase Accession No. MI (0001445, Sequence ID 276) is known.

[0131] The "hsa-miR-3663-3p gene" or "hsa-mi" used in this specification The term "R-3663-3p" is used in the sequence number 53 of hsa-miR-3663- 3p gene (miRBase Accession No. MIMAT0018085) This includes homologs or orthologs of other biological species. hsa-miR-3663 -3p gene, Liao JY et al., 2010, PLoS One, Vol. 5, e1056. It can be obtained by the method described in 3. Also, "hsa-miR-3663-3 "p" has a hairpin-like structure as its precursor, "hsa-mir-3663" (miR Base Accession No. MI0016064 (Sequence ID 277) is known. It is.

[0132] The term "hsa-miR-6784-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6784-5p" is used in the sequence number 54 of hsa-miR-6784- 5p gene (miRBase Accession No. MIMAT0027468) This includes homologs or orthologs of other biological species. hsa-miR-6784 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6784-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6784 (miRBase Accession No. MI0022629, Array No.) Number 278 is known.

[0133] The "hsa-miR-6749-5p gene" or "hsa-mi" used herein The term "R-6749-5p" is used in the sequence number 55 of hsa-miR-6749- 5p gene (miRBase Accession No. MIMAT0027398) This includes homologs or orthologs of other biological species. hsa-miR-6749 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6749-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6749 (miRBase Accession No. MI0022594, Array No.) Number 279 is known.

[0134] The term "hsa-miR-1231 gene" or "hsa-miR-1" as used herein refers to the "hsa-miR-1231 gene" used herein. The term "231" refers to the hsa-miR-1231 gene (miR) described in Sequence ID No. 56. Base Accession No. MIMAT0005586) and other species Homo morphology This includes log or orthologs. The hsa-miR-1231 gene is Bere Zikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. It can be obtained by the method described above. Also, "hsa-miR-1231" is its precursor. The "hsa-mir-1231" (miRBase Acc) has a hairpin-like structure as its body. The known sequence number is MI0006321 (Sequence No. 280).

[0135] The "hsa-miR-4746-3p gene" or "hsa-mi" used in this specification The term "R-4746-3p" is used in the sequence number 57 of hsa-miR-4746- 3p gene (miRBase Accession No. MIMAT0019881) This includes homologs or orthologs of other biological species. hsa-miR-4746 -3p gene, Persson H et al., 2011, Cancer Res, Vol. 71, It can be obtained by the method described on pages 78-86. Also, "hsa-miR-4 "746-3p" has a hairpin-like structure as its precursor, "hsa-mir-4746 (miRBase Accession No. MI0017385, Sequence ID 281) ) is known.

[0136] The terms "hsa-miR-6780b-5p gene" or "hsa-m" used herein refer to the "hsa-miR-6780b-5p gene" used herein. The term "iR-6780b-5p" is used in the sequence number 58 of hsa-miR-678. 0b-5p gene (miRBase Accession No. MIMAT00275) 72) and other species homologs or orthologs are included. hsa-miR-6 The 780b-5p gene was identified by Ladewig E et al., 2012, Genome Res. It can be obtained by the method described in Volume 22, pp. 1634-1645. Also, "h "sa-miR-6780b-5p" has a hairpin-like structure as its precursor, "hsa -mir-6780b” (miRBase Accession No. MI00226 81 (Sequence ID 282) is known.

[0137] The term "hsa-miR-4758-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-4758-5p" is used in the sequence number 59 of hsa-miR-4758- 5p gene (miRBase Accession No. MIMAT0019903) This includes homologs or orthologs of other biological species. hsa-miR-4758 -5p gene, Persson H et al., 2011, Cancer Res, Vol. 71, It can be obtained by the method described on pages 78-86. Also, "hsa-miR-4 "758-5p" has a hairpin-like structure as its precursor, "hsa-mir-4758 (miRBase Accession No. MI0017399, Sequence ID 283) ) is known.

[0138] The "hsa-miR-3679-5p gene" or "hsa-mi" used herein The term "R-3679-5p" is used in the sequence number 60 of hsa-miR-3679- 5p gene (miRBase Accession No. MIMAT0018104) This includes homologs or orthologs of other biological species. hsa-miR-3679 -5p gene: Creighton CJ et al., 2010, PLoS One, Vol. 5. It can be obtained by the method described in e9637. Also, "hsa-miR-36 "79-5p" has a hairpin-like structure as its precursor, "hsa-mir-3679". (miRBase Accession No. MI0016080, Sequence ID 236) It is known that...

[0139] The term "hsa-miR-3184-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-3184-5p" is used in the sequence number 61 of hsa-miR-3184- 5p gene (miRBase Accession No. MIMAT0015064) This includes homologs or orthologs of other biological species. hsa-miR-3184 -5p gene, Stark MS et al., 2010, PLoS One, Vol. 5, e968. It can be obtained by the method described in 5. Also, "hsa-miR-3184-5 "p" is a precursor that takes the hairpin-like structure of "hsa-mir-3184" (miR Base Accession No. MI0014226 (Sequence ID 284) is known. It is.

[0140] The term "hsa-miR-6125 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene used in this specification. The term "125" refers to the hsa-miR-6125 gene (miR) described in Sequence ID No. 62. Base Accession No. MIMAT0024598) and other species Homo morphology This includes log or orthologs. The hsa-miR-6125 gene is Smit h JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. It can be obtained by the method. Also, "hsa-miR-6125" is its precursor and The "hsa-mir-6125" (miRBase Acces) adopts a hairpin-like structure. Ssion No. MI0021259 (Sequence No. 285) is known.

[0141] The term "hsa-miR-6721-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6721-5p" is used in the sequence number 63 of hsa-miR-6721- 5p gene (miRBase Accession No. MIMAT0025852) This includes homologs or orthologs of other biological species. hsa-miR-6721 The -5p gene is described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. It can be obtained by the method described. Also, "hsa-miR-6721-5p" is , and as its precursor, "hsa-mir-6721" (miRBas) takes on a hairpin-like structure. Accession No. MI0022556 (Sequence ID 286) is known. .

[0142] The term "hsa-miR-6791-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6791-5p" is used in the sequence number 64 of hsa-miR-6791- 5p gene (miRBase Accession No. MIMAT0027482) This includes homologs or orthologs of other biological species. hsa-miR-6791 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6791-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6791 (miRBase Accession No. MI0022636, Array No.) No. 287 is known.

[0143] The term "hsa-miR-3185 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3185 gene" or "hsa-miR-3 The term "185" refers to the hsa-miR-3185 gene (miR) described in Sequence ID No. 65. Base Accession No. MIMAT0015065) and other species Homo morphology This includes log or orthologs. The hsa-miR-3185 gene is Star k MS et al., 2010, PLoS One, Vol. 5, e9685, by the method described therein It can be obtained by [method]. In addition, "hsa-miR-3185" is a precursor of hair The "hsa-mir-3185" (miRBase Accession) has a n-like structure. No.MI0014227 (Sequence ID 288) is known.

[0144] The term "hsa-miR-1260a gene" or "hsa-miR-" used herein refers to the "hsa-miR-1260a gene" used herein. The term "1260a" refers to the hsa-miR-1260a gene described in Sequence ID No. 66. miRBase Accession No. MIMAT0005911) and other organisms This includes species homologs or orthologs. The hsa-miR-1260a gene is Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. It can be obtained by the method described. Also, "hsa-miR-1260a" is, Its precursor is "hsa-mir-1260a" (miRBas), which has a hairpin-like structure. Accession No. MI0006394 (Sequence ID 289) is known. .

[0145] The term "hsa-miR-3197 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3197 gene" or "hsa-miR-3 The term "197" refers to the hsa-miR-3197 gene (miR) described in Sequence ID No. 67. Base Accession No. MIMAT0015082) and other species Homo morphology This includes log or orthologs. The hsa-miR-3197 gene is Star k MS et al., 2010, PLoS One, Vol. 5, e9685, by the method described therein It can be obtained by [method]. In addition, "hsa-miR-3197" is a precursor of hair "hsa-mir-3197" (miRBase Accession) takes on a n-like structure. No.MI0014245 (Sequence ID 290) is known.

[0146] The term "hsa-miR-6845-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6845-5p" is used in the sequence number 68 of hsa-miR-6845- 5p gene (miRBase Accession No. MIMAT0027590) This includes homologs or orthologs of other biological species. hsa-miR-6845 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6845-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6845 (miRBase Accession No. MI0022691, Array No.) No. 291 is known.

[0147] The term "hsa-miR-6887-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6887-5p" is used in the sequence number 69 of hsa-miR-6887- 5p gene (miRBase Accession No. MIMAT0027674) This includes homologs or orthologs of other biological species. hsa-miR-6887 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6887-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6887" (miRBase Accession No. MI0022734, Array No.) No. 292 is known.

[0148] The term "hsa-miR-6738-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6738-5p" is used in the sequence number 70 of hsa-miR-6738- 5p gene (miRBase Accession No. MIMAT0027377) This includes homologs or orthologs of other biological species. hsa-miR-6738 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m iR-6738-5p has a hairpin-like structure as its precursor, hsa-mir- 6738 (miRBase Accession No. MI0022583, Array No.) No. 293 is known.

[0149] The term "hsa-miR-6872-3p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6872-3p" is used in the sequence number 71 of hsa-miR-6872- 3p gene (miRBase Accession No. MIMAT0027645) This includes homologs or orthologs of other biological species. hsa-miR-6872 -3p gene, Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m iR-6872-3p has a hairpin-like structure as its precursor, hsa-mir- 6872" (miRBase Accession No. MI0022719, Array No.) No. 294 is known.

[0150] The term "hsa-miR-4497 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "497" refers to the hsa-miR-4497 gene (miR) described in Sequence ID No. 72. Base Accession No. MIMAT0019032) and other species Homo morphology This includes log or orthologs. The hsa-miR-4497 gene is Jima The method described in DD et al., 2010, Blood, Vol. 116, e118-e127 Therefore, it can be obtained. Also, "hsa-miR-4497" is used as a precursor. "hsa-mir-4497" (miRBase Accessio) adopts an appin-like structure. The following is known: (n No.MI0016859, Sequence ID 295)

[0151] The term "hsa-miR-1229-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-1229-5p" is used in the sequence number 73 of hsa-miR-1229- 5p gene (miRBase Accession No. MIMAT0022942) This includes homologs or orthologs of other biological species. hsa-miR-1229 -5p gene: Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-miR "-1229-5p" has a hairpin-like structure as its precursor, "hsa-mir-12 29" (miRBase Accession No. MI0006319, Sequence ID 2) 96) is known.

[0152] The term "hsa-miR-6820-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6820-5p" is used in the sequence number 74 of hsa-miR-6820- 5p gene (miRBase Accession No. MIMAT0027540) This includes homologs or orthologs of other biological species. hsa-miR-6820 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6820-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6820 (miRBase Accession No. MI0022665, Array No.) No. 297 is known.

[0153] The "hsa-miR-6777-5p gene" or "hsa-mi" used herein The term "R-6777-5p" is used in the description of hsa-miR-6777- in Sequence ID No. 75. 5p gene (miRBase Accession No. MIMAT0027454) This includes homologs or orthologs of other biological species. hsa-miR-6777 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6777-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6777" (miRBase Accession No. MI0022622, Array No.) No. 298 is known.

[0154] The term "hsa-miR-3917 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3917 gene" or "hsa-miR-3 The term "917" refers to the hsa-miR-3917 gene (miR) described in Sequence ID No. 76. Base Accession No. MIMAT0018191) and other species Homo morphology This includes log or orthologs. The hsa-miR-3917 gene is Crei The person described in ghton CJ et al., 2010, PLoS One, Vol. 5, e9637. It can be obtained by law. Also, "hsa-miR-3917" is its precursor. The "hsa-mir-3917" (miRBase Access) has a hairpin-like structure. Ion No. MI0016423 (sequence number 299) is known.

[0155] The term "hsa-miR-5787 gene" or "hsa-miR-5" as used herein refers to the "hsa-miR-5" gene used in this specification. The term "787" refers to the hsa-miR-5787 gene (miR) described in Sequence ID No. 77. Base Accession No. MIMAT0023252) and other species Homo morphology This includes log or orthologs. The hsa-miR-5787 gene is Yoo H et al., 2011, Biochem Biophys Res Commun, Vol. 415. It can be obtained by the method described on pages 567-572. Also, "hsa-mi "R-5787" has a hairpin-like structure as its precursor, "hsa-mir-5787" (miRBase Accession No. MI0019797, Sequence ID 300) ) is known.

[0156] The term "hsa-miR-4286 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4286 gene" used in this specification. The term "286" refers to the hsa-miR-4286 gene (miR) described in Sequence ID No. 78. Base Accession No. MIMAT0016916) and other species Homo morphology This includes log or orthologs. The hsa-miR-4286 gene is Goff By the method described in LA et al., 2009, PLoS One, Vol. 4, e7192 It can be obtained. Also, "hsa-miR-4286" is a hairpin as its precursor. "hsa-mir-4286" (miRBase Accession N) takes on a unique structure. o.MI0015894 (Sequence ID 301) is known.

[0157] The term "hsa-miR-6877-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6877-5p" is used in the sequence number 79 of hsa-miR-6877- 5p gene (miRBase Accession No. MIMAT0027654) This includes homologs or orthologs of other biological species. hsa-miR-6877 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6877-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6877" (miRBase Accession No. MI0022724, Array No.) No. 302) is known.

[0158] The "hsa-miR-1225-3p gene" or "hsa-mi" used herein The term "R-1225-3p" is used in the sequence number 80 of hsa-miR-1225- 3p gene (miRBase Accession No. MIMAT0005573) This includes homologs or orthologs of other biological species. hsa-miR-1225 -3p gene: Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-miR "-1225-3p" has a hairpin-like structure as its precursor, "hsa-mir-12 25" (miRBase Accession No. MI0006311, Sequence ID 3) 03) is known.

[0159] The term "hsa-miR-6088 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene used in this specification. The term "088" refers to the hsa-miR-6088 gene (miR) described in Sequence ID No. 81. Base Accession No. MIMAT0023713) and other species Homo morphology This includes log or orthologs. The hsa-miR-6088 gene is Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. It can be obtained by the method described. Also, "hsa-miR-6088" is "hsa-mir-6088" (miRBase), which has a hairpin-like structure as a precursor. Accession No. MI0020365 (Sequence ID 304) is known.

[0160] The term "hsa-miR-6800-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6800-5p" is used in the context of hsa-miR-6800- described in Sequence ID No. 82. 5p gene (miRBase Accession No. MIMAT0027500) This includes homologs or orthologs of other biological species. hsa-miR-6800 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m iR-6800-5p has a hairpin-like structure as its precursor, hsa-mir- 6800" (miRBase Accession No. MI0022645, Array No.) No. 305 is known.

[0161] The term "hsa-miR-1246 gene" or "hsa-miR-1" as used herein refers to the "hsa-miR-1246 gene" used herein. The term "246" refers to the hsa-miR-1246 gene (miR) described in Sequence ID No. 83. Base Accession No. MIMAT0005898) and other species Homo morphology This includes log or orthologs. The hsa-miR-1246 gene is Mori n RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. It can be obtained by the following method. Furthermore, "hsa-miR-1246" is its precursor. "hsa-mir-1246" (miRBase Acce Scsion No. MI0006381 (Sequence No. 306) is known.

[0162] The term "hsa-miR-4467 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene used in this specification. The term "467" refers to the hsa-miR-4467 gene (miR) described in Sequence ID No. 84. Base Accession No. MIMAT0018994) and other species Homo morphology This includes log or orthologs. The hsa-miR-4467 gene is Jima The method described in DD et al., 2010, Blood, Vol. 116, e118-e127 Therefore, it can be obtained. Also, "hsa-miR-4467" is used as its precursor. "hsa-mir-4467" (miRBase Accessio) adopts an appin-like structure. The following is known: (n No.MI0016818, Sequence ID 307)

[0163] The term "hsa-miR-4419b gene" or "hsa-miR-" used herein refers to the "hsa-miR-4419b gene" used herein. The term "4419b" refers to the hsa-miR-4419b gene described in Sequence ID No. 85. miRBase Accession No. MIMAT0019034) and other organisms It includes species homologs or orthologs. The hsa-miR-4419b gene is Jima DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by the following method. Also, "hsa-miR-4419b" is its precursor. "hsa-mir-4419b" (miRBase Ac) takes on a hairpin-like structure as its body. Cession No. MI0016861 (Sequence No. 308) is known.

[0164] The term "hsa-miR-1914-3p gene" or "hsa-mi" used in this specification refers to the "hsa-mi" gene. The term "R-1914-3p" is used in the sequence number 86 of hsa-miR-1914- 3p gene (miRBase Accession No. MIMAT0007890) This includes homologs or orthologs of other biological species. hsa-miR-1914 -3p gene, Bar M et al., 2008, Stem Cells, Vol. 26, p. 249. It can be obtained by the method described in 6-2505. Also, "hsa-miR-1 "914-3p" has a hairpin-like structure as its precursor, "hsa-mir-1914 (miRBase Accession No. MI0008335, Sequence ID 309) ) is known.

[0165] The "hsa-miR-4632-5p gene" or "hsa-mi" used herein The term "R-4632-5p" is used in the sequence number 87 of hsa-miR-4632- 5p gene (miRBase Accession No. MIMAT0022977) This includes homologs or orthologs of other biological species. hsa-miR-4632 -5p gene, Persson H et al., 2011, Cancer Res, Vol. 71, It can be obtained by the method described on pages 78-86. Also, "hsa-miR-4 "632-5p" has a hairpin-like structure as its precursor, "hsa-mir-4632 (miRBase Accession No. MI0017259, Sequence ID 310) ) is known.

[0166] The "hsa-miR-1915-5p gene" or "hsa-mi" used herein The term "R-1915-5p" is used in the sequence number 88 of hsa-miR-1915- 5p gene (miRBase Accession No. MIMAT0007891) This includes homologs or orthologs of other biological species. hsa-miR-1915 -5p gene, Bar M et al., 2008, Stem Cells, Vol. 26, p. 249. It can be obtained by the method described in 6-2505. Also, "hsa-miR-1 "915-5p" has a hairpin-like structure as its precursor, "hsa-mir-1915 (miRBase Accession No. MI0008336, Sequence ID 311) ) is known.

[0167] The "hsa-miR-3940-5p gene" or "hsa-mi" used in this specification The term "R-3940-5p" is used in the sequence number 89 of hsa-miR-3940- 5p gene (miRBase Accession No. MIMAT0019229) This includes homologs or orthologs of other biological species. hsa-miR-3940 -5p gene: Liao JY et al., 2010, PLoS One, Vol. 5, e1056 It can be obtained by the method described in 3. Also, "hsa-miR-3940-5 "p" is a precursor that takes on a hairpin-like structure, "hsa-mir-3940" (miR Base Accession No. MI0016597 (Sequence ID 312) is known. It is.

[0168] The term "hsa-miR-1185-2-3p gene" or "hsa-" used herein refers to the "hsa- The term "miR-1185-2-3p" is used in the sequence number 90 of hsa-miR-1 185-2-3p gene (miRBase Accession No. MIMAT00) This includes 22713) and other species homologs or orthologs. The R-1185-2-3p gene was identified by Berezikov E et al., 2006, in Genom It can be obtained by the method described in e Res, Vol. 16, pp. 1289-1298. Furthermore, "hsa-miR-1185-2-3p" has a hairpin-like structure as its precursor. Take "hsa-mir-1185-2" (miRBase Accession No. .MI0003821 (Sequence ID 313) is known.

[0169] The term "hsa-miR-6746-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-6746-5p" is used in the sequence number 91 of hsa-miR-6746- 5p gene (miRBase Accession No. MIMAT0027392) This includes homologs or orthologs of other biological species. hsa-miR-6746 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6746-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6746 (miRBase Accession No. MI0022591, Array No.) No. 314 is known.

[0170] The "hsa-miR-5001-5p gene" or "hsa-mi" used in this specification The term "R-5001-5p" is used in the sequence number 92 of hsa-miR-5001- 5p gene (miRBase Accession No. MIMAT0021021) This includes homologs or orthologs of other biological species. hsa-miR-5001 -5p gene: Hansen TB et al., 2011, RNA Biol, Vol. 8, p. 37 It can be obtained by the method described in 8-383. Also, "hsa-miR-50 "01-5p" is a precursor to "hsa-mir-5001," which has a hairpin-like structure. (miRBase Accession No. MI0017867, Sequence ID 315) It is known that...

[0171] The term "hsa-miR-1228-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-1228-5p" is used in the sequence number 93 of hsa-miR-1228- 5p gene (miRBase Accession No. MIMAT0005582) This includes homologs or orthologs of other biological species. hsa-miR-1228 -5p gene: Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-miR "-1228-5p" has a hairpin-like structure as its precursor, "hsa-mir-12 28" (miRBase Accession No. MI0006318, Sequence ID 3) 16) is known.

[0172] The term "hsa-miR-5572 gene" or "hsa-miR-5" as used herein refers to the "hsa-miR-5" gene used in this specification. The term "572" refers to the hsa-miR-5572 gene (miR) described in Sequence ID No. 94. Base Accession No. MIMAT0022260) and other species Homo morphology This includes log or orthologs. The hsa-miR-5572 gene is Tand The person described in on M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. It can be obtained by law. Also, "hsa-miR-5572" is its precursor. The "hsa-mir-5572" (miRBase Access) has a hairpin-like structure. Ion No. MI0019117 (Sequence ID 317) is known.

[0173] The term "hsa-miR-4327 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4327 gene" used in this specification. The term "327" refers to the hsa-miR-4327 gene (miR) described in Sequence ID No. 95. Base Accession No. MIMAT0016889) and other species Homo morphology This includes log or orthologs. The hsa-miR-4327 gene is Goff By the method described in LA et al., 2009, PLoS One, Vol. 4, e7192 It can be obtained. Also, "hsa-miR-4327" is a hairpin as its precursor. "hsa-mir-4327" (miRBase Accession N) takes on a unique structure. o.MI0015867 (sequence number 318) is known.

[0174] The term "hsa-miR-4638-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-4638-5p" is used in the sequence number 96 of hsa-miR-4638- 5p gene (miRBase Accession No. MIMAT0019695) This includes homologs or orthologs of other biological species. hsa-miR-4638 -5p gene, Persson H et al., 2011, Cancer Res, Vol. 71, It can be obtained by the method described on pages 78-86. Also, "hsa-miR-4 "638-5p" has a hairpin-like structure as its precursor, "hsa-mir-4638 (miRBase Accession No. MI0017265, Sequence ID 319) ) is known.

[0175] The "hsa-miR-6799-5p gene" or "hsa-mi" used herein The term "R-6799-5p" is used in the sequence number 97 of hsa-miR-6799- 5p gene (miRBase Accession No. MIMAT0027498) This includes homologs or orthologs of other biological species. hsa-miR-6799 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6799-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6799 (miRBase Accession No. MI0022644, Array No.) No. 320 is known.

[0176] The term "hsa-miR-6861-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6861-5p" is used in the sequence number 98 of hsa-miR-6861- 5p gene (miRBase Accession No. MIMAT0027623) This includes homologs or orthologs of other biological species. hsa-miR-6861 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6861-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6861 (miRBase Accession No. MI0022708, Array No.) No. 321 is known.

[0177] The "hsa-miR-6727-5p gene" or "hsa-mi" used herein The term "R-6727-5p" is used in the sequence number 99 of hsa-miR-6727- 5p gene (miRBase Accession No. MIMAT0027355) This includes homologs or orthologs of other biological species. hsa-miR-6727 -5p gene: Ladewig E et al., 2012, Genome Res, Vol. 22, It can be obtained by the method described on pages 1634-1645. Also, "hsa-m "iR-6727-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6727 (miRBase Accession No. MI0022572, Array No.) No. 322) is known.

[0178] The term "hsa-miR-4513 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene used in this specification. The term "513" refers to the hsa-miR-4513 gene (mi) described in Sequence ID No. 100. RBase Accession No. MIMAT0019050) and other biological species This includes mologs or orthologs. The hsa-miR-4513 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4513" is a precursor to [method]. The "hsa-mir-4513" (miRBase Accessi) has a hairpin-like structure. (No.MI0016879, Sequence ID 323) is known.

[0179] The "hsa-miR-6805-3p gene" or "hsa-mi" used herein The term "R-6805-3p" refers to hsa-miR-6805 as described in Sequence ID No. 101. -3p gene (miRBase Accession No. MIMAT0027511) This includes homologs or orthologs of other biological species, etc. hsa-miR-680 The 5-3p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6805-3p" has a hairpin-like structure as its precursor, "hsa-mir -6805 (miRBase Accession No. MI0022650, array) Number 324 is known.

[0180] The term "hsa-miR-6808-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6808-5p" refers to hsa-miR-6808 as described in Sequence ID No. 102. -5p gene (miRBase Accession No. MIMAT0027516) This includes homologs or orthologs of other biological species, etc. hsa-miR-680 The 8-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6808-5p" has a hairpin-like structure as its precursor, "hsa-mir -6808 (miRBase Accession No. MI0022653, array) Number 325) is known.

[0181] The term "hsa-miR-4449 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "449" refers to the hsa-miR-4449 gene (mi) described in Sequence ID No. 103. RBase Accession No. MIMAT0018968) and other biological species This includes mologs or orthologs. The hsa-miR-4449 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4449" is a precursor to [method]. "hsa-mir-4449" (miRBase Accessi) has a hairpin-like structure. (No.MI0016792, Sequence ID 326) is known.

[0182] The term "hsa-miR-1199-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-1199-5p" refers to hsa-miR-1199 as described in Sequence ID No. 104. -5p gene (miRBase Accession No. MIMAT0031119) This includes homologs or orthologs of other biological species. hsa-miR-119 The 9-5p gene was identified by Salvi A et al., 2013, Int J Oncol, Vol. 42. It can be obtained by the method described on pages 391-402. Also, "hsa-miR "-1199-5p" has a hairpin-like structure as its precursor, "hsa-mir-11 99" (miRBase Accession No. MI0020340, Sequence ID 3) 27) is known.

[0183] The term "hsa-miR-1275 gene" or "hsa-miR-1" as used herein refers to the "hsa-miR-1275 gene" used herein. The term "275" refers to the hsa-miR-1275 gene (mi) described in Sequence ID No. 105. RBase Accession No. MIMAT0005929) and other biological species This includes mologs or orthologs. The hsa-miR-1275 gene is Mor In RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. It can be obtained by the method described. Also, "hsa-miR-1275" is its precursor. The "hsa-mir-1275" (miRBase Acc) has a hairpin-like structure as its body. The entry No. MI0006415 (sequence number 328) is known.

[0184] The terms "hsa-miR-4792 gene" or "hsa-miR-4" used herein refer to the "hsa-miR-4" gene. The term "792" refers to the hsa-miR-4792 gene (mi) described in Sequence ID No. 106. RBase Accession No. MIMAT0019964) and other biological species This includes mologs or orthologs. The hsa-miR-4792 gene is Per Sson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the following method. Furthermore, "hsa-miR-4792" is its precursor. "hsa-mir-4792" (miRBase Acce Scsion No. MI0017439 (Sequence No. 329) is known.

[0185] The term "hsa-miR-4443 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene used in this specification. The term "443" refers to the hsa-miR-4443 gene (mi) described in Sequence ID No. 107. RBase Accession No. MIMAT0018961) and other biological species This includes mologs or orthologs. The hsa-miR-4443 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4443" is a precursor to [method]. "hsa-mir-4443" (miRBase Accessi) has a hairpin-like structure. The number (on No.MI0016786, Sequence ID 330) is known.

[0186] The term "hsa-miR-6891-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6891-5p" refers to hsa-miR-6891 as described in Sequence ID No. 108. -5p gene (miRBase Accession No. MIMAT0027682) This includes homologs or orthologs of other biological species. hsa-miR-689 The 1-5p genes were identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6891-5p" has a hairpin-like structure as its precursor, "hsa-mir -6891 (miRBase Accession No. MI0022738, array) Number 331) is known.

[0187] The term "hsa-miR-6826-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6826-5p" refers to hsa-miR-6826 as described in Sequence ID No. 109. -5p gene (miRBase Accession No. MIMAT0027552) This includes homologs or orthologs of other biological species. hsa-miR-682 The 6-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6826-5p" has a hairpin-like structure as its precursor, "hsa-mir -6826 (miRBase Accession No. MI0022671, array) Number 332) is known.

[0188] The term "hsa-miR-6807-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6807-5p" refers to hsa-miR-6807 as described in Sequence ID No. 110. -5p gene (miRBase Accession No. MIMAT0027514) This includes homologs or orthologs of other biological species, etc. hsa-miR-680 The 7-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6807-5p" has a hairpin-like structure as its precursor, "hsa-mir -6807 (miRBase Accession No. MI0022652, array) Number 333) is known.

[0189] The term "hsa-miR-7150 gene" or "hsa-miR-7" as used herein refers to the "hsa-miR-7" gene used in this specification. The term "150" refers to the hsa-miR-7150 gene (mi) described in Sequence ID No. 111. RBase Accession No. MIMAT0028211) and other biological species This includes mologs or orthologs. The hsa-miR-7150 gene is Oul as A et al., 2009, Nucleic Acids Research, Vol. 37, p. 3276- It can be obtained by the method described in 3287. Also, "hsa-miR-715 "0" is a precursor that takes on a hairpin-like structure, "hsa-mir-7150" (miR Base Accession No. MI0023610 (Sequence ID 334) is known. It is.

[0190] The term "hsa-miR-4534 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "534" refers to the hsa-miR-4534 gene (mi) described in Sequence ID No. 112. RBase Accession No. MIMAT0019073) and other biological species This includes mologs or orthologs. The hsa-miR-4534 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4534" is a precursor to [method]. The "hsa-mir-4534" (miRBase Accessi) has a hairpin-like structure. The code on No.MI0016901 (sequence number 335) is known.

[0191] The term "hsa-miR-4476 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "476" refers to the hsa-miR-4476 gene (mi) described in Sequence ID No. 113. RBase Accession No. MIMAT0019003) and other biological species This includes mologs or orthologs. The hsa-miR-4476 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4476" is a precursor to [method]. "hsa-mir-4476" (miRBase Accessi) has a hairpin-like structure. (No.MI0016828, Sequence ID 336) is known.

[0192] The term "hsa-miR-4649-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-4649-5p" refers to hsa-miR-4649 as described in Sequence ID No. 114. -5p gene (miRBase Accession No. MIMAT0019711) This includes homologs or orthologs of other biological species. hsa-miR-464 The 9-5p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4649-5p" has a hairpin-like structure as its precursor, "hsa-mir-464" 9" (miRBase Accession No. MI0017276, Sequence ID 33) 7) is known.

[0193] The term "hsa-miR-4525 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "525" refers to the hsa-miR-4525 gene (mi) described in Sequence ID No. 115. RBase Accession No. MIMAT0019064) and other biological species This includes mologs or orthologs. The hsa-miR-4525 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4525" is a precursor to [method]. The "hsa-mir-4525" (miRBase Accessi) has a hairpin-like structure. (No.MI0016892, Sequence ID 338) is known.

[0194] The term "hsa-miR-1915-3p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-1915-3p" refers to hsa-miR-1915 as described in Sequence ID No. 116. -3p gene (miRBase Accession No. MIMAT0007892) This includes homologs or orthologs of other biological species, etc. hsa-miR-191 The 5-3p gene is described in Bar M et al., 2008, Stem Cells, Vol. 26, p. 24. It can be obtained by the method described in 96-2505. Also, "hsa-miR- "1915-3p" has a hairpin-like structure as its precursor, "hsa-mir-191 5" (miRBase Accession No. MI0008336, Sequence ID 31) 1) is known.

[0195] The term "hsa-miR-4516 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "516" refers to the hsa-miR-4516 gene (mi) described in Sequence ID No. 117. RBase Accession No. MIMAT0019053) and other biological species This includes mologs or orthologs. The hsa-miR-4516 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4516" is a precursor to [method]. The "hsa-mir-4516" (miRBase Accessi) has a hairpin-like structure. (No.MI0016882, Sequence ID 339) is known.

[0196] The term "hsa-miR-4417 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene used in this specification. The term "417" refers to the hsa-miR-4417 gene (mi) described in Sequence ID No. 118. RBase Accession No. MIMAT0018929) and other biological species This includes mologs or orthologs. The hsa-miR-4417 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4417" is a precursor to [method]. The "hsa-mir-4417" (miRBase Accessi) has a hairpin-like structure. The code known as No.MI0016753 (sequence number 340) is also known.

[0197] The term "hsa-miR-642b-3p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-642b-3p" refers to hsa-miR-642b described in Sequence ID No. 119. -3p gene (miRBase Accession No. MIMAT0018444) This includes homologs or orthologs of other biological species. hsa-miR-642 The b-3p gene is described in Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. It can be obtained by the method described in "hsa-miR-642b-3p " is "hsa-mir-642b" (miRB), which has a hairpin-like structure as its precursor. The known sequence number (Accession No. MI0016685, Sequence ID 341) is Yes, they are.

[0198] The term "hsa-miR-3141 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3141 gene" or "hsa-miR-3 The term "141" refers to the hsa-miR-3141 gene (mi) described in Sequence ID No. 120. RBase Accession No. MIMAT0015010) and other biological species This includes mologs or orthologs. The hsa-miR-3141 gene is Sta According to the method described by rk MS et al., 2010, PLoS One, Vol. 5, e9685 It can be obtained in this way. Also, "hsa-miR-3141" is a precursor to hair "hsa-mir-3141" (miRBase Accession) adopts a pin-like structure. No.MI0014165 (Sequence ID 342) is known.

[0199] The "hsa-miR-5100 gene" or "hsa-miR-5" used in this specification The term "100" refers to the hsa-miR-5100 gene (mi) described in Sequence ID No. 121. RBase Accession No. MIMAT0022259) and other biological species This includes mologs or orthologs. The hsa-miR-5100 gene is Tan don M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. It can be obtained by the method. Also, "hsa-miR-5100" is its precursor and The "hsa-mir-5100" (miRBase Acces) adopts a hairpin-like structure. Sion No. MI0019116 (Sequence No. 343) is known.

[0200] The term "hsa-miR-6848-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6848-5p" refers to hsa-miR-6848 as described in Sequence ID No. 122. -5p gene (miRBase Accession No. MIMAT0027596) This includes homologs or orthologs of other biological species. hsa-miR-684 The 8-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6848-5p" has a hairpin-like structure as its precursor, "hsa-mir -6848 (miRBase Accession No. MI0022694, array) Number 344 is known.

[0201] The term "hsa-miR-4739 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "739" refers to the hsa-miR-4739 gene (mi) described in Sequence ID No. 123. RBase Accession No. MIMAT0019868) and other biological species It includes mologs or orthologs. The hsa-miR-4739 gene is Per Sson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the following method. Also, "hsa-miR-4739" is its precursor. The "hsa-mir-4739" (miRBase Acce) has a hairpin-like structure. Scion No. MI0017377 (Sequence No. 345) is known.

[0202] The term "hsa-miR-4459 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "459" refers to the hsa-miR-4459 gene (mi) described in Sequence ID No. 124. RBase Accession No. MIMAT0018981) and other biological species This includes mologs or orthologs. The hsa-miR-4459 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4459" is its precursor. The "hsa-mir-4459" (miRBase Accessi) has a hairpin-like structure. (No.MI0016805, Sequence ID 346) is known.

[0203] The term "hsa-miR-1237-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-1237-5p" refers to hsa-miR-1237 as described in Sequence ID No. 125. -5p gene (miRBase Accession No. MIMAT0022946) This includes homologs or orthologs of other biological species. hsa-miR-123 The 7-5p gene was identified by Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-mi "R-1237-5p" has a hairpin-like structure as its precursor, "hsa-mir-1 237" (miRBase Accession No. MI0006327, Sequence ID) 347) is known.

[0204] The term "hsa-miR-296-3p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-296-3p" refers to hsa-miR-296-3p as described in Sequence ID No. 126. The gene (miRBase Accession No. MIMAT0004679) and so This includes homologs or orthologs of other biological species. hsa-miR-296-3p The gene is from Houbaviy HB et al., 2003, Dev Cell, Vol. 5, p. 351. It can be obtained by the method described in -358. Also, "hsa-miR-296 -3p is a precursor of "hsa-mir-296" (mi), which has a hairpin-like structure. RBase Accession No. MI0000747 (Sequence ID 273) is known. It is being done.

[0205] The "hsa-miR-4665-3p gene" or "hsa-mi" used in this specification The term "R-4665-3p" refers to hsa-miR-4665 as described in Sequence ID No. 127. -3p gene (miRBase Accession No. MIMAT0019740) This includes homologs or orthologs of other biological species. hsa-miR-466 The 5-3p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4665-3p" has a hairpin-like structure as its precursor, "hsa-mir-466 5" (miRBase Accession No. MI0017295, Sequence ID 26) 9) is known.

[0206] The term "hsa-miR-6786-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6786-5p" refers to hsa-miR-6786 as described in Sequence ID No. 128. -5p gene (miRBase Accession No. MIMAT0027472) This includes homologs or orthologs of other biological species. hsa-miR-678 The 6-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6786-5p" has a hairpin-like structure as its precursor, "hsa-mir -6786 (miRBase Accession No. MI0022631, array) Number 348 is known.

[0207] The terms "hsa-miR-4258 gene" or "hsa-miR-4" used herein refer to the "hsa-miR-4258 gene" used herein. The term "258" refers to the hsa-miR-4258 gene (mi) described in Sequence ID No. 129. RBase Accession No. MIMAT0016879) and other biological species This includes mologs or orthologs. The hsa-miR-4258 gene is a Gof f LA et al., 2009, PLoS One, Vol. 4, e7192, by the method described therein It can be obtained by [method]. In addition, "hsa-miR-4258" is a precursor of hair The "hsa-mir-4258" (miRBase Accession) has a n-like structure. No.MI0015857 (Sequence ID 349) is known.

[0208] The "hsa-miR-6510-5p gene" or "hsa-mi" used herein The term "R-6510-5p" refers to hsa-miR-6510 as described in Sequence ID No. 130. -5p gene (miRBase Accession No. MIMAT0025476) This includes homologs or orthologs of other biological species. hsa-miR-651 The 0-5p gene was identified by Joyce CE et al., 2011, Hum Mol Genet, 2 It can be obtained by the method described in Volume 0, pp. 4025-4040. Also, "hs "a-miR-6510-5p" has a hairpin-like structure as its precursor, "hsa-m ir-6510” (miRBase Accession No. MI0022222, Sequence ID 350 is known.

[0209] The term "hsa-miR-1343-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-1343-5p" refers to hsa-miR-1343 as described in Sequence ID No. 131. -5p gene (miRBase Accession No. MIMAT0027038) This includes homologs or orthologs of other biological species. hsa-miR-134 The 3-5p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "1343-5p" has a hairpin-like structure as its precursor, "hsa-mir-134 3" (miRBase Accession No. MI0017320, Sequence ID 22) 5) is known.

[0210] The term "hsa-miR-1247-3p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-1247-3p" refers to hsa-miR-1247 as described in Sequence ID No. 132. -3p gene (miRBase Accession No. MIMAT0022721) This includes homologs or orthologs of other biological species. hsa-miR-124 The 7-3p gene was identified by Morin RD et al., 2008, Genome Res, Vol. 18. It can be obtained by the method described on pages 610-621. Also, "hsa-miR "-1247-3p" has a hairpin-like structure as its precursor, "hsa-mir-12 47" (miRBase Accession No. MI0006382, Sequence ID 3) 51) is known.

[0211] The term "hsa-miR-6805-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-6805-5p" refers to hsa-miR-6805 as described in Sequence ID No. 133. -5p gene (miRBase Accession No. MIMAT0027510) This includes homologs or orthologs of other biological species, etc. hsa-miR-680 The 5-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6805-5p" has a hairpin-like structure as its precursor, "hsa-mir -6805 (miRBase Accession No. MI0022650, array) Number 324 is known.

[0212] The term "hsa-miR-4492 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "492" refers to the hsa-miR-4492 gene (mi) described in Sequence ID No. 134. RBase Accession No. MIMAT0019027) and other biological species This includes mologs or orthologs. The hsa-miR-4492 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4492" is used as its precursor. The "hsa-mir-4492" (miRBase Accessi) has a hairpin-like structure. (No.MI0016854, Sequence ID 352) is known.

[0213] The term "hsa-miR-1469 gene" or "hsa-miR-1" used herein refers to the "hsa-miR-1" gene used in this specification. The term "469" refers to the hsa-miR-1469 gene (mi) described in Sequence ID No. 135. RBase Accession No. MIMAT0007347) and other biological species This includes mologs or orthologs. The hsa-miR-1469 gene is Kaw The person described in aji H et al., 2008, BMC Genomics, Vol. 9, p. 157. It can be obtained by law. Also, "hsa-miR-1469" is its precursor. "hsa-mir-1469" (miRBase Access) adopts a hairpin-like structure. Ion No. MI0007074 (Sequence ID 353) is known.

[0214] The term "hsa-miR-1268b gene" or "hsa-miR-" used herein refers to the "hsa-miR-1268b gene" used herein. The term "1268b" refers to the hsa-miR-1268b gene described in Sequence ID No. 136. (miRBase Accession No.MIMAT0018925) and other This includes species homologs or orthologs. The hsa-miR-1268b gene is Jima DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by the method described above. Also, "hsa-miR-1268b" is the previous The "hsa-mir-1268b" (miRBase A) has a hairpin-like structure as its chassis. Accession No. MI0016748 (Sequence No. 354) is known.

[0215] The term "hsa-miR-6858-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6858-5p" refers to hsa-miR-6858 as described in Sequence ID No. 137. -5p gene (miRBase Accession No. MIMAT0027616) This includes homologs or orthologs of other biological species. hsa-miR-685 The 8-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6858-5p" has a hairpin-like structure as its precursor, "hsa-mir -6858 (miRBase Accession No. MI0022704, array) Number 355) is known.

[0216] The term "hsa-miR-3937 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3937 gene" or "hsa-miR-3 The term "937" refers to the hsa-miR-3937 gene (mi) described in Sequence ID No. 138. RBase Accession No. MIMAT0018352) and other biological species This includes mologs or orthologs. The hsa-miR-3937 gene is Lia o JY et al., 2010, PLoS One, Vol. 5, e10563 by the method described therein It can be obtained in this way. Also, "hsa-miR-3937" is a precursor to hair "hsa-mir-3937" (miRBase Accession) has a pin-like structure. No.MI0016593 (Sequence ID 356) is known.

[0217] The term "hsa-miR-939-5p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-939-5p" refers to hsa-miR-939-5p as described in Sequence ID No. 139. The gene (miRBase Accession No. MIMAT0004982) and so This includes homologs or orthologs of other biological species. hsa-miR-939-5p The gene was identified by Lui WO et al., 2007, Cancer Res, Vol. 67, p. 6031- It can be obtained by the method described in 6043. Also, "hsa-miR-939 -5p is a precursor of "hsa-mir-939" (mi), which has a hairpin-like structure. RBase Accession No. MI0005761 (Sequence ID 357) is known. It is being done.

[0218] The term "hsa-miR-3656 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3656 gene" or "hsa-miR-3 The term "656" refers to the hsa-miR-3656 gene (mi) described in Sequence ID No. 140. RBase Accession No. MIMAT0018076) and other biological species This includes mologs or orthologs. The hsa-miR-3656 gene is Mei ri E et al., 2010, Nucleic Acids Res, Vol. 38, p. 6234- It can be obtained by the method described in 6246. Also, "hsa-miR-365 "6" is "hsa-mir-3656" (miR), which has a hairpin-like structure as its precursor. Base Accession No. MI0016056 (Sequence ID 358) is known. It is.

[0219] The term "hsa-miR-744-5p gene" or "hsa-miR" as used herein refers to the "hsa-miR" gene used in this specification. The term "-744-5p" refers to hsa-miR-744-5p as described in Sequence ID No. 141. The gene (miRBase Accession No. MIMAT0004945) and so This includes homologs or orthologs of other biological species. hsa-miR-744-5p The gene was identified by Berezikov E et al., 2006, Genome Res, Vol. 16, p. It can be obtained by the method described in 1289-1298. Also, "hsa-mi "R-744-5p" has a hairpin-like structure as its precursor, "hsa-mir-74" 4" (miR Base Accession No. MI0005559, Sequence ID 35 9) is known.

[0220] The term "hsa-miR-4687-3p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-4687-3p" refers to hsa-miR-4687 as described in Sequence ID No. 142. -3p gene (miRBase Accession No. MIMAT0019775) This includes homologs or orthologs of other biological species. hsa-miR-468 The 7-3p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4687-3p" has a hairpin-like structure as its precursor, "hsa-mir-468 7" (miRBase Accession No. MI0017319, Sequence ID 36) 0) is known.

[0221] The term "hsa-miR-4763-3p gene" or "hsa-mi" used in this specification refers to the "hsa-miR-4763-3p gene" used herein. The term "R-4763-3p" refers to hsa-miR-4763 as described in Sequence ID No. 143. -3p gene (miRBase Accession No. MIMAT0019913) This includes homologs or orthologs of other biological species. hsa-miR-476 The 3-3p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4763-3p" has a hairpin-like structure as its precursor, "hsa-mir-476 3) (miRBase Accession No. MI0017404, Sequence ID 36) 1) is known.

[0222] The "hsa-miR-3620-5p gene" or "hsa-mi" used herein The term "R-3620-5p" refers to hsa-miR-3620 as described in Sequence ID No. 144. -5p gene (miRBase Accession No. MIMAT0022967) This includes homologs or orthologs of other biological species. hsa-miR-362 The 0-5p gene is described in Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. It can be obtained by the method described in "hsa-miR-3620-5p". " is a precursor that takes the hairpin-like structure of "hsa-mir-3620" (miRB The known sequence number (Accession No. MI0016011, Sequence ID 362) is Yes, they are.

[0223] The term "hsa-miR-3195 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3195 gene" or "hsa-miR-3 The term "195" refers to the hsa-miR-3195 gene (mi) described in Sequence ID No. 145. RBase Accession No. MIMAT0015079) and other biological species This includes mologs or orthologs. The hsa-miR-3195 gene is Sta According to the method described by rk MS et al., 2010, PLoS One, Vol. 5, e9685 It can be obtained in this way. Also, "hsa-miR-3195" is a precursor to hair The "hsa-mir-3195" (miRBase Accession) has a pin-like structure. No.MI0014240 (Sequence ID 363) is known.

[0224] The term "hsa-miR-6842-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6842-5p" refers to hsa-miR-6842 as described in Sequence ID No. 146. -5p gene (miRBase Accession No. MIMAT0027586) This includes homologs or orthologs of other biological species. hsa-miR-684 The 2-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6842-5p" has a hairpin-like structure as its precursor, "hsa-mir -6842 (miRBase Accession No. MI0022688, array) Number 364 is known.

[0225] The term "hsa-miR-4707-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-4707-5p" refers to hsa-miR-4707 as described in Sequence ID No. 147. -5p gene (miRBase Accession No. MIMAT0019807) This includes homologs or orthologs of other biological species. hsa-miR-470 The 7-5p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4707-5p" has a hairpin-like structure as its precursor, "hsa-mir-470 7" (miRBase Accession No. MI0017340, Sequence ID 36) 5) is known.

[0226] The term "hsa-miR-642a-3p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-642a-3p" refers to hsa-miR-642a as described in Sequence ID No. 148. -3p gene (miRBase Accession No. MIMAT0020924) This includes homologs or orthologs of other biological species. hsa-miR-642 The a-3p gene was identified by Cummins JM et al. in 2006 as Proc Natl Aca d Obtained by the method described in Sci USA, Vol. 103, pp. 3687-3692 It is possible to do so. Also, "hsa-miR-642a-3p" is a precursor of hair "hsa-mir-642a" (miRBase Accession) adopts a pin-like structure. No.MI0003657 (sequence number 366) is known.

[0227] The term "hsa-miR-7113-3p gene" or "hsa-mi" used in this specification refers to the "hsa-mi" gene. The term "R-7113-3p" is used in the sequence number 149 of hsa-miR-7113. -3p gene (miRBase Accession No. MIMAT0028124) This includes homologs or orthologs of other biological species. hsa-miR-711 The 3-3p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-7113-3p" has a hairpin-like structure as its precursor, "hsa-mir -7113 (miRBase Accession No.MI0022964, array) Number 367) is known.

[0228] The term "hsa-miR-4728-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-4728-5p" refers to hsa-miR-4728 as described in Sequence ID No. 150. -5p gene (miRBase Accession No. MIMAT0019849) This includes homologs or orthologs of other biological species. hsa-miR-472 The 8-5p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4728-5p" has a hairpin-like structure as its precursor, "hsa-mir-472 8" (miRBase Accession No. MI0017365, Sequence ID 36) 8) is known.

[0229] The term "hsa-miR-5195-3p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-5195-3p" refers to hsa-miR-5195 as described in Sequence ID No. 151. -3p gene (miRBase Accession No. MIMAT0021127) This includes homologs or orthologs of other biological species. hsa-miR-519 The 5-3p gene was identified by Schotte D et al., 2011, Leukemia, Vol. 25, p It can be obtained by the method described in 1389-1399. Also, "hsa-mi "R-5195-3p" has a hairpin-like structure as its precursor, "hsa-mir-5 195 (miRBase Accession No. MI0018174, Sequence ID) 369) is known.

[0230] The term "hsa-miR-1185-1-3p gene" or "hsa-" used herein refers to the "hsa- The term "miR-1185-1-3p" is used in the sequence number 152 of hsa-miR- 1185-1-3p gene (miRBase Accession No. MIMAT0) This includes 022838) and other species homologs or orthologs. hsa-m The iR-1185-1-3p gene was identified by Berezikov E et al., 2006, in Genetics. It can be obtained by the method described in me Res, Vol. 16, pp. 1289-1298. Furthermore, "hsa-miR-1185-1-3p" has a hairpin-like structure as its precursor. The structure is "hsa-mir-1185-1" (miRBase Accession N o.MI0003844 (Sequence ID 370) is known.

[0231] The term "hsa-miR-6774-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-6774-5p" refers to hsa-miR-6774 as described in Sequence ID No. 153. -5p gene (miRBase Accession No. MIMAT0027448) This includes homologs or orthologs of other biological species. hsa-miR-677 The 4-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6774-5p" has a hairpin-like structure as its precursor, "hsa-mir -6774 (miRBase Accession No.MI0022619, array) Number 371) is known.

[0232] The term "hsa-miR-8059 gene" or "hsa-miR-8" as used herein refers to the "hsa-miR-8" gene used in this specification. The term "059" refers to the hsa-miR-8059 gene (mi) described in Sequence ID No. 154. RBase Accession No. MIMAT0030986) and other biological species This includes mologs or orthologs. The hsa-miR-8059 gene is a Wan According to the method described by g HJ et al., 2013, Shock, Vol. 39, pp. 480-487 It can be obtained in this way. Also, "hsa-miR-8059" is a precursor to hair The "hsa-mir-8059" (miRBase Accession) has a pin-like structure. No.MI0025895 (Sequence ID 372) is known.

[0233] The term "hsa-miR-3131 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3131 gene" or "hsa-miR-3 The term "131" refers to the hsa-miR-3131 gene (mi) described in Sequence ID No. 155. RBase Accession No. MIMAT0014996) and other biological species This includes mologs or orthologs. The hsa-miR-3131 gene is Sta According to the method described by rk MS et al., 2010, PLoS One, Vol. 5, e9685 It can be obtained in this way. Also, "hsa-miR-3131" is a precursor to hair The "hsa-mir-3131" (miRBase Accession) has a pin-like structure. No.MI0014151 (Sequence ID 373) is known.

[0234] The term "hsa-miR-7847-3p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-7847-3p" refers to hsa-miR-7847 as described in Sequence ID No. 156. -3p gene (miRBase Accession No. MIMAT0030422) This includes homologs or orthologs of other biological species. hsa-miR-784 The 7-3p gene was identified by Ple H et al., 2012, PLoS One, Vol. 7, e50746. It can be obtained by the method described in "hsa-miR-7847-3p " is a precursor that takes the hairpin-like structure of "hsa-mir-7847" (miRB The accession number (MI0025517, sequence number 374) is known. Yes, they are.

[0235] The term "hsa-miR-4463 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene used in this specification. The term "463" refers to the hsa-miR-4463 gene (mi) described in Sequence ID No. 157. RBase Accession No. MIMAT0018987) and other biological species This includes mologs or orthologs. The hsa-miR-4463 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4463" is a precursor to [method]. "hsa-mir-4463" (miRBase Accessi) has a hairpin-like structure. (No.MI0016811, Sequence ID 375) is known.

[0236] The terms "hsa-miR-128-2-5p gene" or "hsa-m" used herein refer to the "hsa-miR-128-2-5p gene" used herein. The term "iR-128-2-5p" refers to hsa-miR-12 as described in Sequence ID No. 158. 8-2-5p gene (miRBase Accession No. MIMAT0031) This includes 095) and other species homologs or orthologs. The 128-2-5p gene was identified by Lagos-Quintana M et al. in 2002, Cur It can be obtained by the method described in Biol, Vol. 12, pp. 735-739. Furthermore, "hsa-miR-128-2-5p" has a hairpin-like structure as its precursor. "hsa-mir-128-2" (miRBase Accession No. MI 0000727 (sequence number 376) is known.

[0237] The term "hsa-miR-4508 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "508" refers to the hsa-miR-4508 gene (mi) described in Sequence ID No. 159. RBase Accession No. MIMAT0019045) and other biological species This includes mologs or orthologs. The hsa-miR-4508 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4508" is used as its precursor. The "hsa-mir-4508" (miRBase Accessi) has a hairpin-like structure. (No.MI0016872, Sequence ID 377) is known.

[0238] The term "hsa-miR-6806-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6806-5p" refers to hsa-miR-6806 as described in Sequence ID No. 160. -5p gene (miRBase Accession No. MIMAT0027512) This includes homologs or orthologs of other biological species, etc. hsa-miR-680 The 6-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6806-5p" has a hairpin-like structure as its precursor, "hsa-mir -6806 (miRBase Accession No. MI0022651, array) Number 378 is known.

[0239] The term "hsa-miR-7111-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-7111-5p" refers to hsa-miR-7111 as described in Sequence ID No. 161. -5p gene (miRBase Accession No. MIMAT0028119) This includes homologs or orthologs of other biological species. hsa-miR-711 The 1-5p genes were identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-7111-5p" has a hairpin-like structure as its precursor, "hsa-mir -7111 (miRBase Accession No. MI0022962, array) Number 379 is known.

[0240] The term "hsa-miR-6782-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6782-5p" refers to hsa-miR-6782 as described in Sequence ID No. 162. -5p gene (miRBase Accession No. MIMAT0027464) This includes homologs or orthologs of other biological species. hsa-miR-678 The 2-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6782-5p" has a hairpin-like structure as its precursor, "hsa-mir -6782 (miRBase Accession No. MI0022627, array) Number 380 is known.

[0241] The term "hsa-miR-4734 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "734" refers to the hsa-miR-4734 gene (mi) described in Sequence ID No. 163. RBase Accession No. MIMAT0019859) and other biological species This includes mologs or orthologs. The hsa-miR-4734 gene is Per Sson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the following method. Furthermore, "hsa-miR-4734" is its precursor. The "hsa-mir-4734" (miRBase Acce) has a hairpin-like structure. Scsion No. MI0017371 (Sequence No. 381) is known.

[0242] The "hsa-miR-3162-5p gene" or "hsa-mi" used herein The term "R-3162-5p" refers to hsa-miR-3162 as described in Sequence ID No. 164. -5p gene (miRBase Accession No. MIMAT0015036) This includes homologs or orthologs of other biological species. hsa-miR-316 The 2-5p gene was identified by Stark MS et al., 2010, PLoS One, Vol. 5, e96. It can be obtained by the method described in 85. Also, "hsa-miR-3162- "5p" has a hairpin-like structure as its precursor, "hsa-mir-3162" (mi RBase Accession No. MI0014192 (Sequence ID 382) is known. It is being done.

[0243] The term "hsa-miR-887-3p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-887-3p" refers to hsa-miR-887-3p as described in Sequence ID No. 165. The gene (miRBase Accession No. MIMAT0004951) and so This includes homologs or orthologs of other biological species. hsa-miR-887-3p The gene was identified by Berezikov E et al., 2006, Genome Res, Vol. 16, p. It can be obtained by the method described in 1289-1298. Also, "hsa-mi "R-887-3p" has a hairpin-like structure as its precursor, "hsa-mir-88 7" (miRBase Accession No. MI0005562, Sequence ID 38) 3) is known.

[0244] The "hsa-miR-6752-5p gene" or "hsa-mi" used herein The term "R-6752-5p" refers to hsa-miR-6752 as described in Sequence ID No. 166. -5p gene (miRBase Accession No. MIMAT0027404) This includes homologs or orthologs of other biological species. hsa-miR-675 The 2-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6752-5p" has a hairpin-like structure as its precursor, "hsa-mir -6752 (miRBase Accession No. MI0022597, array) Number 384 is known.

[0245] The term "hsa-miR-6724-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6724-5p" refers to hsa-miR-6724 as described in Sequence ID No. 167. -5p gene (miRBase Accession No. MIMAT0025856) This includes homologs or orthologs of other biological species. hsa-miR-672 The 4-5p gene is described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. It can be obtained by the method described. Also, "hsa-miR-6724-5p" Its precursor is "hsa-mir-6724" (miRBa Accession No. MI0022559, Sequence ID 385) is known. ru.

[0246] The term "hsa-miR-23b-3p gene" or "hsa-miR" used in this specification refers to the "hsa-miR" gene. The term "-23b-3p" refers to hsa-miR-23b-3p as described in Sequence ID No. 168. The gene (miRBase Accession No. MIMAT0000418) and so This includes homologs or orthologs of other biological species. hsa-miR-23b-3p The gene was identified by Lagos-Quintana M et al., 2002, Curr Biol, 1 It can be obtained by the method described on pages 735-739 of Volume 2. Also, "hsa- "miR-23b-3p" has a hairpin-like structure as its precursor, "hsa-mir- 23b" (miRBase Accession No. MI0000439, Sequence ID) 386) is known.

[0247] The term "hsa-miR-23a-3p gene" or "hsa-miR" used in this specification refers to the "hsa-miR" gene. The term "-23a-3p" refers to hsa-miR-23a-3p as described in Sequence ID No. 169. The gene (miRBase Accession No. MIMAT0000078) and so This includes homologs or orthologs of other biological species. hsa-miR-23a-3p The gene was identified by Lagos-Quintana M et al., 2001, Science, 294. It can be obtained by the method described in Volume 853-858. Also, "hsa-m "iR-23a-3p" has a hairpin-like structure as its precursor, "hsa-mir-2 3a (miRBase Accession No. MI0000079, Sequence ID 3) 87) is known.

[0248] The term "hsa-miR-625-3p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-625-3p" refers to hsa-miR-625-3p as described in Sequence ID No. 170. The gene (miRBase Accession No. MIMAT0004808) and so This includes homologs or orthologs of other biological species. hsa-miR-625-3p The gene was identified by Cummins JM et al., 2006, Proc Natl Acad Sc. Obtained by the method described in i USA, Vol. 103, pp. 3687-3692. This can be done. Also, "hsa-miR-625-3p" has a hairpin-like structure as its precursor. The design is "hsa-mir-625" (miRBase Accession No.M I0003639 (Sequence ID 388) is known.

[0249] The term "hsa-miR-1228-3p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-1228-3p" refers to hsa-miR-1228 as described in Sequence ID No. 171. -3p gene (miRBase Accession No. MIMAT0005583) This includes homologs or orthologs of other biological species. hsa-miR-122 The 8-3p gene was identified by Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-mi "R-1228-3p" has a hairpin-like structure as its precursor, "hsa-mir-1 228 (miRBase Accession No. MI0006318, Sequence ID) 316) is known.

[0250] The term "hsa-miR-614 gene" or "hsa-miR-61" used in this specification refers to the "hsa-miR-614 gene" or "hsa-miR-61 The term "4" refers to the hsa-miR-614 gene (miRBa) described in Sequence ID No. 172. (se Accession No. MIMAT0003282) and other species homologs Alternatively, it may include orthologs, etc. The hsa-miR-614 gene is Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103 It can be obtained by the method described on pages 3687-3692. Also, "hsa- "miR-614" has a hairpin-like structure as its precursor, "hsa-mir-614" (miRBase Accession No. MI0003627, Sequence ID 389) ) is known.

[0251] The term "hsa-miR-1913 gene" or "hsa-miR-1" used in this specification refers to the "hsa-miR-1913 gene" or "hsa-miR-1 The term "913" refers to the hsa-miR-1913 gene (mi) described in Sequence ID No. 173. RBase Accession No. MIMAT0007888) and other biological species This includes mologs or orthologs. The hsa-miR-1913 gene is Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. It can be obtained by the following method. Also, "hsa-miR-1913" is its precursor. "hsa-mir-1913" (miRBase Acce Scsion No. MI0008334 (Sequence No. 390) is known.

[0252] The terms "hsa-miR-92a-2-5p gene" or "hsa-m" used herein refer to the "hsa-miR-92a-2-5p gene" used herein. The term "iR-92a-2-5p" refers to hsa-miR-92 as described in Sequence ID No. 174. a-2-5p gene (miRBase Accession No. MIMAT0004) This includes 508) and other species homologs or orthologs. The 92a-2-5p gene was identified by Mourelatos Z et al., 2002, and Genes D. It can be obtained by the method described in ev, volume 16, pp. 720-728. Also, "hsa-miR-92a-2-5p" has a hairpin-like structure as its precursor, "hs a-mir-92a-2” (miRBase Accession No. MI0000 (Sequence ID 094, Sequence ID 391) is known.

[0253] The term "hsa-miR-187-5p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-187-5p" refers to hsa-miR-187-5p as described in Sequence ID No. 175. The gene (miRBase Accession No. MIMAT0004561) and so This includes homologs or orthologs of other biological species. hsa-miR-187-5p The gene was described by Lim LP et al., 2003, Science, Vol. 299, p. 1540. It can be obtained by the method described. Also, "hsa-miR-187-5p" is "hsa-mir-187" (miRBase A), which takes on a hairpin-like structure as a precursor, is a precursor of [the product name]. Accession No. MI0000274 (Sequence No. 392) is known.

[0254] The term "hsa-miR-16-5p gene" or "hsa-miR-" used herein refers to the "hsa-miR-16-5p gene" used herein. The term "16-5p" refers to the hsa-miR-16-5p gene described in Sequence ID No. 176. (miRBase Accession No.MIMAT0000069) and other This includes species homologs or orthologs. The hsa-miR-16-5p gene is Lagos-Quintana M et al., 2001, Science, Vol. 294, p. 8 It can be obtained by the method described in 53-858. Also, "hsa-miR-1 "6-5p" has a hairpin-like structure as its precursor, "hsa-mir-16-1". "hsa-mir-16-2" (miRBase Accession No. MI00 (00070, MI0000115, SEQ ID NOs: 393, 394) are known.

[0255] The term "hsa-miR-92b-3p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-92b-3p" refers to hsa-miR-92b-3p as described in Sequence ID No. 177. The gene (miRBase Accession No. MIMAT0003218) and so This includes homologs or orthologs of other biological species. hsa-miR-92b-3p The gene was identified by Cummins JM et al., 2006, Proc Natl Acad Sc. i. USA, Vol. 103, pp. 3687-3692 can be obtained by the method described therein. Yes, it is possible. Also, "hsa-miR-92b-3p" has a hairpin-like structure as its precursor. Take "hsa-mir-92b" (miRBase Accession No. MI (0003560, Sequence ID 395) is known.

[0256] The term "hsa-miR-150-3p gene" or "hsa-miR" used in this specification refers to the "hsa-miR" gene. The term "-150-3p" refers to hsa-miR-150-3p as described in Sequence ID No. 178. The gene (miRBase Accession No. MIMAT0004610) and so This includes homologs or orthologs of other biological species. hsa-miR-150-3p The gene was identified by Lagos-Quintana M et al., 2002, Curr Biol, 1 It can be obtained by the method described on pages 735-739 of Volume 2. Also, "hsa- "miR-150-3p" has a hairpin-like structure as its precursor, "hsa-mir- 150 (miRBase Accession No. MI0000479, Sequence ID) 396) is known.

[0257] The term "hsa-miR-564 gene" or "hsa-miR-564 gene" used herein refers to the "hsa-miR-564 gene" used herein. The term "4" refers to the hsa-miR-564 gene (miRBa) described in Sequence ID No. 179. (se Accession No. MIMAT0003228) and other species homologs Alternatively, it may include orthologs, etc. The hsa-miR-564 gene is Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103 It can be obtained by the method described on pages 3687-3692. Also, "hsa- "miR-564" has a hairpin-like structure as its precursor, "hsa-mir-564" (miRBase Accession No. MI0003570, Sequence ID 397) ) is known.

[0258] The term "hsa-miR-125a-3p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-125a-3p" refers to hsa-miR-125a as described in Sequence ID No. 180. -3p gene (miRBase Accession No. MIMAT0004602) This includes homologs or orthologs of other biological species. hsa-miR-125 The a-3p gene was identified by Lagos-Quintana M et al. in 2002, and by Curr Biology. It can be obtained by the method described in ol, Vol. 12, pp. 735-739. "hsa-miR-125a-3p" is a precursor of "hsa" which has a hairpin-like structure. -mir-125a” (miRBase Accession No. MI000046 9. Sequence ID 398 is known.

[0259] The term "hsa-miR-92b-5p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-92b-5p" refers to hsa-miR-92b-5p as described in Sequence ID No. 181. The gene (miRBase Accession No. MIMAT0004792) and so This includes homologs or orthologs of other biological species. hsa-miR-92b-5p The gene was identified by Cummins JM et al., 2006, Proc Natl Acad Sc. i. USA, Vol. 103, pp. 3687-3692 can be obtained by the method described therein. Yes, it is possible. Also, "hsa-miR-92b-5p" has a hairpin-like structure as its precursor. Take "hsa-mir-92b" (miRBase Accession No. MI (0003560, Sequence ID 395) is known.

[0260] The term "hsa-miR-92a-3p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-92a-3p" refers to hsa-miR-92a-3p as described in Sequence ID No. 182. The gene (miRBase Accession No. MIMAT0000092) and so This includes homologs or orthologs of other biological species. hsa-miR-92a-3p The gene was identified by Mourelatos Z et al., 2002, Genes Dev, Vol. 16, p. It can be obtained by the method described in 720-728. Also, "hsa-miR- "92a-3p" has a hairpin-like structure as its precursor, "hsa-mir-92a- 1”, “hsa-mir-92a-2” (miRBase Accession No. MI0000093, MI0000094, and sequence numbers 399 and 391 are known.

[0261] The "hsa-miR-663a gene" or "hsa-miR-6" used in this specification The term "63a" refers to the hsa-miR-663a gene (mi) described in Sequence ID No. 183. RBase Accession No. MIMAT0003326) and other biological species This includes mologs or orthologs. The hsa-miR-663a gene is Cumm Mins JM et al., 2006, Proc Natl Acad Sci USA, It can be obtained by the method described in Volume 103, pp. 3687-3692. "hsa-miR-663a" has a hairpin-like structure as its precursor, "hsa-mi r-663a” (miRBase Accession No. MI0003672, Column number 400) is known.

[0262] The terms "hsa-miR-4688 gene" or "hsa-miR-4" used herein refer to the "hsa-miR-4" gene. The term "688" refers to the hsa-miR-4688 gene (mi) described in Sequence ID No. 184. RBase Accession No. MIMAT0019777) and other biological species It includes mologs or orthologs. The hsa-miR-4688 gene is Per Sson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the following method. Furthermore, "hsa-miR-4688" is its precursor. "hsa-mir-4688" (miRBase Acce Scsion No. MI0017321 (Sequence No. 401) is known.

[0263] The term "hsa-miR-4648 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "648" refers to the hsa-miR-4648 gene (mi) described in Sequence ID No. 185. RBase Accession No. MIMAT0019710) and other biological species This includes mologs or orthologs. The hsa-miR-4648 gene is Per Sson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the following method. Furthermore, "hsa-miR-4648" is its precursor. "hsa-mir-4648" (miRBase Acce Scsion No. MI0017275 (Sequence No. 402) is known.

[0264] The term "hsa-miR-6085 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene used in this specification. The term "085" refers to the hsa-miR-6085 gene (mi) described in Sequence ID No. 186. RBase Accession No. MIMAT0023710) and other biological species This includes mologs or orthologs. The hsa-miR-6085 gene is Voe The person described in Ilenkle C et al., 2012, RNA, Vol. 18, pp. 472-484. It can be obtained by law. Also, "hsa-miR-6085" is its precursor. The "hsa-mir-6085" (miRBase Access) has a hairpin-like structure. Ion No. MI0020362 (Sequence ID 403) is known.

[0265] The term "hsa-miR-6126 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene used in this specification. The term "126" refers to the hsa-miR-6126 gene (mi) described in Sequence ID No. 187. RBase Accession No. MIMAT0024599) and other biological species This includes mologs or orthologs. The hsa-miR-6126 gene is Smi This is described in JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. It can be obtained by the following method. Furthermore, "hsa-miR-6126" is its precursor. The "hsa-mir-6126" (miRBase Acce) takes on a hairpin-like structure. Scsion No. MI0021260 (Sequence No. 404) is known.

[0266] The term "hsa-miR-6880-5p gene" or "hsa-mi" used herein refers to the same gene used in this specification. The term "R-6880-5p" refers to hsa-miR-6880 as described in Sequence ID No. 188. -5p gene (miRBase Accession No. MIMAT0027660) This includes homologs or orthologs of other biological species. hsa-miR-688 The 0-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6880-5p" has a hairpin-like structure as its precursor, "hsa-mir -6880" (miRBase Accession No. MI0022727, array) Number 405 is known.

[0267] The term "hsa-miR-328-5p gene" or "hsa-miR" as used herein refers to the "hsa-miR" gene used in this specification. The term "-328-5p" refers to hsa-miR-328-5p as described in Sequence ID No. 189. The gene (miRBase Accession No. MIMAT0026486) and so This includes homologs or orthologs of other biological species. hsa-miR-328-5p The gene was identified by Kim J et al., 2004, Proc Natl Acad Sci US. It can be obtained by the method described in Volume A, Vol. 101, pp. 360-365. Also, "hsa-miR-328-5p" has a hairpin-like structure as its precursor "hsa -mir-328” (miRBase Accession No. MI0000804 (Sequence number 406) is known.

[0268] The term "hsa-miR-6768-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6768-5p" refers to hsa-miR-6768 as described in Sequence ID No. 190. -5p gene (miRBase Accession No. MIMAT0027436) This includes homologs or orthologs of other biological species. hsa-miR-676 The 8-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6768-5p" has a hairpin-like structure as its precursor, "hsa-mir -6768 (miRBase Accession No. MI0022613, array) Number 407) is known.

[0269] The term "hsa-miR-3180 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3180 gene" or "hsa-miR-3 The term "180" refers to the hsa-miR-3180 gene (mi) described in Sequence ID No. 191. RBase Accession No. MIMAT0018178) and other biological species This includes mologs or orthologs. The hsa-miR-3180 gene is Cre Nighton CJ et al., 2010, PLoS One, Vol. 5, e9637. It can be obtained by the method. Also, "hsa-miR-3180" is its precursor and The "hsa-mir-3180-4" and "hsa-mir-31" have a hairpin-like structure. 80-5” (miRBase Accession No. MI0016408, MI0 The sequence numbers 016409, 408, and 409 are known.

[0270] The term "hsa-miR-6087 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene. The term "087" refers to the hsa-miR-6087 gene (mi) described in Sequence ID No. 192. RBase Accession No. MIMAT0023712) and other biological species This includes mologs or orthologs. The hsa-miR-6087 gene is Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. It can be obtained by the method described in [the document]. Also, "hsa-miR-6087" is Its precursor is "hsa-mir-6087" (miRBase), which has a hairpin-like structure. Accession No. MI0020364 (Sequence ID 410) is known.

[0271] The terms "hsa-miR-1273g-3p gene" or "hsa-m" used in this specification refer to the "hsa-miR-1273g-3p gene" used herein. The term "iR-1273g-3p" refers to hsa-miR-12 as described in Sequence ID No. 193. 73g-3p gene (miRBase Accession No. MIMAT0022) This includes 742) and other species homologs or orthologs. The 1273g-3p gene was identified by Reshmi G et al., 2011, Genomics, 97. It can be obtained by the method described in Volume 333-340. Also, "hsa-m "iR-1273g-3p" has a hairpin-like structure as its precursor, "hsa-mir". -1273g” (miRBase Accession No. MI0018003, Column number 411) is known.

[0272] The term "hsa-miR-1225-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-1225-5p" refers to hsa-miR-1225 as described in Sequence ID No. 194. -5p gene (miRBase Accession No. MIMAT0005572) This includes homologs or orthologs of other biological species. hsa-miR-122 The 5-5p gene was identified by Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-mi "R-1225-5p" has a hairpin-like structure as its precursor, "hsa-mir-1 225 (miRBase Accession No. MI0006311, Sequence ID) 303) is known.

[0273] The term "hsa-miR-3196 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3196 gene" or "hsa-miR-3 The term "196" refers to the hsa-miR-3196 gene (mi) described in Sequence ID No. 195. RBase Accession No. MIMAT0015080) and other biological species This includes mologs or orthologs. The hsa-miR-3196 gene is Sta According to the method described by rk MS et al., 2010, PLoS One, Vol. 5, e9685 It can be obtained in this way. Also, "hsa-miR-3196" is a precursor to hair "hsa-mir-3196" (miRBase Accession) adopts a pin-like structure. No.MI0014241 (Sequence ID 412) is known.

[0274] The "hsa-miR-4695-5p gene" or "hsa-mi" used herein The term "R-4695-5p" refers to hsa-miR-4695 as described in Sequence ID No. 196. -5p gene (miRBase Accession No. MIMAT0019788) This includes homologs or orthologs of other biological species. hsa-miR-469 The 5-5p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4695-5p" has a hairpin-like structure as its precursor, "hsa-mir-469 5" (miRBase Accession No. MI0017328, Sequence ID 41) 3) is known.

[0275] The "hsa-miR-6732-5p gene" or "hsa-mi" used herein The term "R-6732-5p" refers to hsa-miR-6732 as described in Sequence ID No. 197. -5p gene (miRBase Accession No. MIMAT0027365) This includes homologs or orthologs of other biological species. hsa-miR-673 The 2-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6732-5p" has a hairpin-like structure as its precursor, "hsa-mir -6732 (miRBase Accession No. MI0022577, array) Number 414 is known.

[0276] The term "hsa-miR-638 gene" or "hsa-miR-638 gene" used in this specification refers to the "hsa-miR-638 gene" used in this specification. The term "8" refers to the hsa-miR-638 gene (miRBa) described in Sequence ID No. 198. (se Accession No. MIMAT0003308) and other species homologs Alternatively, it may include orthologs, etc. The hsa-miR-638 gene is Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103 It can be obtained by the method described on pages 3687-3692. Also, "hsa- "miR-638" has a hairpin-like structure as its precursor, "hsa-mir-638" (miRBase Accession No. MI0003653, Sequence ID 415) ) is known.

[0277] The term "hsa-miR-6813-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6813-5p" refers to hsa-miR-6813 as described in Sequence ID No. 199. -5p gene (miRBase Accession No. MIMAT0027526) This includes homologs or orthologs of other biological species. hsa-miR-681 The 3-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6813-5p" has a hairpin-like structure as its precursor, "hsa-mir -6813 (miRBase Accession No. MI0022658, array) Number 416) is known.

[0278] The term "hsa-miR-665 gene" or "hsa-miR-665 gene" used in this specification refers to the "hsa-miR-665 gene" used in this specification. The term "5" refers to the hsa-miR-665 gene (miRBa) described in Sequence ID No. 200. (se Accession No. MIMAT0004952) and other species homologs Alternatively, it includes orthologs, etc. The hsa-miR-665 gene is Berezik ov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298. It can be obtained by the method described. Also, "hsa-miR-665" is its precursor. The "hsa-mir-665" (miRBase Acce) has a hairpin-like structure as its body. Scsion No. MI0005563 (Sequence No. 417) is known.

[0279] The term "hsa-miR-486-3p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-486-3p" refers to hsa-miR-486-3p as described in Sequence ID No. 201. The gene (miRBase Accession No. MIMAT0004762) and so This includes homologs or orthologs of other biological species. hsa-miR-486-3p The gene is described in Fu H et al., 2005, FEBS Lett, Vol. 579, pp. 3849-38. It can be obtained by the method described in 54. Also, "hsa-miR-486-3 "p" has a hairpin-like structure as its precursor, "hsa-mir-486", "hsa -mir-486-2” (miRBase Accession No. MI00024 70, MI0023622, SEQ ID NOs. 418, 419 are known.

[0280] The term "hsa-miR-4466 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "466" refers to the hsa-miR-4466 gene (mi) described in Sequence ID No. 202. RBase Accession No. MIMAT0018993) and other biological species This includes mologs or orthologs. The hsa-miR-4466 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4466" is a precursor to [method]. "hsa-mir-4466" (miRBase Accessi) has a hairpin-like structure. (No.MI0016817, Sequence ID 420) is known.

[0281] The terms "hsa-miR-30c-1-3p gene" or "hsa-m" used in this specification refer to the "hsa-miR-30c-1-3p gene" used herein. The term "iR-30c-1-3p" is used in the HSA-MIR-30 sequence number 203. c-1-3p gene (miRBase Accession No. MIMAT0004) This includes 674) and other species homologs or orthologs. The 30c-1-3p gene was identified by Lagos-Quintana M et al. in 2002, Cur It can be obtained by the method described in Biol, Vol. 12, pp. 735-739. Furthermore, "hsa-miR-30c-1-3p" has a hairpin-like structure as its precursor. "hsa-mir-30c-1" (miRBase Accession No. MI 0000736 (sequence number 421) is known.

[0282] The term "hsa-miR-3621 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3621 gene" or "hsa-miR-3 The term "621" refers to the hsa-miR-3621 gene (mi) described in Sequence ID No. 204. RBase Accession No. MIMAT0018002) and other biological species This includes mologs or orthologs. The hsa-miR-3621 gene is Wit By the method described in ten D et al., 2010, BMC Biol, Vol. 8, p. 58 It can be obtained. Also, "hsa-miR-3621" is a hairpin as its precursor. "hsa-mir-3621" (miRBase Accession N) takes a unique structure. o.MI0016012 (sequence number 422) is known.

[0283] The "hsa-miR-6743-5p gene" or "hsa-mi" used herein The term "R-6743-5p" refers to hsa-miR-6743 as described in Sequence ID No. 205. -5p gene (miRBase Accession No. MIMAT0027387) This includes homologs or orthologs of other biological species. hsa-miR-674 The 3-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6743-5p" has a hairpin-like structure as its precursor, "hsa-mir -6743 (miRBase Accession No. MI0022588, array) Number 423) is known.

[0284] The term "hsa-miR-4298 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4298 gene" used in this specification. The term "298" refers to the hsa-miR-4298 gene (mi) described in Sequence ID No. 206. RBase Accession No. MIMAT0016852) and other biological species This includes mologs or orthologs. The hsa-miR-4298 gene is a Gof f LA et al., 2009, PLoS One, Vol. 4, e7192, by the method described therein It can be obtained by [method]. In addition, "hsa-miR-4298" is a precursor of hair "hsa-mir-4298" (miRBase Accession) takes on a n-like structure. No.MI0015830 (Sequence ID 424) is known.

[0285] The term "hsa-miR-4741 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "741" refers to the hsa-miR-4741 gene (mi) described in Sequence ID No. 207. RBase Accession No. MIMAT0019871) and other biological species This includes mologs or orthologs. The hsa-miR-4741 gene is Per Sson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the following method. Furthermore, "hsa-miR-4741" is its precursor. "hsa-mir-4741" (miRBase Acce Scion No. MI0017379 (Sequence No. 425) is known.

[0286] The term "hsa-miR-3619-3p gene" or "hsa-mi" used in this specification refers to the "hsa-mi" gene. The term "R-3619-3p" refers to hsa-miR-3619 as described in Sequence ID No. 208. -3p gene (miRBase Accession No. MIMAT0019219) This includes homologs or orthologs of other biological species. hsa-miR-361 The 9-3p gene is described in Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. It can be obtained by the method described in "hsa-miR-3619-3p " is a precursor that takes the hairpin-like structure of "hsa-mir-3619" (miRB The known sequence number (Accession No. MI0016009, Sequence ID 426) is Yes, they are.

[0287] The term "hsa-miR-6824-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6824-5p" refers to hsa-miR-6824 as described in Sequence ID No. 209. -5p gene (miRBase Accession No. MIMAT0027548) This includes homologs or orthologs of other biological species. hsa-miR-682 The 4-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6824-5p" has a hairpin-like structure as its precursor, "hsa-mir -6824 (miRBase Accession No. MI0022669, array) Number 427) is known.

[0288] The term "hsa-miR-5698 gene" or "hsa-miR-5" as used herein refers to the "hsa-miR-5698 gene" used herein. The term "698" refers to the hsa-miR-5698 gene (mi) described in Sequence ID No. 210. RBase Accession No. MIMAT0022491) and other biological species This includes mologs or orthologs. The hsa-miR-5698 gene is Wat The person described in ahiki A et al., 2011, PLoS One, Vol. 6, e24950. It can be obtained by law. Also, "hsa-miR-5698" is its precursor. "hsa-mir-5698" (miRBase Access) takes on a hairpin-like structure. Ion No. MI0019305 (Sequence ID 428) is known.

[0289] The term "hsa-miR-371a-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-371a-5p" refers to hsa-miR-371a as described in Sequence ID No. 211. -5p gene (miRBase Accession No. MIMAT0004687) This includes homologs or orthologs of other biological species. hsa-miR-371 The a-5p gene is described in Suh MR et al., 2004, Dev Biol, Vol. 270, p. 48. It can be obtained by the method described in 8-498. Also, "hsa-miR-37 "1a-5p" has a hairpin-like structure as its precursor, "hsa-mir-371a". (miRBase Accession No. MI0000779, Sequence ID 429) It is known that...

[0290] The terms "hsa-miR-4488 gene" or "hsa-miR-4" used herein refer to the "hsa-miR-4" gene. The term "488" refers to the hsa-miR-4488 gene (mi) described in Sequence ID No. 212. RBase Accession No. MIMAT0019022) and other biological species This includes mologs or orthologs. The hsa-miR-4488 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4488" is its precursor. The "hsa-mir-4488" (miRBase Accessi) has a hairpin-like structure. (No.MI0016849, Sequence ID 430) is known.

[0291] The term "hsa-miR-1233-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-1233-5p" is used in the sequence number 213 of hsa-miR-1233. -5p gene (miRBase Accession No. MIMAT0022943) This includes homologs or orthologs of other biological species. hsa-miR-123 The 3-5p gene was identified by Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-mi "R-1233-5p" has a hairpin-like structure as its precursor, "hsa-mir-1 233-1”, “hsa-mir-1233-2” (miRBase Accessio n No.MI0006323, MI0015973, Sequence IDs 431, 432 are known. It is being done.

[0292] The term "hsa-miR-4723-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-4723-5p" refers to hsa-miR-4723 as described in Sequence ID No. 214. -5p gene (miRBase Accession No. MIMAT0019838) This includes homologs or orthologs of other biological species. hsa-miR-472 The 3-5p gene was identified by Persson H et al., 2011, Cancer Res, Vol. 71. It can be obtained by the method described on pages 78-86. Also, "hsa-miR- "4723-5p" has a hairpin-like structure as its precursor, "hsa-mir-472 3) (miRBase Accession No. MI0017359, Sequence ID 43) 3) is known.

[0293] The term "hsa-miR-24-3p gene" or "hsa-miR-" used herein refers to the "hsa-miR-24-3p gene" used herein. The term "24-3p" refers to the hsa-miR-24-3p gene described in Sequence ID No. 215. (miRBase Accession No.MIMAT0000080) and other raw materials This includes species homologs or orthologs. The hsa-miR-24-3p gene is Lagos-Quintana M et al., 2001, Science, Vol. 294, p. 8 It can be obtained by the method described in 53-858. Also, "hsa-miR-2 "4-3p" has a hairpin-like structure as its precursor, "hsa-mir-24-1". "hsa-mir-24-2" (miRBase Accession No. MI00 (00080, MI0000081, SEQ ID NOs. 434, 435) are known.

[0294] The term "hsa-miR-1238-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-1238-5p" refers to hsa-miR-1238 as described in Sequence ID No. 216. -5p gene (miRBase Accession No. MIMAT0022947) This includes homologs or orthologs of other biological species. hsa-miR-123 The 8-5p gene was identified by Berezikov E et al., 2007, Mol Cell, Vol. 28. It can be obtained by the method described on pages 328-336. Also, "hsa-mi "R-1238-5p" has a hairpin-like structure as its precursor, "hsa-mir-1 238 (miRBase Accession No. MI0006328, Sequence ID) 436) is known.

[0295] The term "hsa-miR-4442 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "442" refers to the hsa-miR-4442 gene (mi) described in Sequence ID No. 217. RBase Accession No. MIMAT0018960) and other biological species This includes mologs or orthologs. The hsa-miR-4442 gene is Jim a. The method described by DD et al., 2010, Blood, Vol. 116, e118-e127. It can be obtained by [method]. In addition, "hsa-miR-4442" is a precursor to [method]. "hsa-mir-4442" (miRBase Accessi) has a hairpin-like structure. (No.MI0016785, Sequence ID 437) is known.

[0296] The term "hsa-miR-3928-3p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-3928-3p" refers to hsa-miR-3928 as described in Sequence ID No. 218. -3p gene (miRBase Accession No. MIMAT0018205) This includes homologs or orthologs of other biological species. hsa-miR-392 The 8-3p gene was identified by Creighton CJ et al., 2010, PLoS One, Vol. 5. It can be obtained by the method described in e9637. Also, "hsa-miR-3 "928-3p" has a hairpin-like structure as its precursor, "hsa-mir-3928 (miRBase Accession No. MI0016438, Sequence ID 438) ) is known.

[0297] The term "hsa-miR-6716-5p gene" or "hsa-mi" used herein refers to the same gene used in this document. The term "R-6716-5p" refers to hsa-miR-6716 as described in Sequence ID No. 219. -5p gene (miRBase Accession No. MIMAT0025844) This includes homologs or orthologs of other biological species. hsa-miR-671 The 6-5p gene is described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. It can be obtained by the method described. Also, "hsa-miR-6716-5p" Its precursor is "hsa-mir-6716" (miRBa), which has a hairpin-like structure. Accession No. MI0022550, Sequence ID 439 is known. ru.

[0298] The term "hsa-miR-6089 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene. The term "089" refers to the hsa-miR-6089 gene (mi) described in Sequence ID No. 220. RBase Accession No. MIMAT0023714) and other biological species This includes mologs or orthologs. The hsa-miR-6089 gene is Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. It can be obtained by the method described in [the document]. Also, "hsa-miR-6089" is As a precursor, it has a hairpin-like structure, "hsa-mir-6089-1", "hsa- mir-6089-2” (miRBase Accession No. MI00203 66, MI0023563, and sequence numbers 440 and 441 are known.

[0299] The term "hsa-miR-6124 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene used in this specification. The term "124" refers to the hsa-miR-6124 gene (mi) described in Sequence ID No. 221. RBase Accession No. MIMAT0024597) and other biological species This includes mologs or orthologs. The hsa-miR-6124 gene is Smi This is described in JL et al., 2012, J Virol, Vol. 86, pp. 5278-5287. It can be obtained by the following method. Furthermore, "hsa-miR-6124" is its precursor. The "hsa-mir-6124" (miRBase Acce) has a hairpin-like structure. Scsion No. MI0021258 (Sequence No. 442) is known.

[0300] The term "hsa-miR-6778-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi The term "R-6778-5p" refers to hsa-miR-6778 as described in Sequence ID No. 222. -5p gene (miRBase Accession No. MIMAT0027456) This includes homologs or orthologs of other biological species. hsa-miR-677 The 8-5p gene was identified by Ladewig E et al., 2012, Genome Res, Vol. 22. It can be obtained by the method described on pages 1634-1645. Also, "hsa- "miR-6778-5p" has a hairpin-like structure as its precursor, "hsa-mir -6778 (miRBase Accession No. MI0022623, array) Number 443 is known.

[0301] The term "hsa-miR-557 gene" or "hsa-miR-55" as used herein refers to the "hsa-miR-557 gene" used herein. The term "7" refers to the hsa-miR-557 gene (miRBa) described in Sequence ID No. 223. (se Accession No. MIMAT0003221) and other species homologs Alternatively, it may include orthologs, etc. The hsa-miR-557 gene is Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103 It can be obtained by the method described on pages 3687-3692. Also, "hsa- "miR-557" has a hairpin-like structure as its precursor, "hsa-mir-557" (miRBase Accession No. MI0003563, Sequence ID 444) ) is known.

[0302] The term "hsa-miR-6090 gene" or "hsa-miR-6" as used herein refers to the "hsa-miR-6" gene used in this specification. The term "090" refers to the hsa-miR-6090 gene (mi) described in Sequence ID No. 224. RBase Accession No. MIMAT0023715) and other biological species This includes mologs or orthologs. The hsa-miR-6090 gene is Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. It can be obtained by the method described in [the document]. Also, "hsa-miR-6090" is Its precursor is "hsa-mir-6090" (miRBase), which has a hairpin-like structure. Accession No. MI0020367 (Sequence ID 445) is known.

[0303] The "hsa-miR-6757-5p gene" or "hsa-mi" used herein The term "R-6757-5p" refers to hsa-miR-6757 as described in Sequence ID No. 714. -5p gene (miRBase Accession No. MIMAT0027414) This includes homologs or orthologs of other biological species, etc. hsa-miR-67 The 57-5p gene was identified by Ladewig E et al., 2012, Genome Res., 2 It can be obtained by the method described in Volume 2, pp. 1634-1645. Also, "hs "a-miR-6757-5p" has a hairpin-like structure as its precursor, "hsa-m ir-6757” (miRBase Accession No. MI0022602, Sequence ID 730 is known.

[0304] The term "hsa-miR-4448 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "448" refers to the hsa-miR-4448 gene (mi) described in Sequence ID No. 715. RBase Accession No. MIMAT0018967) and other biological species This includes mologs or orthologs. The hsa-miR-4448 gene is Ji The person described in ma DD et al., 2010, Blood, Vol. 116, e118-e127 It can be obtained by law. Also, "hsa-miR-4448" is its precursor. The "hsa-mir-4448" (miRBase Access) has a hairpin-like structure. Ion No. MI0016791 (Sequence ID 731) is known.

[0305] The term "hsa-miR-671-5p gene" or "hsa-miR" used herein refers to the "hsa-miR" gene used in this specification. The term "-671-5p" refers to hsa-miR-671-5p as described in Sequence ID No. 716. The gene (miRBase Accession No. MIMAT0003880) and so This includes homologs or orthologs of other biological species. hsa-miR-671-5 The p gene was identified by Berezikov E et al., 2006, Genome Res, Vol. 16. It can be obtained by the method described on pages 1289-1298. Also, "hsa-m "iR-671-5p" has a hairpin-like structure as its precursor, "hsa-mir-6 71" (miRBase Accession No. MI0003760, Sequence ID 7) 32) is known.

[0306] The term "hsa-miR-3178 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3178 gene" or "hsa-miR-3 The term "178" refers to the hsa-miR-3178 gene (mi) described in Sequence ID No. 717. RBase Accession No. MIMAT0015055) and other biological species This includes mologs or orthologs. The hsa-miR-3178 gene is St The method described in ark MS et al., 2010, PLoS One, Vol. 5, e9685 Therefore, it can be obtained. Also, "hsa-miR-3178" is used as its precursor. "hsa-mir-3178" (miRBase Accessio) adopts an appin-like structure. The following is known: (n No.MI0014212, Sequence ID 733)

[0307] The term "hsa-miR-4725-3p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-4725-3p" refers to hsa-miR-4725 as described in Sequence ID No. 718. -3p gene (miRBase Accession No. MIMAT0019844) This includes homologs or orthologs of other biological species. hsa-miR-47 The 25-3p gene was identified by Persson H et al., 2011, Cancer Res, 71. It can be obtained by the method described in Volume 78-86. Also, "hsa-miR "-4725-3p" has a hairpin-like structure as its precursor, "hsa-mir-47 25" (miRBase Accession No. MI0017362, Sequence ID 7) 34) is known.

[0308] The term "hsa-miR-940 gene" or "hsa-miR-94" as used herein refers to the same gene used in this document. The term "0" refers to the hsa-miR-940 gene (miRBa) described in Sequence ID No. 719. (Se Accession No. MIMAT0004983) and other species homologs Alternatively, orthologs may be included. The hsa-miR-940 gene is Lui WO Furthermore, it was published in A Cancer Res., Vol. 67, pp. 6031-6043, in 2007. It can be obtained by the following method. Also, "hsa-miR-940" is its precursor. The "hsa-mir-940" (miRBase Acces) has a hairpin-like structure. Ssion No. MI0005762 (Sequence No. 735) is known.

[0309] The term "hsa-miR-6789-5p gene" or "hsa-mi" as used herein refers to the "hsa-mi" gene used in this specification. The term "R-6789-5p" refers to hsa-miR-6789 as described in Sequence ID No. 720. -5p gene (miRBase Accession No. MIMAT0027478) This includes homologs or orthologs of other biological species, etc. hsa-miR-67 The 89-5p gene was identified by Ladewig E et al., 2012, Genome Res., 2 It can be obtained by the method described in issue 2, pp. 1634-1645. Also, "hs a-miR-6789-5p has a hairpin-like structure as its precursor, hsa-m ir-6789” (miRBase Accession No. MI0022634, Sequence ID 736 is known.

[0310] The term "hsa-miR-4484 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "484" refers to the hsa-miR-4484 gene (mi) described in Sequence ID No. 721. RBase Accession No. MIMAT0019018) and other biological species This includes mologs or orthologs. The hsa-miR-4484 gene is Ji ma DD et al., 2010, Blood., Vol. 116, e118-e127. It can be obtained by the method. Also, "hsa-miR-4484" is its precursor and The "hsa-mir-4484" (miRBase Acces) adopts a hairpin-like structure. Sion No. MI0016845 (Sequence No. 737) is known.

[0311] The term "hsa-miR-4634 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4634 gene" used in this specification. The term "634" refers to the hsa-miR-4634 gene (mi) described in Sequence ID No. 722. RBase Accession No. MIMAT0019691) and other biological species This includes mologs or orthologs. The hsa-miR-4634 gene is Pe Rrsson H et al., 2011, Cancer Res., Vol. 71, pp. 78-86. It can be obtained by the method described. Also, "hsa-miR-4634" is the previous The "hsa-mir-4634" (miRBase Ac) has a hairpin-like structure as its chassis. Cession No. MI0017261 (Sequence No. 738) is known.

[0312] The term "hsa-miR-4745-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-4745-5p" is used in the HSA-MI R-4745 described in Sequence ID No. 723. -5p gene (miRBase Accession No. MIMAT0019878) This includes homologs or orthologs of other biological species. hsa-miR-47 The 45-5p gene was identified by Persson H et al., 2011, Cancer Res, 71. It can be obtained by the method described in Volume 78-86. Also, "hsa-miR "-4745-5p" has a hairpin-like structure as its precursor, "hsa-mir-47 45" (miRBase Accession No. MI0017384, Sequence ID 7) 39) is known.

[0313] The term "hsa-miR-4730 gene" or "hsa-miR-4" as used herein refers to the "hsa-miR-4" gene. The term "730" refers to the hsa-miR-4730 gene (mi) described in Sequence ID No. 724. RBase Accession No. MIMAT0019852) and other biological species This includes mologs or orthologs. The hsa-miR-4730 gene is Pe Rrsson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. It can be obtained by the method described above. Also, "hsa-miR-4730" is its precursor. The "hsa-mir-4730" (miRBase Acc) has a hairpin-like structure as its body. The entry No. MI0017367 (sequence number 740) is known.

[0314] The term "hsa-miR-6803-5p gene" or "hsa-mi" used herein refers to the "hsa-mi" gene used in this specification. The term "R-6803-5p" refers to hsa-miR-6803 as described in Sequence ID No. 725. -5p gene (miRBase Accession No. MIMAT0027506) This includes homologs or orthologs of other biological species. hsa-miR-68 The 03-5p gene was identified by Ladewig E et al., 2012, Genome Res, 22 It can be obtained by the method described in Volume 1634-1645. Also, "hsa "-miR-6803-5p" has a hairpin-like structure as its precursor, "hsa-mi r-6803” (miRBase Accession No. MI0022648, Column number 741) is known.

[0315] The "hsa-miR-6798-5p gene" or "hsa-mi" used herein The term "R-6798-5p" refers to hsa-miR-6798 as described in Sequence ID No. 726. -5p gene (miRBase Accession No. MIMAT0027496) This includes homologs or orthologs of other biological species, etc. hsa-miR-67 The 98-5p gene was identified by Ladewig E et al., 2012, Genome Res, 22 It can be obtained by the method described in Volume 1634-1645. Also, "hsa -miR-6798-5p is a precursor to "hsa-mi" which has a hairpin-like structure. r-6798” (miRBase Accession No. MI0022643, Column number 742) is known.

[0316] The term "hsa-miR-3648 gene" or "hsa-miR-3" used in this specification refers to the "hsa-miR-3648 gene" or "hsa-miR-3 The term "648" refers to the hsa-miR-3648 gene (mi) described in Sequence ID No. 727. RBase Accession No. MIMAT0018068) and other biological species This includes mologs or orthologs. The hsa-miR-3648 gene is Me iri E et al., 2010, Nucleic Acids Res, Vol. 38, p. 62-34. It can be obtained by the method described in -6246. Also, "hsa-miR-36 "48" is a precursor that takes the hairpin-like structure of "hsa-mir-3648" (mi RBase Accession No. MI0016048 (Sequence ID 743) is known. It is being done.

[0317] The term "hsa-miR-4783-3p gene" or "hsa-mi" used in this specification refers to the "hsa-mi" gene. The term "R-4783-3p" refers to hsa-miR-4783 as described in Sequence ID No. 728. -3p gene (miRBase Accession No. MIMAT0019947) This includes homologs or orthologs of other biological species. hsa-miR-47 The 83-3p gene was identified by Persson H et al., 2011, Cancer Res, 71. It can be obtained by the method described in Volume 78-86. Also, "hsa-miR "-4783-3p" has a hairpin-like structure as its precursor, "hsa-mir-47 83" (miRBase Accession No. MI0017428, Sequence ID 7) 44) is known.

[0318] The term "hsa-miR-6836-3p gene" or "hsa-mi" used in this specification refers to the "hsa-mi" gene. The term "R-6836-3p" refers to hsa-miR-6836 as described in Sequence ID No. 729. -3p gene (miRBase Accession No. MIMAT0027575) This includes homologs or orthologs of other biological species. hsa-miR-68 The 36-3p gene was identified by Ladewig E et al., 2012, Genome Res., 2 It can be obtained by the method described in issue 2, pp. 1634-1645. Also, "hs a-miR-6836-3p has a hairpin-like structure as its precursor, hsa-m ir-6836” (miRBase Accession No. MI0022682, Sequence ID 745 is known.

[0319] Furthermore, mature miRNAs are formed from RNA precursors that take on a hairpin-like structure. When A is excised, one to several bases before and after the sequence may be excised to be shorter or longer. Base substitutions can occur, resulting in mutants called isomiR (Morin R D. et al., 2008, Genome Res., Vol. 18, pp. 610-621). In RBase Release 20, either sequence numbers 1-224 or 714-729 In addition to the base sequence represented by , there are numerous isomiR sequences, number 446-713. Variants and fragments of the base sequence represented by any of the 746-765 are also shown. These variants also have bases represented by SEQ ID NOs: 1-224 and 714-729. It can be obtained as a miRNA having a sequence.

[0320] That is, the sequence numbers 1, 3, 4, 6, 7, 10, 11, 13, 14, 16, 1 of the present invention 7, 20, 22, 26, 29, 36, 38, 39, 40, 42, 43, 44, 46, 49 , 52, 59, 60, 62, 63, 65, 66, 67, 72, 76, 77, 78, 81, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 96, 100, 103, 105, 106, 107, 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 124, 125, 126, 130, 132, 134, 136, 139, 140, 141, 142, 143, 144, 145, 147, 148, 150, 151, 152, 155, 157, 158, 159, 163, 164, 165, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 187, 189, 191, 192, 193, 195, 196, 198, 200, 201, 202, 203, 206, 207, 210, 211, 212, 213, 214, 215, 217, 218, 219, 220, 221, 715, 716, 717, 718, 719, 721, The base sequence represented by 723, 724, 727, and 728, or in said base sequence, u Among the variants of a polynucleotide consisting of the base sequence t, for example, miRBase As the longest variants registered in Release 20, each is sequence number 446. ,448,450,452,454,456,458,460,462,464,466 ,468,470,472,474,476,478,480,482,484,486 ,488,490,492,494,496,498,500,502,504,506 , 508, 510, 512, 514, 516, 518, 520, 522, 524, 526 , 528, 530, 532, 534, 536, 538, 540, 542, 544, 546 , 548, 550, 552, 554, 556, 558, 560, 562, 564, 566 , 568, 570, 572, 574, 576, 578, 580, 582, 584, 586 , 588, 590, 592, 594, 596, 598, 600, 602, 604, 606 ,608,610,612,614,616,618,620,622,624,626 ,628,630,632,634,636,638,640,642,644,646 ,648,650,652,654,656,658,660,662,664,666 ,668,670,672,674,676,678,680,682,684,686 ,688,690,692,694,696,698,700,702,704,706 , 708, 710, 712, 746, 748, 750, 752, 754, 756, 758 Examples include polynucleotides represented by 760, 762, and 764.

[0321] Also, the sequence numbers 1, 3, 4, 6, 7, 10, 11, 13, 14, 16, 17 of the present invention, 20, 22, 26, 29, 36, 38, 39, 40, 42, 43, 44, 46, 49, 5 2, 59, 60, 62, 63, 65, 66, 67, 72, 76, 77, 78, 81, 83 , 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 96, 100, 10 3, 105, 106, 107, 113, 114, 115, 116, 117, 118, 11 9, 120, 121, 123, 124, 125, 126, 130, 132, 134, 13 6, 139, 140, 141, 142, 143, 144, 145, 147, 148, 15 0, 151, 152, 155, 157, 158, 159, 163, 164, 165, 16 7, 168, 169, 170, 171, 172, 173, 174, 175, 176, 17 7, 178, 179, 180, 181, 182, 183, 184, 185, 187, 18 9, 191, 192, 193, 195, 196, 198, 200, 201, 202, 20 3, 206, 207, 210, 211, 212, 213, 214, 215, 217, 21 8, 219, 220, 221, 715, 716, 717, 718, 719, 721, 72 3, 724, 727 and 728 are base sequences, or in said base sequences, u is t Among the variants of a polynucleotide consisting of a certain base sequence, for example, miRBase Re The shortest variants registered in lease 20 are, respectively, sequence numbers 447 and 4. 49, 451, 453, 455, 457, 459, 461, 463, 465, 467, 4 69, 471, 473, 475, 477, 479, 481, 483, 485, 487, 4 89, 491, 493, 495, 497, 499, 501, 503, 505, 507, 5 09, 511, 513, 515, 517, 519, 521, 523, 525, 527, 5 29, 531, 533, 535, 537, 539, 541, 543, 545, 547, 5 49, 551, 553, 555, 557, 559, 561, 563, 565, 567, 5 69, 571, 573, 575, 577, 579, 581, 583, 585, 587, 5 89, 591, 593, 595, 597, 599, 601, 603, 605, 607, 6 09, 611, 613, 615, 617, 619, 621, 623, 625, 627, 6 29, 631, 633, 635, 637, 639, 641, 643, 645, 647, 6 49, 651, 653, 655, 657, 659, 661, 663, 665, 667, 6 69, 671, 673, 675, 677, 679, 681, 683, 685, 687, 6 89, 691, 693, 695, 697, 699, 701, 703, 705, 707, 7 09, 711, 713, 747, 749, 751, 753, 755, 757, 759, 7 Examples include polynucleotides with sequences represented by 61, 763, and 765.

[0322] In addition to these mutants and fragments, there are also the following registered in miRBase, SEQ ID NOs: 1- Examples include polynucleotides that are isomiR, such as 224 and 714-729. Furthermore, the base sequence containing any of the sequence numbers 1-224 and 714-729 is included. Examples of dinucleotides include their precursors, SEQ ID NOs. 225-445 and 730, respectively. Examples of polynucleotides represented by any of the following numbers: ~745.

[0323] Gene names and miRBase Accessions represented by Sequence IDs 1-765 The registration numbers are listed in Table 1.

[0324] In this specification, "specifically binding" means the nucleic acid probe or protozoan used in the present invention. This means that the lymer binds to a specific target nucleic acid and is effectively unable to bind to other nucleic acids. .

[0325] [Table 1] TIFF2026063107000002.tif248108TIFF2026063107000003.tif248107TIFF2026063107000004.tif 247106TIFF2026063107000005.tif248107TIFF2026063107000006.tif247106TIFF20260631070000 07.tif247107TIFF2026063107000008.tif247107TIFF2026063107000009.tif247108TIFF20260631 07000010.tif247108TIFF2026063107000011.tif247109TIFF2026063107000012.tif246107TIFF20 26063107000013.tif246107TIFF2026063107000014.tif246108TIFF2026063107000015.tif247107 TIFF2026063107000016.tif246107TIFF2026063107000017.tif247107TIFF2026063107000018.tif 246109TIFF2026063107000019.tif246107TIFF2026063107000020.tif246108TIFF2026063107000021.tif247108TIFF2026063107000022.tif23107This specification is based on the specification of Japanese Patent Application No. 2014-124880, which is the basis for the priority of this application and It includes the contents described in the drawing. [Effects of the Invention]

[0326] This invention makes it possible to easily and accurately detect liver cancer. For example, This refers to the measurement of several miRNA levels in the patient's blood, serum, and / or plasma, which can be collected minimally invasively. This allows for easy detection of whether or not a patient has liver cancer. [Brief explanation of the drawing]

[0327] [Figure 1] This figure shows the sequence relationship between hsa-miR-1343-5p, represented by sequence number 131, and hsa-miR-1343-3p, represented by sequence number 1, which are generated from the precursor hsa-mir-1343, represented by sequence number 225. [Figure 2] Left figure: The vertical axis shows the measured values ​​of hsa-miR-1343-3p (Sequence ID 1) for healthy individuals (100 people) and liver cancer patients (34 people) selected as the training sample group. The horizontal line in the figure indicates the threshold (7.09) for distinguishing between the two groups, optimized by Fisher's discriminant analysis. Right figure: The vertical axis shows the measured values ​​of hsa-miR-1343-3p (Sequence ID 1) for healthy individuals (50 people) and liver cancer patients (16 people) selected as the test sample group. The horizontal line in the figure indicates the threshold (7.09) for distinguishing between the two groups, set for the training sample group. [Figure 3] Left figure: The horizontal axis shows the measured values ​​of hsa-miR-1343-3p (SEQ ID NO: 1) and the vertical axis shows the measured values ​​of hsa-miR-6726-5p (SEQ ID NO: 2) for the training sample group consisting of healthy individuals (100 people, circles) and liver cancer patients (34 people, triangles). The line in the figure shows the discriminant function (0=0.77x+y-15.07) optimized by Fisher's discriminant analysis to distinguish between the two groups. Right figure: The horizontal axis shows the measured values ​​of hsa-miR-1343-3p (SEQ ID NO: 1) and the vertical axis shows the measured values ​​of hsa-miR-6726-5p (SEQ ID NO: 2) for the test sample group consisting of healthy individuals (50 people, circles) and liver cancer patients (16 people, triangles). The line in the figure shows the threshold (0=0.77x+y-15.07) set for the training sample group to distinguish between the two groups. [Figure 4] Figure above: hsa-miR-6131 (SEQ ID NO: 7), hsa-miR-642a-3p (SEQ ID NO: 148), hsa-miR-7641 (SEQ ID NO: 9),42a-3p (SEQ ID NO: 148), hsa-miR-642a-3p (SEQ ID NO: 148), hsa-miR-642a-3p (SEQ ID NO: 148), hsa-miR-642a-3p (SEQ ID NO: 9), hsa-miR-642a-3p (SEQ ID NO: 148), hsa-miR-642a-3p (SEQ ID NO A discriminant formula was created using Fisher's discriminant analysis from the measured values ​​of R-6729-5p (sequence number 27) (0.88xhsa-miR-6131-1.58xhsa-miR-642a-3p+0.39xhsa-miR-7641-0.33xhsa-miR-6729-5p+5.19). The discriminant score obtained from this formula is plotted on the vertical axis, and the sample group is plotted on the horizontal axis. The dotted line in the figure indicates the discriminant boundary where the two groups are distinguished by a discriminant score of 0. The figure below shows the measured values ​​of hsa-miR-6131 (SEQ ID NO: 7), hsa-miR-642a-3p (SEQ ID NO: 148), hsa-miR-7641 (SEQ ID NO: 9), and hsa-miR-6729-5p (SEQ ID NO: 27) from 17 liver cancer patients, 51 healthy individuals, 28 pancreatic cancer patients, 37 biliary tract cancer patients, 15 colorectal cancer patients, 12 gastric cancer patients, 25 esophageal cancer patients, and 5 patients with benign pancreatic and biliary tract diseases, selected as the test sample group. The discriminant score obtained from the discriminant formula created for the training sample group is on the vertical axis, and the sample group is on the horizontal axis. The dotted line in the figure indicates the discriminant boundary where the discriminant score is 0, thus distinguishing between the two groups. [Modes for carrying out the invention]

[0328] The present invention will be described in more detail below.

[0329] 1. Target nucleic acids for liver cancer Using the nucleic acid probe or primer for liver cancer detection as defined above in the present invention, the liver As a liver cancer marker for detecting the presence and / or absence of liver cancer cells The main target nucleic acids include hsa-miR-1343-3p, hsa-miR-6726- 5p、hsa-miR-6515-3p、hsa-miR-4651、hsa-miR- 4257、hsa-miR-3188、hsa-miR-6131、hsa-miR-6 766-3p、hsa-miR-7641、hsa-miR-1249、hsa-miR -3679-3p、hsa-miR-6787-5p、hsa-miR-4454、hs a-miR-3135b, hsa-miR-6765-3p, hsa-miR-7975 hsa-miR-204-3p hsa-miR-7977 hsa-miR-711 0-5p、hsa-miR-6717-5p、hsa-miR-6870-5p、hsa -miR-663b、hsa-miR-6875-5p、hsa-miR-8072、h sa-miR-6816-5p, hsa-miR-4281, hsa-miR-6729 -5p, hsa-miR-8069, hsa-miR-4706, hsa-miR-71 08-5p、hsa-miR-4433b-3p、hsa-miR-6893-5p、h sa-miR-6857-5p, hsa-miR-1227-5p, hsa-miR-6 741-5p, hsa-miR-451a, hsa-miR-8063, hsa-miR -3622a-5p、hsa-miR-615-5p、hsa-miR-128-1-5 p、hsa-miR-6825-5p、hsa-miR-1260b、hsa-miR- 4433-3p、hsa-miR-4665-5p、hsa-miR-7845-5p、 hsa-miR-1908-5p, hsa-miR-6840-3p, hsa-miR- 6765-5p、hsa-miR-296-5p、hsa-miR-3675-3p、h sa-miR-6781-5p, hsa-miR-423-5p, hsa-miR-36 63-3p、hsa-miR-6784-5p、hsa-miR-6749-5p、hs a-miR-1231、hsa-miR-4746-3p、hsa-miR-6780b -5p、hsa-miR-4758-5p、hsa-miR-3679-5p、hsa- miR-3184-5p, hsa-miR-6125, hsa-miR-6721-5p hsa-miR-6791-5p hsa-miR-3185 hsa-miR-12 60a, hsa-miR-3197, hsa-miR-6845-5p, hsa-miR -6887-5p、hsa-miR-6738-5p、hsa-miR-6872-3p hsa-miR-4497 hsa-miR-1229-5p hsa-miR-68 20-5p、hsa-miR-6777-5p、hsa-miR-3917、hsa-m iR-5787, hsa-miR-4286, hsa-miR-6877-5p, hsa -miR-1225-3p、hsa-miR-6088、hsa-miR-6800-5 p、hsa-miR-1246、hsa-miR-4467、hsa-miR-4419 b、hsa-miR-1914-3p、hsa-miR-4632-5p、hsa-mi R-1915-5p、hsa-miR-3940-5p、hsa-miR-1185-2 -3p、hsa-miR-6746-5p、hsa-miR-5001-5p、hsa- miR-1228-5p, hsa-miR-5572, hsa-miR-4327, hs a-miR-4638-5p, hsa-miR-6799-5p, hsa-miR-68 61-5p、hsa-miR-6727-5p、hsa-miR-4513、hsa-m iR-6805-3p, hsa-miR-6808-5p, hsa-miR-4449 hsa-miR-1199-5p, hsa-miR-1275, hsa-miR-479 2、hsa-miR-4443、hsa-miR-6891-5p、hsa-miR-6 826-5p、hsa-miR-6807-5p、hsa-miR-7150、hsa- miR-4534, hsa-miR-4476, hsa-miR-4649-5p, hs a-miR-4525、hsa-miR-1915-3p、hsa-miR-4516、 hsa-miR-4417, hsa-miR-642b-3p, hsa-miR-314 1、hsa-miR-5100、hsa-miR-6848-5p、hsa-miR-4 739、hsa-miR-4459、hsa-miR-1237-5p、hsa-miR -296-3p、hsa-miR-4665-3p、hsa-miR-6786-5p、 hsa-miR-4258, hsa-miR-6510-5p, hsa-miR-134 3-5p、hsa-miR-1247-3p、hsa-miR-6805-5p、hsa -miR-4492、hsa-miR-1469、hsa-miR-1268b、hsa -miR-6858-5p、hsa-miR-3937、hsa-miR-939-5p hsa-miR-3656 hsa-miR-744-5p hsa-miR-468 7-3p、hsa-miR-4763-3p、hsa-miR-3620-5p、hsa -miR-3195、hsa-miR-6842-5p、hsa-miR-4707-5 p, hsa-miR-642a-3p, hsa-miR-7113-3p, hsa-mi R-4728-5p, hsa-miR-5195-3p, hsa-miR-1185-1 -3p, hsa-miR-6774-5p, hsa-miR-8059, hsa-miR -3131, hsa-miR-7847-3p, hsa-miR-4463, hsa-m iR-128-2-5p, hsa-miR-4508, hsa-miR-6806-5p , hsa-miR-7111-5p, hsa-miR-6782-5p, hsa-miR -4734, hsa-miR-3162-5p, hsa-miR-887-3p, hsa -miR-6752-5p, hsa-miR-6724-5p, hsa-miR-675 7-5p, hsa-miR-4448, hsa-miR-671-5p, hsa-miR -3178, hsa-miR-4725-3p, hsa-miR-940, hsa-mi R-6789-5p, hsa-miR-4484, hsa-miR-4634, hsa- miR-4745-5p, hsa-miR-4730, hsa-miR-6803-5p , hsa-miR-6798-5p, hsa-miR-3648, hsa-miR-47 At least one selected from the group consisting of 83-3p and hsa-miR-6836-3p More than one miRNA can be used. Furthermore, these miRNAs can be combined. Other liver cancer markers that can be used include, namely, hsa-miR-23b-3p, hsa- miR-23a-3p, hsa-miR-625-3p, hsa-miR-1228-3 p, hsa-miR-614, hsa-miR-1913, hsa-miR-92a-2 -5p, hsa-miR-187-5p, hsa-miR-16-5p, hsa-miR -92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-m iR-125a-3p, hsa-miR-92b-5p, hsa-miR-92a-3p and at least one miRN selected from the group consisting of hsa-miR-663a. A can also be preferably used as a target nucleic acid. Furthermore, these miRNAs can be combined Other liver cancer markers that can be used include hsa-miR-4688, hsa -miR-4648, hsa-miR-6085, hsa-miR-6126, hsa- miR-6880-5p, hsa-miR-328-5p, hsa-miR-6768- 5p, hsa-miR-3180, hsa-miR-6087, hsa-miR-127 3g-3p, hsa-miR-1225-5p, hsa-miR-3196, hsa-m iR-4695-5p, hsa-miR-6732-5p, hsa-miR-638, h sa-miR-6813-5p, hsa-miR-665, hsa-miR-486-3 p, hsa-miR-4466, hsa-miR-30c-1-3p, hsa-miR- 3621, hsa-miR-6743-5p, hsa-miR-4298, hsa-mi R-4741, hsa-miR-3619-3p, hsa-miR-6824-5p, h sa-miR-5698, hsa-miR-371a-5p, hsa-miR-4488 , hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR -24-3p, hsa-miR-1238-5p, hsa-miR-4442, hsa- miR-3928-3p, hsa-miR-6716-5p, hsa-miR-6089 , hsa-miR-6124, hsa-miR-6778-5p, hsa-miR-55 At least one miR selected from the group consisting of 7 and hsa-miR-6090 NA can also be preferably used as a target nucleic acid.

[0330] The above miRNAs include, for example, one of the sequence numbers 1-224 and 714-729. Human genes containing the represented base sequence (i.e., hsa-miR-1343- 3p, hsa-miR-6726-5p, hsa-miR-6515-3p, hsa-m iR-4651, hsa-miR-4257, hsa-miR-3188, hsa-mi R-6131, hsa-miR-6766-3p, hsa-miR-7641, hsa- miR-1249, hsa-miR-3679-3p, hsa-miR-6787-5p , hsa-miR-4454, hsa-miR-3135b, hsa-miR-6765 -3p, hsa-miR-7975, hsa-miR-204-3p, hsa-miR- 7977, hsa-miR-7110-5p, hsa-miR-6717-5p, hsa -miR-6870-5p, hsa-miR-663b, hsa-miR-6875-5 p, hsa-miR-8072, hsa-miR-6816-5p, hsa-miR-4 281, hsa-miR-6729-5p, hsa-miR-8069, hsa-miR -4706, hsa-miR-7108-5p, hsa-miR-4433b-3p, h sa-miR-6893-5p, hsa-miR-6857-5p, hsa-miR-1 227-5p, hsa-miR-6741-5p, hsa-miR-451a, hsa- miR-8063, hsa-miR-3622a-5p, hsa-miR-615-5p , hsa-miR-128-1-5p, hsa-miR-6825-5p, hsa-mi R-1260b、hsa-miR-4433-3p、hsa-miR-4665-5p、 hsa-miR-7845-5p、hsa-miR-1908-5p、hsa-miR- 6840-3p、hsa-miR-6765-5p、hsa-miR-296-5p、h sa-miR-3675-3p, hsa-miR-6781-5p, hsa-miR-4 23-5p、hsa-miR-3663-3p、hsa-miR-6784-5p、hs a-miR-6749-5p、hsa-miR-1231、hsa-miR-4746- 3p、hsa-miR-6780b-5p、hsa-miR-4758-5p、hsa- miR-3679-5p, hsa-miR-3184-5p, hsa-miR-6125 hsa-miR-6721-5p hsa-miR-6791-5p hsa-miR -3185, hsa-miR-1260a, hsa-miR-3197, hsa-miR -6845-5p、hsa-miR-6887-5p、hsa-miR-6738-5p hsa-miR-6872-3p hsa-miR-4497 hsa-miR-12 29-5p、hsa-miR-6820-5p、hsa-miR-6777-5p、hs a-miR-3917、hsa-miR-5787、hsa-miR-4286、hsa -miR-6877-5p、hsa-miR-1225-3p、hsa-miR-608 8、hsa-miR-6800-5p、hsa-miR-1246、hsa-miR-4 467、hsa-miR-4419b、hsa-miR-1914-3p、hsa-mi R-4632-5p、hsa-miR-1915-5p、hsa-miR-3940-5 p、hsa-miR-1185-2-3p、hsa-miR-6746-5p、hsa- miR-5001-5p, hsa-miR-1228-5p, hsa-miR-5572 hsa-miR-4327 hsa-miR-4638-5p hsa-miR-67 99-5p、hsa-miR-6861-5p、hsa-miR-6727-5p、hs a-miR-4513、hsa-miR-6805-3p、hsa-miR-6808- 5p、hsa-miR-4449、hsa-miR-1199-5p、hsa-miR- 1275、hsa-miR-4792、hsa-miR-4443、hsa-miR-6 891-5p、hsa-miR-6826-5p、hsa-miR-6807-5p、h sa-miR-7150, hsa-miR-4534, hsa-miR-4476, hs a-miR-4649-5p, hsa-miR-4525, hsa-miR-1915- 3p、hsa-miR-4516、hsa-miR-4417、hsa-miR-642 b-3p, hsa-miR-3141, hsa-miR-5100, hsa-miR-6 848-5p, hsa-miR-4739, hsa-miR-4459, hsa-miR -1237-5p、hsa-miR-296-3p、hsa-miR-4665-3p、 hsa-miR-6786-5p, hsa-miR-4258, hsa-miR-651 0-5p、hsa-miR-1343-5p、hsa-miR-1247-3p、hsa -miR-6805-5p、hsa-miR-4492、hsa-miR-1469、h sa-miR-1268b, hsa-miR-6858-5p, hsa-miR-393 7、hsa-miR-939-5p、hsa-miR-3656、hsa-miR-74 4-5p、hsa-miR-4687-3p、hsa-miR-4763-3p、hsa -miR-3620-5p、hsa-miR-3195、hsa-miR-6842-5 p、hsa-miR-4707-5p、hsa-miR-642a-3p、hsa-mi R-7113-3p, hsa-miR-4728-5p, hsa-miR-5195-3 p、hsa-miR-1185-1-3p、hsa-miR-6774-5p、hsa- miR-8059, hsa-miR-3131, hsa-miR-7847-3p, hs a-miR-4463, hsa-miR-128-2-5p, hsa-miR-4508 hsa-miR-6806-5p hsa-miR-7111-5p hsa-miR -6782-5p、hsa-miR-4734、hsa-miR-3162-5p、hs a-miR-887-3p, hsa-miR-6752-5p, hsa-miR-672 4-5p、hsa-miR-6757-5p、hsa-miR-4448、hsa-mi R-671-5p、hsa-miR-3178、hsa-miR-4725-3p、hs a-miR-940, hsa-miR-6789-5p, hsa-miR-4484, h sa-miR-4634, hsa-miR-4745-5p, hsa-miR-4730 hsa-miR-6803-5p hsa-miR-6798-5p hsa-miR -3648、hsa-miR-4783-3p、hsa-miR-6836-3p、hs a-miR-23b-3p、hsa-miR-23a-3p、hsa-miR-625- 3p、hsa-miR-1228-3p、hsa-miR-614、hsa-miR-1 913、hsa-miR-92a-2-5p、hsa-miR-187-5p、hsa- miR-16-5p, hsa-miR-92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-miR-125a-3p, hsa-miR-92b- 5p, hsa-miR-92a-3p, hsa-miR-663a, hsa-miR-4 688, hsa-miR-4648, hsa-miR-6085, hsa-miR-61 26, hsa-miR-6880-5p, hsa-miR-328-5p, hsa-mi R-6768-5p, hsa-miR-3180, hsa-miR-6087, hsa- miR-1273g-3p, hsa-miR-1225-5p, hsa-miR-319 6, hsa-miR-4695-5p, hsa-miR-6732-5p, hsa-mi R-638, hsa-miR-6813-5p, hsa-miR-665, hsa-mi R-486-3p, hsa-miR-4466, hsa-miR-30c-1-3p, h sa-miR-3621, hsa-miR-6743-5p, hsa-miR-4298 、hsa-miR-4741, hsa-miR-3619-3p, hsa-miR-68 24-5p, hsa-miR-5698, hsa-miR-371a-5p, hsa-m iR-4488, hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR-24-3p, hsa-miR-1238-5p, hsa-miR-44 42, hsa-miR-3928-3p, hsa-miR-6716-5p, hsa-m iR-6089, hsa-miR-6124, hsa-miR-6778-5p, hsa -miR-557 and hsa-miR-6090), its homologs, its transcriptional products, and its This includes variants or derivatives of the gene, homolog, transcript, variant, and derivative. This is as defined above.

[0331] Preferred target nucleic acids include human genomes containing a base sequence represented by any of SEQ ID NOs: 1 to 765. A gene, or its transcript, more preferably the transcript, i.e., miRNA, It is a precursor RNA, either pri-miRNA or pre-miRNA.

[0332] The first target gene is the hsa-miR-1343-3p gene, its congener, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0333] The second target gene is the hsa-miR-6726-5p gene, its congener, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0334] The third target gene is the hsa-miR-6515-3p gene, its congener, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0335] The fourth target gene is the hsa-miR-4651 gene, its congeners, and their derivatives. These are the photoproducts, or their variants or derivatives. To date, this gene or its transcripts have been produced. There are no known reports suggesting that changes in the expression of certain substances can serve as markers for liver cancer.

[0336] The fifth target gene is the hsa-miR-4257 gene, its congeners, and their derivatives. These are the photoproducts, or their variants or derivatives. To date, this gene or its transcripts have been produced. There are no known reports suggesting that changes in the expression of certain substances can serve as markers for liver cancer.

[0337] The sixth target gene is the hsa-miR-3188 gene, its congeners, and their derivatives. These are the photoproducts, or their variants or derivatives. To date, this gene or its transcripts have been produced. There are no known reports suggesting that changes in the expression of certain substances can serve as markers for liver cancer.

[0338] The seventh target gene is the hsa-miR-6131 gene, its congeners, and their derivatives. These are the photoproducts, or their variants or derivatives. To date, this gene or its transcripts have been produced. There are no known reports suggesting that changes in the expression of certain substances can serve as markers for liver cancer.

[0339] The eighth target gene is the hsa-miR-6766-3p gene, its congener, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0340] The ninth target gene is the hsa-miR-7641 gene, its congeners, and their derivatives. These are the photoproducts, or their variants or derivatives. To date, this gene or its transcripts have been produced. There are no known reports suggesting that changes in the expression of certain substances can serve as markers for liver cancer.

[0341] The tenth target gene is the hsa-miR-1249 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0342] The eleventh target gene is the hsa-miR-3679-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0343] The twelfth target gene is the hsa-miR-6787-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0344] The 13th target gene is the hsa-miR-4454 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0345] The 14th target gene is the hsa-miR-3135b gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0346] The 15th target gene is the hsa-miR-6765-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0347] The 16th target gene is the hsa-miR-7975 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0348] The 17th target gene is the hsa-miR-204-3p gene, its congeners, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0349] The 18th target gene is the hsa-miR-7977 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0350] The 19th target gene is the hsa-miR-7110-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0351] The 20th target gene is the hsa-miR-6717-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0352] The 21st target gene is the hsa-miR-6870-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0353] The 22nd target gene is the hsa-miR-663b gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0354] The 23rd target gene is the hsa-miR-6875-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0355] The 24th target gene is the hsa-miR-8072 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0356] The 25th target gene is the hsa-miR-6816-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0357] The 26th target gene is the hsa-miR-4281 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0358] The 27th target gene is the hsa-miR-6729-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0359] The 28th target gene is the hsa-miR-8069 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0360] The 29th target gene is the hsa-miR-4706 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0361] The 30th target gene is the hsa-miR-7108-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0362] The 31st target gene is the hsa-miR-4433b-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0363] The 32nd target gene is the hsa-miR-6893-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0364] The 33rd target gene is the hsa-miR-6857-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0365] The 34th target gene is the hsa-miR-1227-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0366] The 35th target gene is the hsa-miR-6741-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0367] The 36th target gene is the hsa-miR-451a gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0368] The 37th target gene is the hsa-miR-8063 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0369] The 38th target gene is the hsa-miR-3622a-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0370] The 39th target gene is the hsa-miR-615-5p gene, its congeners, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0371] The 40th target gene is the hsa-miR-128-1-5p gene and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0372] The 41st target gene is the hsa-miR-6825-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0373] The 42nd target gene is the hsa-miR-1260b gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0374] The 43rd target gene is the hsa-miR-4433-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0375] The 44th target gene is the hsa-miR-4665-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0376] The 45th target gene is the hsa-miR-7845-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0377] The 46th target gene is the hsa-miR-1908-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0378] The 47th target gene is the hsa-miR-6840-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0379] The 48th target gene is the hsa-miR-6765-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0380] The 49th target gene is the hsa-miR-296-5p gene, its congener, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0381] The 50th target gene is the hsa-miR-3675-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0382] The 51st target gene is the hsa-miR-6781-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0383] The 52nd target gene is the hsa-miR-423-5p gene, its congener, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0384] The 53rd target gene is the hsa-miR-3663-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0385] The 54th target gene is the hsa-miR-6784-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0386] The 55th target gene is the hsa-miR-6749-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0387] The 56th target gene is the hsa-miR-1231 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0388] The 57th target gene is the hsa-miR-4746-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0389] The 58th target gene is the hsa-miR-6780b-5p gene and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0390] The 59th target gene is the hsa-miR-4758-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0391] The 60th target gene is the hsa-miR-3679-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0392] The 61st target gene is the hsa-miR-3184-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0393] The 62nd target gene is the hsa-miR-6125 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0394] The 63rd target gene is the hsa-miR-6721-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0395] The 64th target gene is the hsa-miR-6791-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0396] The 65th target gene is the hsa-miR-3185 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0397] The 66th target gene is the hsa-miR-1260a gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0398] The 67th target gene is the hsa-miR-3197 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0399] The 68th target gene is the hsa-miR-6845-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0400] The 69th target gene is the hsa-miR-6887-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0401] The 70th target gene is the hsa-miR-6738-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0402] The 71st target gene is the hsa-miR-6872-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0403] The 72nd target gene is the hsa-miR-4497 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0404] The 73rd target gene is the hsa-miR-1229-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0405] The 74th target gene is the hsa-miR-6820-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0406] The 75th target gene is the hsa-miR-6777-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0407] The 76th target gene is the hsa-miR-3917 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0408] The 77th target gene is the hsa-miR-5787 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0409] The 78th target gene is the hsa-miR-4286 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0410] The 79th target gene is the hsa-miR-6877-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0411] The 80th target gene is the hsa-miR-1225-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0412] The 81st target gene is the hsa-miR-6088 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0413] The 82nd target gene is the hsa-miR-6800-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0414] The 83rd target gene is the hsa-miR-1246 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0415] The 84th target gene is the hsa-miR-4467 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0416] The 85th target gene is the hsa-miR-4419b gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0417] The 86th target gene is the hsa-miR-1914-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0418] The 87th target gene is the hsa-miR-4632-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0419] The 88th target gene is the hsa-miR-1915-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0420] The 89th target gene is the hsa-miR-3940-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0421] The 90th target gene is the hsa-miR-1185-2-3p gene and its congeners. , their transcripts, or their variants or derivatives. To date, this gene or There are no known reports that changes in the expression of its transcript can serve as a marker for liver cancer. stomach.

[0422] The 91st target gene is the hsa-miR-6746-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0423] The 92nd target gene is the hsa-miR-5001-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0424] The 93rd target gene is the hsa-miR-1228-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0425] The 94th target gene is the hsa-miR-5572 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0426] The 95th target gene is the hsa-miR-4327 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0427] The 96th target gene is the hsa-miR-4638-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0428] The 97th target gene is the hsa-miR-6799-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0429] The 98th target gene is the hsa-miR-6861-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0430] The 99th target gene is the hsa-miR-6727-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0431] The 100th target gene is the hsa-miR-4513 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0432] The 101st target gene is the hsa-miR-6805-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0433] The 102nd target gene is the hsa-miR-6808-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0434] The 103rd target genes are the hsa-miR-4449 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0435] The 104th target gene is the hsa-miR-1199-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0436] The 105th target genes are the hsa-miR-1275 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0437] The 106th target genes are the hsa-miR-4792 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0438] The 107th target gene is the hsa-miR-4443 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0439] The 108th target gene is the hsa-miR-6891-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0440] The 109th target gene is the hsa-miR-6826-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0441] The 110th target gene is the hsa-miR-6807-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0442] The 111th target gene is the hsa-miR-7150 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0443] The 112th target gene is the hsa-miR-4534 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0444] The 113th target gene is the hsa-miR-4476 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0445] The 114th target gene is the hsa-miR-4649-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0446] The 115th target gene is the hsa-miR-4525 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0447] The 116th target gene is the hsa-miR-1915-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0448] The 117th target gene is the hsa-miR-4516 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0449] The 118th target gene is the hsa-miR-4417 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0450] The 119th target gene is the hsa-miR-642b-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0451] The 120th target gene is the hsa-miR-3141 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0452] The 121st target genes are the hsa-miR-5100 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0453] The 122nd target gene is the hsa-miR-6848-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0454] The 123rd target gene is the hsa-miR-4739 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0455] The 124th target gene is the hsa-miR-4459 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0456] The 125th target gene is the hsa-miR-1237-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0457] The 126th target gene is the hsa-miR-296-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0458] The 127th target gene is the hsa-miR-4665-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0459] The 128th target gene is the hsa-miR-6786-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0460] The 129th target gene is the hsa-miR-4258 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0461] The 130th target gene is the hsa-miR-6510-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0462] The 131st target gene is the hsa-miR-1343-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0463] The 132nd target gene is the hsa-miR-1247-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0464] The 133rd target gene is the hsa-miR-6805-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0465] The 134th target genes are the hsa-miR-4492 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0466] The 135th target gene is the hsa-miR-1469 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0467] The 136th target gene is the hsa-miR-1268b gene, its congener, and These are transcripts of the gene or its variants or derivatives. There are no known reports suggesting that changes in transcript expression can serve as markers for liver cancer.

[0468] The 137th target gene is the hsa-miR-6858-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0469] The 138th target gene is the hsa-miR-3937 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0470] The 139th target gene is the hsa-miR-939-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0471] The 140th target gene is the hsa-miR-3656 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0472] The 141st target gene is the hsa-miR-744-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0473] The 142nd target gene is the hsa-miR-4687-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0474] The 143rd target gene is the hsa-miR-4763-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0475] The 144th target gene is the hsa-miR-3620-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0476] The 145th target genes are the hsa-miR-3195 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0477] The 146th target gene is the hsa-miR-6842-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0478] The 147th target gene is the hsa-miR-4707-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0479] The 148th target gene is the hsa-miR-642a-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0480] The 149th target gene is the hsa-miR-7113-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0481] The 150th target gene is the hsa-miR-4728-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0482] The 151st target gene is the hsa-miR-5195-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0483] The 152nd target gene is the hsa-miR-1185-1-3p gene and its relatives. This refers to the organism, its transcripts, or their variants or derivatives. Alternatively, it is known that changes in the expression of its transcript can serve as a marker for liver cancer. do not have.

[0484] The 153rd target gene is the hsa-miR-6774-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0485] The 154th target gene is the hsa-miR-8059 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0486] The 155th target gene is the hsa-miR-3131 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0487] The 156th target gene is the hsa-miR-7847-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0488] The 157th target gene is the hsa-miR-4463 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0489] The 158th target gene is the hsa-miR-128-2-5p gene and its congeners. , their transcripts, or their variants or derivatives. To date, this gene or There are no known reports that changes in the expression of its transcript can serve as a marker for liver cancer. stomach.

[0490] The 159th target gene is the hsa-miR-4508 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0491] The 160th target gene is the hsa-miR-6806-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0492] The 161st target gene is the hsa-miR-7111-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0493] The 162nd target gene is the hsa-miR-6782-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0494] The 163rd target gene is the hsa-miR-4734 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0495] The 164th target gene is the hsa-miR-3162-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0496] The 165th target gene is the hsa-miR-887-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0497] The 166th target gene is the hsa-miR-6752-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0498] The 167th target gene is the hsa-miR-6724-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0499] The 168th target gene is the hsa-miR-23b-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. (Authorized documents 2 and 3).

[0500] The 169th target gene is the hsa-miR-23a-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. Permitted document 2).

[0501] The 170th target gene is the hsa-miR-625-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. Permitted document 4).

[0502] The 171st target gene is the hsa-miR-1228-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0503] The 172nd target gene is the hsa-miR-614 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. It has been reported that changes in the expression of a certain product can serve as a marker for liver cancer (Patent Document). 2).

[0504] The 173rd target genes are the hsa-miR-1913 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. It has been reported that changes in the expression of photoproteins can serve as markers for liver cancer (Patent document) Reference 4).

[0505] The 174th target gene is the hsa-miR-92a-2-5p gene and its congeners. , their transcripts, or their variants or derivatives. To date, this gene or It has been reported that changes in the expression of its transcript can serve as a marker for liver cancer. (Patent Document 1).

[0506] The 175th target gene is the hsa-miR-187-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. Permitted document 5).

[0507] The 176th target gene is the hsa-miR-16-5p gene, its congeners, and These are transcripts of the gene or its variants or derivatives. It has been reported that changes in transcript expression can serve as a marker for liver cancer (Patent References 4 and 5).

[0508] The 177th target gene is the hsa-miR-92b-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. Permitted document 1).

[0509] The 178th target gene is the hsa-miR-150-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. Permitted document 2).

[0510] The 179th target gene is the hsa-miR-564 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. It has been reported that changes in the expression of a certain product can serve as a marker for liver cancer (Patent Document). 2).

[0511] The 180th target gene is the hsa-miR-125a-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or It has been reported that changes in the expression of that transcript may serve as a marker for liver cancer. Patent Document 3).

[0512] The 181st target gene is the hsa-miR-92b-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. Permitted document 1).

[0513] The 182nd target gene is the hsa-miR-92a-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. (Authorized documents 1, 4, and 5).

[0514] The 183rd target gene is the hsa-miR-663a gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. It has been reported that changes in the expression of photoproteins can serve as markers for liver cancer (Patent document) Reference 4).

[0515] The 184th target gene is the hsa-miR-4688 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0516] The 185th target gene is the hsa-miR-4648 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0517] The 186th target gene is the hsa-miR-6085 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0518] The 187th target gene is the hsa-miR-6126 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0519] The 188th target gene is the hsa-miR-6880-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0520] The 189th target gene is the hsa-miR-328-5p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its There are no known reports suggesting that changes in the expression of this transcript can serve as a marker for liver cancer.

[0521] The 190th target gene is the hsa-miR-6768-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0522] The 191st target genes are the hsa-miR-3180 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0523] The 192nd target gene is the hsa-miR-6087 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0524] The 193rd target gene is the hsa-miR-1273g-3p gene and its congeners. , their transcripts, or their variants or derivatives. To date, this gene or There are no known reports that changes in the expression of its transcript can serve as a marker for liver cancer. stomach.

[0525] The 194th target gene is the hsa-miR-1225-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0526] The 195th target gene is the hsa-miR-3196 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0527] The 196th target gene is the hsa-miR-4695-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0528] The 197th target gene is the hsa-miR-6732-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0529] The 198th target gene is the hsa-miR-638 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0530] The 199th target gene is the hsa-miR-6813-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0531] The 200th target gene is the hsa-miR-665 gene, its congeners, and their This refers to the transcript, or its variants or derivatives. There are no known reports suggesting that changes in the expression of certain products can serve as markers for liver cancer.

[0532] The 201st target gene is the hsa-miR-486-3p gene, its congeners, and These are their transcripts, or their variants or derivatives. To date, this gene or its It has been reported that changes in the expression of the transcript of can serve as a marker for liver cancer. (Authorized documents 2 and 3).

[0533] The 202nd target gene is the hsa-miR-4466 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0534] The 203rd target gene is the hsa-miR-30c-1-3p gene and its congeners. , their transcripts, or their variants or derivatives. To date, this gene or It has been reported that changes in the expression of its transcript can serve as a marker for liver cancer. (Patent Documents 3 and 5).

[0535] The 204th target gene is the hsa-miR-3621 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0536] The 205th target gene is the hsa-miR-6743-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0537] The 206th target gene is the hsa-miR-4298 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0538] The 207th target gene is the hsa-miR-4741 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0539] The 208th target gene is the hsa-miR-3619-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0540] The 209th target gene is the hsa-miR-6824-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0541] The 210th target gene is the hsa-miR-5698 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0542] The 211th target gene is the hsa-miR-371a-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0543] The 212th target gene is the hsa-miR-4488 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0544] The 213th target gene is the hsa-miR-1233-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0545] The 214th target gene is the hsa-miR-4723-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0546] The 215th target gene is the hsa-miR-24-3p gene, its congeners, and These are transcripts of the gene or its variants or derivatives. It has been reported that changes in transcript expression can serve as a marker for liver cancer (Patent Reference 2).

[0547] The 216th target gene is the hsa-miR-1238-5p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that transcript could serve as a marker for liver cancer. .

[0548] The 217th target gene is the hsa-miR-4442 gene, its congeners, and their These are transcripts of this gene, or their variants or derivatives. There are no known reports suggesting that changes in the expression of photoproteins can serve as markers for liver cancer.

[0549] The 218th target gene is the hsa-miR-3928-3p gene, and its congeners. These are their transcripts, or their variants or derivatives. To date, this gene or There are no known reports suggesting that changes in the expression of that t...

Claims

1. A liver cancer detection kit containing nucleic acids that can specifically bind to the liver cancer marker miR-1247-3p polynucleotide.

2. The kit according to claim 1, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof, as shown in (a) to (e) below: (a) (1) A polynucleotide consisting of the base sequence represented by Sequence ID No. 132 or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases, (2) A polynucleotide or fragment thereof that includes the deletion, substitution, addition or insertion of one or two bases in the polynucleotide or fragment of (1), (3) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment in (1), (4) A polynucleotide or fragment thereof, which includes modified nucleic acids and / or modified nucleotides, of any of (1) to (3), (b) A polynucleotide containing the base sequence represented by Sequence ID No. 132, or a fragment thereof containing 15 or more consecutive bases, (c) (5) A polynucleotide consisting of a base sequence represented by Sequence ID No. 132 or a base sequence complementary to the base sequence in said base sequence where u is t, or a fragment thereof containing 15 or more consecutive bases. (6) The polynucleotide or fragment of the same, comprising the deletion, substitution, addition or insertion of one or two bases in the polynucleotide or fragment of the same, (7) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment in (5), (8) A polynucleotide or fragment thereof, which includes a modified nucleic acid and / or a modified nucleotide, of any of (5) to (7), (d) A polynucleotide containing a nucleotide sequence represented by Sequence ID No. 132 or a nucleotide sequence complementary to the nucleotide sequence in said nucleotide sequence where u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (e) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (a) to (d) above under stringent conditions.

3. The kit includes miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p, miR-3917, miR-4286, miR-6877-5p, miR-1225-3p, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p, which are another liver cancer marker.The group consisting of miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p and miR-6836-3p; and / or miR-23b-3p, miR-23a-3p,miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-9 2b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688, miR -4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR -1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-6 65, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR- 3619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24 The kit according to claim 1 or 2, further comprising nucleic acids that can specifically bind to at least one polynucleotide selected from the group consisting of -3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557, and miR-6090.

4. The kit according to claim 3, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof as shown in (f) to (j) below: (f) (9) A polynucleotide consisting of a base sequence represented by any of sequence numbers 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (10) (9) The polynucleotide or fragment thereof comprises a deletion, substitution, addition or insertion of one or two bases, (11) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment of (9), (12) A polynucleotide or fragment thereof, any of (9) to (11), including a modified nucleic acid and / or a modified nucleotide, (g) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224, or a fragment thereof containing 15 or more consecutive bases. (h) (13) A polynucleotide consisting of a nucleotide sequence represented by any of sequence numbers 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides. (14) The polynucleotide or fragment of the same, comprising the deletion, substitution, addition or insertion of one or two bases in the polynucleotide or fragment of the same, (15) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment of (13), (16) A polynucleotide or fragment thereof, any of (13) to (15), including a modified nucleic acid and / or a modified nucleotide. (i) A polynucleotide containing a nucleotide sequence represented by any of SEQ ID NOs: 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (j) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (f) to (i) above under stringent conditions.

5. A liver cancer detection device containing a nucleic acid that can specifically bind to the polynucleotide miR-1247-3p, a liver cancer marker.

6. The device according to claim 5, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof as shown in (a) to (e) below: (a) (25) A polynucleotide consisting of the base sequence represented by Sequence ID No. 132 or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (26) A polynucleotide or fragment thereof in which the polynucleotide or fragment of (25) includes the deletion, substitution, addition or insertion of one or two bases; (27) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment of (25), (28) A polynucleotide or fragment thereof of any of (25) to (27), including a modified nucleic acid and / or a modified nucleotide, (b) A polynucleotide containing the base sequence represented by Sequence ID No. 132, or a fragment thereof containing 15 or more consecutive bases, (c) (29) A polynucleotide consisting of a base sequence represented by Sequence ID No. 132 or a base sequence complementary to the base sequence in said base sequence where u is t, or a fragment thereof containing 15 or more consecutive bases. (30) (29) The polynucleotide or fragment thereof comprises a deletion, substitution, addition or insertion of one or two bases, (31) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment of (29), (32) A polynucleotide or fragment thereof, any of (29) to (31), including a modified nucleic acid and / or a modified nucleotide. (d) A polynucleotide containing a nucleotide sequence represented by Sequence ID No. 132 or a nucleotide sequence complementary to the nucleotide sequence in said nucleotide sequence where u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (e) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (a) to (d) above under stringent conditions.

7. The device is another liver cancer marker, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p, miR-3917, miR-4286, miR-6877-5p, miR-1225-3p, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p,The group consisting of miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p, and miR-6836-3p; and / or miR-23b-3p, miR-23a-3p,miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-9 2b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688, miR -4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR -1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-6 65, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3 619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24- The device according to claim 5 or 6, further comprising nucleic acids that can specifically bind to at least one polynucleotide selected from the group consisting of 3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557, and miR-6090.

8. The device according to claim 7, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof, as shown in (f) to (j) below: (f) (33) A polynucleotide consisting of a base sequence represented by any of sequence numbers 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, and 714-729 and 168-224, or a base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases. (34) The polynucleotide or fragment of the same, comprising the deletion, substitution, addition or insertion of one or two bases in the polynucleotide or fragment of the same, (35) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment of (33), (36) A polynucleotide or fragment thereof of any of (33) to (35), including a modified nucleic acid and / or a modified nucleotide, (g) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224, or a fragment thereof containing 15 or more consecutive bases. (h) (37) A polynucleotide consisting of a nucleotide sequence represented by any of sequence numbers 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides. (38) (37) The polynucleotide or fragment thereof comprising the deletion, substitution, addition or insertion of one or two bases, (39) A polynucleotide or fragment thereof that exhibits 90% or more identity with the base sequence of the polynucleotide or fragment of (37), (40) A polynucleotide or fragment thereof, any of (37) to (39), including a modified nucleic acid and / or a modified nucleotide, (i) A polynucleotide containing a nucleotide sequence represented by any of SEQ ID NOs: 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224, or a nucleotide sequence complementary to the nucleotide sequence in which u is t, or a fragment thereof containing 15 or more consecutive nucleotides, and (j) A polynucleotide that hybridizes with any of the polynucleotides or fragments thereof described in (f) to (i) above under stringent conditions.

9. The device according to any one of claims 5 to 8, wherein the device is a device for measurement by hybridization technology.

10. The device according to claim 9, wherein the hybridization technology is nucleic acid array technology.

11. A method for evaluating the presence or absence of liver cancer, comprising measuring the expression level of a target nucleic acid in a subject's sample using the kit described in any one of claims 1 to 4 or the device described in any one of claims 5 to 10, and evaluating in vitro whether the subject has liver cancer or not using the measured expression level and the similarly measured control expression level of a healthy individual.

12. The method according to claim 11, wherein the subject is a human.

13. The method according to claim 11 or 12, wherein the specimen is blood, serum, or plasma.

14. Use of the miR-1247-3p polynucleotide as a liver cancer marker to assess the presence or absence of liver cancer.

15. The polynucleotide of the aforementioned miR-1247-3p is miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p, miR-3917, miR-4286, miR-6877-5p, miR-1225-3p, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p,The group consisting of miR-1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p and miR-6836-3p; and / or miR-23b-3p,miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5 p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688 , miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, mi R-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665 , miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3 p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1 The use according to claim 14, in combination with at least one polynucleotide selected from the group consisting of 238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557, and miR-6090, used as a liver cancer marker for evaluating the presence or absence of liver cancer.

16. The above-mentioned at least one polynucleotide is (f) and (g) below: (f) A polynucleotide consisting of a base sequence represented by any of the following sequence numbers: 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224. The use according to claim 15, wherein (g) at least one polynucleotide selected from the group consisting of polynucleotides comprising a base sequence represented by any of SEQ ID NOs: 2-21, 23-53, 55-76, 78-80, 82-131, 133-167, 714-729, and 168-224.

Images